US20230260595A1 - Determination of nfkb pathway activity using unique combination of target genes - Google Patents
Determination of nfkb pathway activity using unique combination of target genes Download PDFInfo
- Publication number
- US20230260595A1 US20230260595A1 US17/931,919 US202217931919A US2023260595A1 US 20230260595 A1 US20230260595 A1 US 20230260595A1 US 202217931919 A US202217931919 A US 202217931919A US 2023260595 A1 US2023260595 A1 US 2023260595A1
- Authority
- US
- United States
- Prior art keywords
- nfkb
- target genes
- signaling pathway
- cellular signaling
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 539
- 230000037361 pathway Effects 0.000 title claims abstract description 461
- 230000000694 effects Effects 0.000 title claims description 267
- 230000005754 cellular signaling Effects 0.000 claims abstract description 404
- 230000014509 gene expression Effects 0.000 claims abstract description 251
- 238000000034 method Methods 0.000 claims abstract description 121
- 239000000523 sample Substances 0.000 claims description 260
- 102000040945 Transcription factor Human genes 0.000 claims description 235
- 108091023040 Transcription factor Proteins 0.000 claims description 235
- 206010028980 Neoplasm Diseases 0.000 claims description 89
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 claims description 68
- 101000961071 Homo sapiens NF-kappa-B inhibitor alpha Proteins 0.000 claims description 68
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 68
- 102100039337 NF-kappa-B inhibitor alpha Human genes 0.000 claims description 68
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims description 65
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 claims description 65
- 102100039398 C-X-C motif chemokine 2 Human genes 0.000 claims description 64
- 101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 claims description 64
- 101000830568 Homo sapiens Tumor necrosis factor alpha-induced protein 2 Proteins 0.000 claims description 64
- 102000004890 Interleukin-8 Human genes 0.000 claims description 64
- 108090001007 Interleukin-8 Proteins 0.000 claims description 64
- 102100024595 Tumor necrosis factor alpha-induced protein 2 Human genes 0.000 claims description 64
- 108090001005 Interleukin-6 Proteins 0.000 claims description 59
- 101000979338 Homo sapiens Nuclear factor NF-kappa-B p100 subunit Proteins 0.000 claims description 57
- 102100023059 Nuclear factor NF-kappa-B p100 subunit Human genes 0.000 claims description 57
- 108091058560 IL8 Proteins 0.000 claims description 55
- 201000011510 cancer Diseases 0.000 claims description 51
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 50
- 102100036848 C-C motif chemokine 20 Human genes 0.000 claims description 50
- 102100036189 C-X-C motif chemokine 3 Human genes 0.000 claims description 50
- 102100034221 Growth-regulated alpha protein Human genes 0.000 claims description 50
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 claims description 50
- 101000947193 Homo sapiens C-X-C motif chemokine 3 Proteins 0.000 claims description 50
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 claims description 50
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 claims description 50
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims description 50
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 claims description 44
- 108700003785 Baculoviral IAP Repeat-Containing 3 Proteins 0.000 claims description 36
- 102100021662 Baculoviral IAP repeat-containing protein 3 Human genes 0.000 claims description 36
- 101150104237 Birc3 gene Proteins 0.000 claims description 36
- 101100379220 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) API2 gene Proteins 0.000 claims description 36
- 101000622304 Homo sapiens Vascular cell adhesion protein 1 Proteins 0.000 claims description 35
- 102000004398 TNF receptor-associated factor 1 Human genes 0.000 claims description 35
- 108090000920 TNF receptor-associated factor 1 Proteins 0.000 claims description 35
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 35
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 claims description 35
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 35
- 101000598002 Homo sapiens Interferon regulatory factor 1 Proteins 0.000 claims description 34
- 101000998194 Homo sapiens NF-kappa-B inhibitor epsilon Proteins 0.000 claims description 34
- 102100036981 Interferon regulatory factor 1 Human genes 0.000 claims description 34
- 102100033104 NF-kappa-B inhibitor epsilon Human genes 0.000 claims description 34
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims description 31
- 201000010099 disease Diseases 0.000 claims description 25
- 108010037462 Cyclooxygenase 2 Proteins 0.000 claims description 24
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims description 24
- -1 CCL22 Proteins 0.000 claims description 23
- BSFODEXXVBBYOC-UHFFFAOYSA-N 8-[4-(dimethylamino)butan-2-ylamino]quinolin-6-ol Chemical compound C1=CN=C2C(NC(CCN(C)C)C)=CC(O)=CC2=C1 BSFODEXXVBBYOC-UHFFFAOYSA-N 0.000 claims description 21
- 101150008012 Bcl2l1 gene Proteins 0.000 claims description 21
- 102100023471 E-selectin Human genes 0.000 claims description 21
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 claims description 21
- 102100039065 Interleukin-1 beta Human genes 0.000 claims description 21
- 108700000711 bcl-X Proteins 0.000 claims description 21
- 102100020997 Fractalkine Human genes 0.000 claims description 20
- 101000854520 Homo sapiens Fractalkine Proteins 0.000 claims description 20
- 101000663000 Homo sapiens TNFAIP3-interacting protein 1 Proteins 0.000 claims description 20
- 101150058731 STAT5A gene Proteins 0.000 claims description 20
- 102100024481 Signal transducer and activator of transcription 5A Human genes 0.000 claims description 20
- 102100037667 TNFAIP3-interacting protein 1 Human genes 0.000 claims description 20
- 101000622123 Homo sapiens E-selectin Proteins 0.000 claims description 18
- 210000001072 colon Anatomy 0.000 claims description 18
- 206010025323 Lymphomas Diseases 0.000 claims description 17
- 210000000481 breast Anatomy 0.000 claims description 11
- 208000032612 Glial tumor Diseases 0.000 claims description 8
- 206010018338 Glioma Diseases 0.000 claims description 8
- 208000032839 leukemia Diseases 0.000 claims description 8
- 210000004556 brain Anatomy 0.000 claims description 5
- 238000003752 polymerase chain reaction Methods 0.000 claims description 5
- 210000004072 lung Anatomy 0.000 claims description 3
- 210000002307 prostate Anatomy 0.000 claims description 3
- 102000004889 Interleukin-6 Human genes 0.000 claims 7
- 239000012472 biological sample Substances 0.000 claims 3
- 102000055104 bcl-X Human genes 0.000 claims 2
- 238000012545 processing Methods 0.000 abstract description 20
- 238000004590 computer program Methods 0.000 abstract description 11
- 230000008569 process Effects 0.000 abstract description 5
- 230000001976 improved effect Effects 0.000 abstract description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 111
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 111
- 210000004027 cell Anatomy 0.000 description 63
- 102000026633 IL6 Human genes 0.000 description 58
- 238000012549 training Methods 0.000 description 53
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 46
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 39
- 238000012360 testing method Methods 0.000 description 28
- 108020004999 messenger RNA Proteins 0.000 description 27
- 230000000638 stimulation Effects 0.000 description 27
- 238000002493 microarray Methods 0.000 description 25
- 239000013615 primer Substances 0.000 description 23
- 238000013178 mathematical model Methods 0.000 description 22
- 238000005259 measurement Methods 0.000 description 22
- 238000013518 transcription Methods 0.000 description 22
- 230000035897 transcription Effects 0.000 description 22
- 239000010410 layer Substances 0.000 description 20
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 description 19
- 210000003719 b-lymphocyte Anatomy 0.000 description 17
- 238000010606 normalization Methods 0.000 description 17
- 238000010586 diagram Methods 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 16
- 238000011529 RT qPCR Methods 0.000 description 15
- 239000003112 inhibitor Substances 0.000 description 15
- 230000001105 regulatory effect Effects 0.000 description 15
- 206010006187 Breast cancer Diseases 0.000 description 14
- 208000026310 Breast neoplasm Diseases 0.000 description 14
- 230000027455 binding Effects 0.000 description 14
- 239000002158 endotoxin Substances 0.000 description 14
- 229920006008 lipopolysaccharide Polymers 0.000 description 14
- 230000019491 signal transduction Effects 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 13
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 13
- 238000003559 RNA-seq method Methods 0.000 description 13
- 238000013459 approach Methods 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 238000003556 assay Methods 0.000 description 12
- 230000000670 limiting effect Effects 0.000 description 12
- 208000003200 Adenoma Diseases 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 239000002987 primer (paints) Substances 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 206010001233 Adenoma benign Diseases 0.000 description 10
- 206010009944 Colon cancer Diseases 0.000 description 10
- 238000004364 calculation method Methods 0.000 description 10
- 208000035475 disorder Diseases 0.000 description 10
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 9
- 238000002487 chromatin immunoprecipitation Methods 0.000 description 9
- 201000003444 follicular lymphoma Diseases 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 102000003945 NF-kappa B Human genes 0.000 description 8
- 108010057466 NF-kappa B Proteins 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 210000001672 ovary Anatomy 0.000 description 8
- 206010042971 T-cell lymphoma Diseases 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 230000001276 controlling effect Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000002489 hematologic effect Effects 0.000 description 7
- 201000001441 melanoma Diseases 0.000 description 7
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 7
- 230000011664 signaling Effects 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 description 6
- 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 description 6
- 206010033128 Ovarian cancer Diseases 0.000 description 6
- 238000004422 calculation algorithm Methods 0.000 description 6
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 6
- 230000002074 deregulated effect Effects 0.000 description 6
- 239000000975 dye Substances 0.000 description 6
- 201000004653 inflammatory breast carcinoma Diseases 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 238000004393 prognosis Methods 0.000 description 6
- 230000002103 transcriptional effect Effects 0.000 description 6
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 5
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 5
- 208000006404 Large Granular Lymphocytic Leukemia Diseases 0.000 description 5
- 206010027476 Metastases Diseases 0.000 description 5
- 208000034578 Multiple myelomas Diseases 0.000 description 5
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 5
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 description 5
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 210000001124 body fluid Anatomy 0.000 description 5
- 239000010839 body fluid Substances 0.000 description 5
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 5
- 230000002596 correlated effect Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 230000009401 metastasis Effects 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 201000009030 Carcinoma Diseases 0.000 description 4
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 4
- 206010061818 Disease progression Diseases 0.000 description 4
- 101710128765 Enhancer of filamentation 1 Proteins 0.000 description 4
- 208000017604 Hodgkin disease Diseases 0.000 description 4
- 101000736088 Homo sapiens PC4 and SFRS1-interacting protein Proteins 0.000 description 4
- 101000708741 Homo sapiens Transcription factor RelB Proteins 0.000 description 4
- 101001002507 Mus musculus Immunoglobulin-binding protein 1 Proteins 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 4
- 208000033759 Prolymphocytic T-Cell Leukemia Diseases 0.000 description 4
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 4
- 201000008717 T-cell large granular lymphocyte leukemia Diseases 0.000 description 4
- 208000026651 T-cell prolymphocytic leukemia Diseases 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 102100032727 Transcription factor RelB Human genes 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 208000013056 classic Hodgkin lymphoma Diseases 0.000 description 4
- 235000017471 coenzyme Q10 Nutrition 0.000 description 4
- 238000005094 computer simulation Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000000539 dimer Substances 0.000 description 4
- 230000005750 disease progression Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000011223 gene expression profiling Methods 0.000 description 4
- 201000009277 hairy cell leukemia Diseases 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 238000002966 oligonucleotide array Methods 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 238000003498 protein array Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 description 4
- MTHORRSSURHQPZ-UHFFFAOYSA-N 2-[(1-benzylindazol-3-yl)methoxy]-2-methylpropanoic acid Chemical compound C12=CC=CC=C2C(COC(C)(C)C(O)=O)=NN1CC1=CC=CC=C1 MTHORRSSURHQPZ-UHFFFAOYSA-N 0.000 description 3
- IUOMATKBBPCLFR-TUAOUCFPSA-N 2-hydroxy-n-[(1s,2s,6s)-2-hydroxy-5-oxo-7-oxabicyclo[4.1.0]hept-3-en-3-yl]benzamide Chemical group O=C([C@H]1O[C@H]1[C@H]1O)C=C1NC(=O)C1=CC=CC=C1O IUOMATKBBPCLFR-TUAOUCFPSA-N 0.000 description 3
- 102100030755 5-aminolevulinate synthase, nonspecific, mitochondrial Human genes 0.000 description 3
- 102100040881 60S acidic ribosomal protein P0 Human genes 0.000 description 3
- 102100040623 60S ribosomal protein L41 Human genes 0.000 description 3
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 3
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical group NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 3
- 208000003950 B-cell lymphoma Diseases 0.000 description 3
- 102100038326 Beta-defensin 4A Human genes 0.000 description 3
- 206010005003 Bladder cancer Diseases 0.000 description 3
- 208000003174 Brain Neoplasms Diseases 0.000 description 3
- 208000011691 Burkitt lymphomas Diseases 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- 102100021429 DNA-directed RNA polymerase II subunit RPB1 Human genes 0.000 description 3
- 102100030801 Elongation factor 1-alpha 1 Human genes 0.000 description 3
- 208000002460 Enteropathy-Associated T-Cell Lymphoma Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 3
- 101000843649 Homo sapiens 5-aminolevulinate synthase, nonspecific, mitochondrial Proteins 0.000 description 3
- 101000673456 Homo sapiens 60S acidic ribosomal protein P0 Proteins 0.000 description 3
- 101000674326 Homo sapiens 60S ribosomal protein L41 Proteins 0.000 description 3
- 101000884714 Homo sapiens Beta-defensin 4A Proteins 0.000 description 3
- 101001106401 Homo sapiens DNA-directed RNA polymerase II subunit RPB1 Proteins 0.000 description 3
- 101000920078 Homo sapiens Elongation factor 1-alpha 1 Proteins 0.000 description 3
- 101000896557 Homo sapiens Eukaryotic translation initiation factor 3 subunit B Proteins 0.000 description 3
- 101000988834 Homo sapiens Hypoxanthine-guanine phosphoribosyltransferase Proteins 0.000 description 3
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 3
- 101000616974 Homo sapiens Pumilio homolog 1 Proteins 0.000 description 3
- 101000653679 Homo sapiens Translationally-controlled tumor protein Proteins 0.000 description 3
- 101000838456 Homo sapiens Tubulin alpha-1B chain Proteins 0.000 description 3
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 3
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 102100026236 Interleukin-8 Human genes 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 3
- 208000000172 Medulloblastoma Diseases 0.000 description 3
- 206010027406 Mesothelioma Diseases 0.000 description 3
- PSPFQEBFYXJZEV-UHFFFAOYSA-N N'-(1,8-dimethyl-4-imidazo[1,2-a]quinoxalinyl)ethane-1,2-diamine Chemical compound C1=C(C)C=C2N3C(C)=CN=C3C(NCCN)=NC2=C1 PSPFQEBFYXJZEV-UHFFFAOYSA-N 0.000 description 3
- ZBZXYUYUUDZCNB-UHFFFAOYSA-N N-cyclohexa-1,3-dien-1-yl-N-phenyl-4-[4-(N-[4-[4-(N-[4-[4-(N-phenylanilino)phenyl]phenyl]anilino)phenyl]phenyl]anilino)phenyl]aniline Chemical compound C1=CCCC(N(C=2C=CC=CC=2)C=2C=CC(=CC=2)C=2C=CC(=CC=2)N(C=2C=CC=CC=2)C=2C=CC(=CC=2)C=2C=CC(=CC=2)N(C=2C=CC=CC=2)C=2C=CC(=CC=2)C=2C=CC(=CC=2)N(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 ZBZXYUYUUDZCNB-UHFFFAOYSA-N 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 102100021672 Pumilio homolog 1 Human genes 0.000 description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 102100029887 Translationally-controlled tumor protein Human genes 0.000 description 3
- 102100028969 Tubulin alpha-1B chain Human genes 0.000 description 3
- 201000006966 adult T-cell leukemia Diseases 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 229950009949 bindarit Drugs 0.000 description 3
- 208000002458 carcinoid tumor Diseases 0.000 description 3
- 208000009060 clear cell adenocarcinoma Diseases 0.000 description 3
- 229940110767 coenzyme Q10 Drugs 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 239000003596 drug target Substances 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 210000001102 germinal center b cell Anatomy 0.000 description 3
- 208000005017 glioblastoma Diseases 0.000 description 3
- 239000003862 glucocorticoid Substances 0.000 description 3
- 201000010536 head and neck cancer Diseases 0.000 description 3
- 208000014829 head and neck neoplasm Diseases 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 3
- 210000001806 memory b lymphocyte Anatomy 0.000 description 3
- 201000005962 mycosis fungoides Diseases 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000002611 ovarian Effects 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 239000013610 patient sample Substances 0.000 description 3
- 208000023958 prostate neoplasm Diseases 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 229940037128 systemic glucocorticoids Drugs 0.000 description 3
- 238000012353 t test Methods 0.000 description 3
- 238000010200 validation analysis Methods 0.000 description 3
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 2
- 101710168331 ALK tyrosine kinase receptor Proteins 0.000 description 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 2
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 2
- 206010002412 Angiocentric lymphomas Diseases 0.000 description 2
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 2
- 108091012583 BCL2 Proteins 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 2
- 208000016778 CD4+/CD56+ hematodermic neoplasm Diseases 0.000 description 2
- 201000004085 CLL/SLL Diseases 0.000 description 2
- 101100245267 Caenorhabditis elegans pas-1 gene Proteins 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 2
- 201000009273 Endometriosis Diseases 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 102100039696 Glutamate-cysteine ligase catalytic subunit Human genes 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 206010066476 Haematological malignancy Diseases 0.000 description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 2
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 2
- 101001034527 Homo sapiens Glutamate-cysteine ligase catalytic subunit Proteins 0.000 description 2
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 2
- 101001054334 Homo sapiens Interferon beta Proteins 0.000 description 2
- 101000852992 Homo sapiens Interleukin-12 subunit beta Proteins 0.000 description 2
- 101000852980 Homo sapiens Interleukin-23 subunit alpha Proteins 0.000 description 2
- 101001128158 Homo sapiens Nanos homolog 2 Proteins 0.000 description 2
- 101001124991 Homo sapiens Nitric oxide synthase, inducible Proteins 0.000 description 2
- 101000999079 Homo sapiens Radiation-inducible immediate-early gene IEX-1 Proteins 0.000 description 2
- 101000638161 Homo sapiens Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 2
- 102100026720 Interferon beta Human genes 0.000 description 2
- 102100036701 Interleukin-12 subunit beta Human genes 0.000 description 2
- 102100036705 Interleukin-23 subunit alpha Human genes 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 2
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 2
- 201000003791 MALT lymphoma Diseases 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 208000037538 Myelomonocytic Juvenile Leukemia Diseases 0.000 description 2
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 2
- 206010029461 Nodal marginal zone B-cell lymphomas Diseases 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 2
- 206010058674 Pelvic Infection Diseases 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 206010036711 Primary mediastinal large B-cell lymphomas Diseases 0.000 description 2
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 2
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 2
- 239000013614 RNA sample Substances 0.000 description 2
- 102100036900 Radiation-inducible immediate-early gene IEX-1 Human genes 0.000 description 2
- 201000000582 Retinoblastoma Diseases 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 102100032891 Superoxide dismutase [Mn], mitochondrial Human genes 0.000 description 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 2
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 2
- 208000008383 Wilms tumor Diseases 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000035508 accumulation Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000011748 cell maturation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 208000023738 chronic lymphocytic leukemia/small lymphocytic lymphoma Diseases 0.000 description 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- FOCAHLGSDWHSAH-UHFFFAOYSA-N difluoromethanethione Chemical compound FC(F)=S FOCAHLGSDWHSAH-UHFFFAOYSA-N 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 201000011066 hemangioma Diseases 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 201000005992 juvenile myelomonocytic leukemia Diseases 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000000370 laser capture micro-dissection Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 201000011649 lymphoblastic lymphoma Diseases 0.000 description 2
- 230000000527 lymphocytic effect Effects 0.000 description 2
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 208000025113 myeloid leukemia Diseases 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 201000011519 neuroendocrine tumor Diseases 0.000 description 2
- 208000029974 neurofibrosarcoma Diseases 0.000 description 2
- 208000025275 nodular sclerosis classical Hodgkin lymphoma Diseases 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 231100000590 oncogenic Toxicity 0.000 description 2
- 230000002246 oncogenic effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 230000016087 ovulation Effects 0.000 description 2
- 201000002530 pancreatic endocrine carcinoma Diseases 0.000 description 2
- 210000003899 penis Anatomy 0.000 description 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 208000000814 primary cutaneous anaplastic large cell lymphoma Diseases 0.000 description 2
- 230000001686 pro-survival effect Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000007781 signaling event Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 208000000649 small cell carcinoma Diseases 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 description 2
- 108010045815 superoxide dismutase 2 Proteins 0.000 description 2
- 230000002381 testicular Effects 0.000 description 2
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 210000003708 urethra Anatomy 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- VHSRMPMVGSQIGB-UHFFFAOYSA-N 6-amino-7h-purine-2-carbaldehyde Chemical compound NC1=NC(C=O)=NC2=C1NC=N2 VHSRMPMVGSQIGB-UHFFFAOYSA-N 0.000 description 1
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 1
- 208000011043 ALK-negative anaplastic large cell lymphoma Diseases 0.000 description 1
- 208000017726 ALK-positive large B-cell lymphoma Diseases 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 206010048998 Acute phase reaction Diseases 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 208000036764 Adenocarcinoma of the esophagus Diseases 0.000 description 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 1
- 208000012791 Alpha-heavy chain disease Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000010566 B-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classical Hodgkin lymphoma Diseases 0.000 description 1
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 description 1
- 206010003908 B-cell small lymphocytic lymphoma Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 description 1
- 206010058354 Bronchioloalveolar carcinoma Diseases 0.000 description 1
- 101100353517 Caenorhabditis elegans pas-2 gene Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 description 1
- 208000005024 Castleman disease Diseases 0.000 description 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 208000033816 Chronic lymphoproliferative disorder of natural killer cells Diseases 0.000 description 1
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000006402 Ductal Carcinoma Diseases 0.000 description 1
- 208000001708 Dupuytren contracture Diseases 0.000 description 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 206010015108 Epstein-Barr virus infection Diseases 0.000 description 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
- 208000036566 Erythroleukaemia Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 208000016937 Extranodal nasal NK/T cell lymphoma Diseases 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 208000012841 Gamma-heavy chain disease Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 1
- 208000021309 Germ cell tumor Diseases 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- 206010060980 Granular cell tumour Diseases 0.000 description 1
- 201000000439 HCL-V Diseases 0.000 description 1
- 208000010956 Hairy cell leukemia variant Diseases 0.000 description 1
- 208000006050 Hemangiopericytoma Diseases 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 208000031953 Hereditary hemorrhagic telangiectasia Diseases 0.000 description 1
- 208000025795 Hodgkin lymphoma, lymphocytic depletion Diseases 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 241001502974 Human gammaherpesvirus 8 Species 0.000 description 1
- 201000003803 Inflammatory myofibroblastic tumor Diseases 0.000 description 1
- 206010067917 Inflammatory myofibroblastic tumour Diseases 0.000 description 1
- 206010023421 Kidney fibrosis Diseases 0.000 description 1
- 206010023791 Large granular lymphocytosis Diseases 0.000 description 1
- 206010024305 Leukaemia monocytic Diseases 0.000 description 1
- 206010024612 Lipoma Diseases 0.000 description 1
- 208000000265 Lobular Carcinoma Diseases 0.000 description 1
- 201000005978 Loeys-Dietz syndrome Diseases 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 206010025312 Lymphoma AIDS related Diseases 0.000 description 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000001826 Marfan syndrome Diseases 0.000 description 1
- 208000009018 Medullary thyroid cancer Diseases 0.000 description 1
- 206010027193 Meningioma malignant Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000012799 Mu-heavy chain disease Diseases 0.000 description 1
- 208000007727 Muscle Tissue Neoplasms Diseases 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010052399 Neuroendocrine tumour Diseases 0.000 description 1
- 201000004404 Neurofibroma Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 206010030137 Oesophageal adenocarcinoma Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 description 1
- 206010031112 Oropharyngeal squamous cell carcinoma Diseases 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 206010061332 Paraganglion neoplasm Diseases 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000002163 Phyllodes Tumor Diseases 0.000 description 1
- 206010071776 Phyllodes tumour Diseases 0.000 description 1
- 206010065857 Primary Effusion Lymphoma Diseases 0.000 description 1
- 208000024588 Primary cutaneous follicle center lymphoma Diseases 0.000 description 1
- 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 description 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 101100127690 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) FAA2 gene Proteins 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 208000002669 Sex Cord-Gonadal Stromal Tumors Diseases 0.000 description 1
- 208000003252 Signet Ring Cell Carcinoma Diseases 0.000 description 1
- 208000032383 Soft tissue cancer Diseases 0.000 description 1
- 208000011783 Splenic diffuse red pulp small B-cell lymphoma Diseases 0.000 description 1
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 description 1
- 208000010502 Subcutaneous panniculitis-like T-cell lymphoma Diseases 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000011778 T-cell/histiocyte rich large B cell lymphoma Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000000728 Thymus Neoplasms Diseases 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010046799 Uterine leiomyosarcoma Diseases 0.000 description 1
- 208000034259 Vascular Ehlers-Danlos syndrome Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 230000004658 acute-phase response Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 208000015230 aggressive NK-cell leukemia Diseases 0.000 description 1
- 208000009887 angiolipoma Diseases 0.000 description 1
- 208000000252 angiomatosis Diseases 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000011948 assay development Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 201000007180 bile duct carcinoma Diseases 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 201000003714 breast lobular carcinoma Diseases 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 230000008777 canonical pathway Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000004640 cellular pathway Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 208000011654 childhood malignant neoplasm Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 208000014620 chronic lymphoproliferative disorder of NK-cells Diseases 0.000 description 1
- 210000005266 circulating tumour cell Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 208000024558 digestive system cancer Diseases 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 201000011523 endocrine gland cancer Diseases 0.000 description 1
- 201000003908 endometrial adenocarcinoma Diseases 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 208000018463 endometrial serous adenocarcinoma Diseases 0.000 description 1
- 208000027858 endometrioid tumor Diseases 0.000 description 1
- 208000029382 endometrium adenocarcinoma Diseases 0.000 description 1
- 208000028653 esophageal adenocarcinoma Diseases 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 201000006569 extramedullary plasmacytoma Diseases 0.000 description 1
- 201000010972 female reproductive endometrioid cancer Diseases 0.000 description 1
- 206010016629 fibroma Diseases 0.000 description 1
- 206010049444 fibromatosis Diseases 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 201000010231 gastrointestinal system cancer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003197 gene knockdown Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 208000030316 grade III meningioma Diseases 0.000 description 1
- 201000006604 granular cell tumor Diseases 0.000 description 1
- 239000001046 green dye Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000025750 heavy chain disease Diseases 0.000 description 1
- 206010066957 hepatosplenic T-cell lymphoma Diseases 0.000 description 1
- 208000017728 hydroa vacciniforme-like lymphoma Diseases 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 208000026876 intravascular large B-cell lymphoma Diseases 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 206010073096 invasive lobular breast carcinoma Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 208000003849 large cell carcinoma Diseases 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 201000002250 liver carcinoma Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 208000016992 lung adenocarcinoma in situ Diseases 0.000 description 1
- 208000012804 lymphangiosarcoma Diseases 0.000 description 1
- 208000037515 lymphocytic depletion Hodgkin lymphoma Diseases 0.000 description 1
- 208000037652 lymphocytic-histiocytic predominance Hodgkin lymphoma Diseases 0.000 description 1
- 208000006116 lymphomatoid granulomatosis Diseases 0.000 description 1
- 208000007282 lymphomatoid papulosis Diseases 0.000 description 1
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 description 1
- 201000001268 lymphoproliferative syndrome Diseases 0.000 description 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 1
- 208000021937 marginal zone lymphoma Diseases 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 210000000716 merkel cell Anatomy 0.000 description 1
- 201000008806 mesenchymal cell neoplasm Diseases 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 1
- 208000037524 mixed cellularity Hodgkin lymphoma Diseases 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 201000006894 monocytic leukemia Diseases 0.000 description 1
- 201000010879 mucinous adenocarcinoma Diseases 0.000 description 1
- 208000010492 mucinous cystadenocarcinoma Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000024305 myofibroblastoma Diseases 0.000 description 1
- 208000001611 myxosarcoma Diseases 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 208000016065 neuroendocrine neoplasm Diseases 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 201000002740 oral squamous cell carcinoma Diseases 0.000 description 1
- 208000022698 oropharynx squamous cell carcinoma Diseases 0.000 description 1
- 230000037443 ovarian carcinogenesis Effects 0.000 description 1
- 231100001249 ovarian carcinogenesis Toxicity 0.000 description 1
- 208000011937 ovarian epithelial tumor Diseases 0.000 description 1
- 201000008033 ovary epithelial cancer Diseases 0.000 description 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 208000007312 paraganglioma Diseases 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 201000003913 parathyroid carcinoma Diseases 0.000 description 1
- 208000017954 parathyroid gland carcinoma Diseases 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 201000009612 pediatric lymphoma Diseases 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 208000007525 plasmablastic lymphoma Diseases 0.000 description 1
- 210000003281 pleural cavity Anatomy 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 1
- 230000000722 protumoral effect Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 206010039667 schwannoma Diseases 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000028467 sex cord-stromal tumor Diseases 0.000 description 1
- 201000008123 signet ring cell adenocarcinoma Diseases 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 201000006576 solitary osseous plasmacytoma Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 208000008732 thymoma Diseases 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 230000009750 upstream signaling Effects 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000037965 uterine sarcoma Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/20—Polymerase chain reaction [PCR]; Primer or probe design; Probe optimisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
- G16B5/20—Probabilistic models
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Definitions
- the present invention is in the field of systems biology, bioinformatics, genomic mathematical processing and proteomic mathematical processing.
- the invention includes a systems-based mathematical process for determining the activity of a NFkB cellular signaling pathway in a subject based on expression levels of a unique set of selected target genes in a subject.
- the invention further provides an apparatus that includes a digital processor configured to perform such a method, a non-transitory storage medium storing instructions that are executable by a digital processing device to perform such a method, and a computer program comprising a program code means for causing a digital processing device to perform such a method.
- the present invention also includes kits for the determination of expression levels of the unique combinations of target genes.
- Tumors and cancers have a wide range of genotypes and phenotypes, they are influenced by their individualized cell receptors (or lack thereof), micro-environment, extracellular matrix, tumor vascularization, neighboring immune cells, and accumulations of mutations, with differing capacities for proliferation, migration, stem cell properties and invasion.
- This scope of heterogeneity exists even among same classes of tumors. See generally: Nature Insight: Tumor Heterogeneity (entire issue of articles), 19 Sep. 2013 (Vol. 501, Issue 7467); Zellmer and Zhang, “Evolving concepts of tumor heterogeneity”, Cell and Bioscience 2014, 4:69.
- a number of companies and institutions are active in the area of classical, and some more advanced, genetic testing, diagnostics, and predictions for the development of human diseases, including, for example: Affymetrix, Inc.; Bio-Rad, Inc; Roche Diagnostics; Genomic Health, Inc.; Regents of the University of California; Illumina; Fluidigm Corporation; Sequenom, Inc.; High Throughput Genomics; NanoString Technologies; Thermo Fisher; Danaher; Becton, Dickinson and Company; bioMerieux; Johnson & Johnson, Myriad Genetics, and Hologic.
- Genomic Health, Inc. is the assignee of numerous patents pertaining to gene expression profiling, for example: U.S. Pat. Nos. 7,081,340; 8,808,994; 8,034,565; 8,206,919; 7,858,304; 8,741,605; 8,765,383; 7,838,224; 8,071,286; 8,148,076; 8,008,003; 8,725,426; 7,888,019; 8,906,625; 8,703,736; 7,695,913; 7,569,345; 8,067,178; 7,056,674; 8,153,379; 8,153,380; 8,153,378; 8,026,060; 8,029,995; 8,198,024; 8,273,537; 8,632,980; 7,723,033; 8,367,345; 8,911,940; 7,939,261; 7,526,637; 8,868,352; 7,9
- U.S. Pat. No. 9,076,104 to the Regents of the University of California titled “Systems and Methods for Identifying Drug Targets using Biological Networks” claims a method with computer executable instructions by a processor for predicting gene expression profile changes on inhibition of proteins or genes of drug targets on treating a disease, that includes constructing a genetic network using a dynamic Bayesian network based at least in part on knowledge of drug inhibiting effects on a disease, associating a set of parameters with the constructed dynamic Bayesian network, determining the values of a joint probability distribution via an automatic procedure, deriving a mean dynamic Bayesian network with averaged parameters and calculating a quantitative prediction based at least in part on the mean dynamic Bayesian network, wherein the method searches for an optimal combination of drug targets whose perturbed gene expression profiles are most similar to healthy cells.
- Affymetrix has developed a number of products related to gene expression profiling.
- Non-limiting examples of U.S. patents to Affymetrix include: U.S. Pat. Nos. 6,884,578; 8,029,997; 6,308,170; 6,720,149; 5,874,219; 6,171,798; and 6,391,550.
- Bio-Rad has a number of products directed to gene expression profiling.
- Illustrative examples of U.S. patents to Bio-Rad include: U.S. Pat. Nos. 8,021,894; 8,451,450; 8,518,639; 6,004,761; 6,146,897; 7,299,134; 7,160,734; 6,675,104; 6,844,165; 6,225,047; 7,754,861 and 6,004,761.
- Nuclear factor-kappa B is an inducible transcription factor that regulates the expression of many genes involved in the immune response.
- the NFkB cellular signaling pathway is a key cellular signaling pathway involved in immune, inflammatory, and acute phase response, but is also implicated in the control of cell survival, proliferation, and apoptosis.
- the NFkB cellular signaling pathway associated transcription factors that are composed of dimers originating from five genes (NFKB1 or p50/p105, NFKB2 or p52/p100, RELA or p65, REL, and RELB) are predominantly cytoplasmic due to their interaction with the inhibitors of NFkB (IkBs) and therefore remain transcriptionally inactive, thus keeping the NFkB cellular signaling pathway inactive.
- IkBs inhibitors of NFkB
- the IkBs phosphorylated and undergo ubiquitin-dependent degradation by the proteasome, and NFkB dimers are translocated to the nucleus where they act as transcription factors.
- NFkB cellular signaling pathway preferably refers to any signaling process that leads to transcriptional activity of the above mentioned NFkB transcription factors.
- a cancer e.g., a diffuse large B-cell lymphoma (DLBCL), a multiple myeloma, a cancer of another haematological origin, or a solid tumor, such as a breast, melanoma, or prostate tumor, which is at least partially driven by a deregulated NFkB cellular signaling pathway, and that are therefore likely to respond to inhibitors of the NFkB cellular signaling pathway.
- a cancer e.g., a diffuse large B-cell lymphoma (DLBCL), a multiple myeloma, a cancer of another haematological origin, or a solid tumor, such as a breast, melanoma, or prostate tumor, which is at least partially driven by a deregulated NFkB cellular signaling pathway, and that are therefore likely to respond to inhibitors of the NFkB cellular signaling pathway.
- a cancer e.g., a diffuse large B-cell lymphoma (DLBCL), a multiple
- the present invention includes methods and apparatuses for determining the activity level of a NFkB cellular signaling pathway in a subject, typically a human with diseased tissue such as a tumor or cancer, wherein the activity level of the NFkB cellular signaling pathway is determined by calculating a level of NFkB transcription factor element in a sample of the involved tissue isolated from the subject, wherein the level of the NFkB transcription factor element in the sample are determined by measuring the expression levels of a unique set of target genes controlled by the NFkB transcription factor element using a calibrated pathway model that compares the expression levels of the target genes in the sample with expression levels of the target genes in the calibrated pathway model.
- the unique set of target genes whose expression level is analyzed in the model includes at least six target genes, at least seven target genes, at least eight target genes, at least nine target genes, at least ten or more target genes selected from BCL2L1, BIRC3, CCL2, CCL3, CCL4, CCL5, CCL20, CCL22, CX3CL1, CXCL1, CXCL2, CXCL3, ICAM1, IL1B, IL6, IL8, IRF1, MMP9, NFKB2, NFKBIA, NFKBIE, PTGS2, SELE, STAT5A, TNF, TNFAIP2, TNIP1, TRAF1, and VCAM1.
- the unique set of target genes whose expression level is analyzed in the model is selected from BIRC3, CCL2, CCL5, CCL20, CXCL1, CXCL2, CXCL3, ICAM1, IL6, IL8, IRF1, MMP9, NFKB2, NFKBIA, NFKBIE, TNF, TNFAIP2, TRAF1, and VCAM1.
- the unique set of target genes comprises at least three target genes, at least four target genes, at least five target genes, at least six or more target genes selected from CCL2, CCL5, CCL20, CXCL1, CXCL2, CXCL3, ICAM1, IL6, IL8, MMP9, NFKB2, NFKBIA, and TNFAIP2.
- the unique set of target genes comprises at least three target genes, at least four target genes, at least five target genes, at least six or more target genes selected from CCL5, CXCL2, ICAM1, IL6, IL8, NFKBIA, and TNFAIP2.
- such cellular signaling pathway status can be used to, for example but not limited to, identify the presence or absence of disease and/or particular disease state or advancement, identify the presence or absence of a disorder or disease state, identify a particular subtype within a disease or disorder based one the activity level of the NFkB cellular signaling pathway, derive a course of treatment based on the presence or absence of NFkB signaling activity for example by administering a NFkB inhibitor, and/or monitor disease progression in order to, for example, adjust therapeutic protocols based on a predicted drug efficacy in light of the determined activity of the NFkB cellular signaling pathway in the sample.
- NFkB transcriptional factor element or “NFkB TF element” or “TF element” refers to a protein complex containing at least one or, preferably, a dimer of the NFkB members (NFKB1 or p50/p105, NFKB2 or p52/p100, RELA or p65, REL, and RELB), which is capable of binding to specific DNA sequences, thereby controlling transcription of target genes.
- NFkB transcriptional factor element or NFkB TF element or “TF element” refers to a protein complex containing at least one or, preferably, a dimer of the NFkB members (NFKB1 or p50/p105, NFKB2 or p52/p100, RELA or p65, REL, and RELB), which is capable of binding to specific DNA sequences, thereby controlling transcription of target genes.
- the present invention is based on the realization of the inventors that a suitable way of identifying effects occurring in the NFkB cellular signaling pathway can be based on a measurement of the signaling output of the NFkB cellular signaling pathway, which is—amongst others—the transcription of the unique target genes described herein by a NFkB transcription factor (TF) element controlled by the NFkB cellular signaling pathway.
- TF NFkB transcription factor
- the NFkB cellular signaling pathway targeted herein is known to be associated with different types of cancer and to support the pro-survival phenotypes of cancer cells as the NFkB cellular signaling pathway is known to regulate genes that control cell proliferation and cell survival processes. Many different types of human tumors are found to have a deregulated activity of the NFkB cellular signaling pathway. Furthermore, studies have shown that the inhibition of constitutive NFkB cellular signaling pathway activity blocks the oncogenic potential of cancerous cells.
- the present invention makes it possible to determine the activity of the NFkB cellular signaling pathway by (i) determining a level of an NFkB TF element in the sample, wherein the determining is based at least in part on evaluating a mathematical model relating expression levels of at least six target genes of the NFkB cellular signaling pathway, the transcription of which is controlled by the NFkB TF element, to the level of the NFkB TF element, and by (ii) inferring the activity of the NFkB cellular signaling pathway based on the determined level of the NFkB TF element in the sample.
- a cancer e.g., a diffuse large B-cell lymphoma (DLBCL), a multiple myeloma, a cancer of another haematological origin, or a solid tumor, such as a breast, melanoma, or prostate tumor, which is at least partially driven by a deregulated NFkB cellular signaling pathway, and that are therefore likely to respond to inhibitors of the NFkB cellular signaling pathway.
- An important advantage of the present invention is that it makes it possible to determine
- treatment determination can be based on specific NFkB activity.
- the NFkB cellular signaling status can be set at a cutoff value of odds of the NFkB cellular signaling pathway being activate of, for example, 10:1, 5:1, 4:1, 2:1, 1:1, 1:2, 1:4, 1:5, or 1:10.
- a computer implemented method for determining the activity level of a NFkB cellular signaling pathway in a subject performed by a computerized device having a processor comprising:
- the method further comprises assigning a NFkB cellular signaling pathway activity status to the calculated activity level of the NFkB cellular signaling pathway in the sample wherein the activity status is indicative of either an active NFkB cellular signaling pathway or a passive NFkB cellular signaling pathway.
- the at least six target genes are selected from BIRC3, CCL2, CCL5, CCL20, CXCL1, CXCL2, CXCL3, ICAM1, IL6, IL8, IRF1, MMP9, NFKB2, NFKBIA, NFKBIE, TNF, TNFAIP2, TRAF1, and VCAM1.
- the at least six target genes comprise at least three target genes selected from CCL2, CCL5, CCL20, CXCL1, CXCL2, CXCL3, ICAM1, IL6, IL8, MMP9, NFKB2, NFKBIA, and TNFAIP2.
- the at least three target genes are selected from CCL5, CXCL2, ICAM1, IL6, IL8, NFKBIA, and TNFAIP2.
- the status of the NFkB cellular signaling pathway is established by establishing a specific threshold for activity as described further below.
- the threshold is set as a probability that the cellular signaling pathway is active, for example, a 10:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:4, 1:5, or 1:10.
- the activity status is based, for example, on a minimum calculated activity.
- the method further comprises assigning to the calculated NFkB cellular signaling in the sample a probability that the NFkB cellular signaling pathway is active.
- the level of the NFkB transcription factor element is determined using a calibrated pathway model executed by one or more computer processors, as further described below.
- the calibrated pathway model compares the expression levels of the at least six target genes in the sample with expression levels of the at least six target genes in the calibrated pathway model which define a level of a NFkB transcription factor element.
- the calibrated pathway model is a probabilistic model incorporating conditional probabilistic relationships that compare the expression levels of the at least six target genes in the sample with expression levels of the at least six target genes in the model which define a level of a NFkB transcription factor element to determine the level of the NFkB transcription factor element in the sample.
- the probabilistic model is a Bayesian network model.
- the calibrated pathway model can be a linear or pseudo-linear model.
- the linear or pseudo-linear model is a linear or pseudo-linear combination model.
- the expression levels of the unique set of target genes can be determined using standard methods known in the art.
- the expression levels of the target genes can be determined by measuring the level of mRNA of the target genes, through quantitative reverse transcriptase-polymerase chain reaction techniques, using probes associated with a mRNA sequence of the target genes, using a DNA or RNA microarray, and/or by measuring the protein level of the protein encoded by the target genes.
- the expression levels of the target genes within the sample can be utilized in the model in a raw state or, alternatively, following normalization of the expression level data.
- expression level data can be normalized by transforming it into continuous data, z-score data, discrete data, or fuzzy data.
- the calculation of NFkB signaling in the sample is performed on a computerized device having a processor capable of executing a readable program code for calculating the NFkB signaling in the sample according to the methods described above.
- the computerized device can include means for receiving expression level data, wherein the data is expression levels of at least six target genes derived from the sample, a means for calculating the level of a NFkB transcription factor element in the sample using a calibrated pathway model, wherein the calibrated pathway model compares the expression levels of the at least six target genes in the sample with expression levels of the at least six target genes in the model which define a level a NFkB transcription factor element; a means for calculating the NFkB cellular signaling in the sample based on the calculated levels of a NFkB transcription factor element in the sample; and a means for assigning a NFkB cellular signaling pathway activity probability or status to the calculated NFkB cellular signaling in the sample, and, optionally,
- non-transitory storage medium capable of storing instructions that are executable by a digital processing device to perform the method according to the present invention as described herein.
- the non-transitory storage medium may be a computer-readable storage medium, such as a hard drive or other magnetic storage medium, an optical disk or other optical storage medium, a random access memory (RAM), read only memory (ROM), flash memory, or other electronic storage medium, a network server, or so forth.
- the digital processing device may be a handheld device (e.g., a personal data assistant or smartphone), a notebook computer, a desktop computer, a tablet computer or device, a remote network server, or so forth.
- NFkB cellular signaling pathway activity is based on the methods described above, and administering to the subject a NFkB inhibitor if the information regarding the activity level of NFkB cellular signaling pathway is indicative of an active NFkB cellular signaling pathway.
- the disorder is one of an auto-immune and other immune disorders, cancer, bronchial asthma, heart disease, diabetes, hereditary hemorrhagic telangiectasia, Marfan syndrome, Vascular Ehlers-Danlos syndrome, Loeys-Dietz syndrome, Parkinson's disease, Chronic kidney disease, Multiple Sclerosis, fibrotic diseases such as liver, Ing, or kidney fibrosis, Dupuytren's disease, or Alzheimer's disease.
- the subject is suffering from a cancer, for example, a breast cancer, lung cancer, a colon cancer, pancreatic cancer, brain cancer, or breast cancer.
- the cancer is a breast cancer.
- kits for measuring the expression levels of at least six or more NFkB cellular signaling pathway target genes for example, seven, eight, nine, ten, eleven, twelve, or more target genes as described herein.
- the kit includes one or more components, for example probes, for example labeled probes, and/or PCR primers, for measuring the expression levels of at least six target genes, at least seven target genes, at least eight target genes, or at least nine or more target genes selected from BCL2L1, BIRC3, CCL2, CCL3, CCL4, CCL5, CCL20, CCL22, CX3CL1, CXCL1, CXCL2, CXCL3, ICAM1, IL1B, IL6, IL8, IRF1, MMP9, NFKB2, NFKBIA, NFKBIE, PTGS2, SELE, STAT5A, TNF, TNFAIP2, TNIP1, TRAF1, and VCAM1.
- the kit includes one or more components for measurng the expression levels of at least six target genes, at least seven target genes, at least eight target genes, or at least nine or more target genes selected from B1RC3, CCL2, CCL5, CCL20, CXCL1, CXCL2, CXCL3, ICAM1, IL6, IL8, IRF1, MMP9, NFKB2, NFKBIA, NFKBIE, TNF, TNFAIP2, TRAF1, and VCAM1.
- the one or more components comprise one or more components for measuring the expression levels of at least three target genes, at least four target genes, at least five target genes, or at least six or more target genes selected from CCL2, CCL5, CCL20, CXCL1, CXCL2, CXCL3, ICAM1, IL6, IL8, MMP9, NFKB2, NFKBIA, and TNFAIP2.
- the one or more components comprise one or more components for measuring the expression levels of at least three target genes, at least four target genes, at least five target genes, or at least six or more target genes selected from CCL5, CXCL2, ICAM1, IL6, IL8, NFKBIA, and TNFAIP2.
- the one or more components or means for measuring the expression levels of the particular target genes can be selected from the group consisting of: an DNA array chip, an oligonucleotide array chip, a protein array chip, an antibody, a plurality of probes, for example, labeled probes, a set of RNA reverser-transcriptase sequencing components, and/or RNA or DNA, including cDNA, amplification primers.
- the kit includes a set of labeled probes directed to a portion of an mRNA or cDNA sequence of the targeted genes as described herein.
- the kit includes a set of primers and probes directed to a portion of an mRNA or cDNA sequence of the targeted genes as described further below, wherein, for example, the set includes specific primers or probes selected from the sequences of Table 1.
- the labeled probes are contained in a standardized 96-well plate.
- the kit further includes primers or probes directed to a set of reference genes, for example, as represented in Table 2.
- reference genes can be, for example, constitutively expressed genes useful in normalizing or standardizing expression levels of the target gene expression levels described herein.
- the kit further includes a non-transitory storage medium containing instructions that are executable by a digital processing device to perform a method according to the present invention as described herein.
- the kit includes an identification code that provides access to a server or computer network for analyzing the activity level of the NFkB cellular signaling pathway based on the expression levels of the target genes and the methods described herein.
- FIG. 1 shows schematically and exemplarily canonical and alternative pathways of NFkB activation (see Dolcet X. et al, “NF-kB in development and progression of human cancer”, Virchows Archives, Vol. 446. No. 5, 2005, pages 475 to 482).
- FIG. 2 shows schematically and exemplarily a mathematical model, herein, a Bayesian network model, useful in modelling the transcriptional program of the NFkB cellular signaling pathway.
- FIG. 3 shows an exemplary flow chart for calculating the activity level of the NFkB cellular signaling pathway based on expression levels of target genes derived from a sample.
- FIG. 4 shows an exemplary flow chart for obtaining a calibrated pathway model as described herein.
- FIG. 5 shows an exemplary flow chart for calculating the Transcription Factor (TF) Element as described herein.
- FIG. 6 shows an exemplary flow chart for calculating the NFkB cellular signaling pathway activity level using discretized observables.
- FIG. 7 shows an exemplary flow chart for calculating the NFkB cellular signaling pathway activity level using continuous observables.
- FIG. 8 shows an exemplary flow chart for determining Cq values from RT-qPCR analysis of the target genes of the NFkB cellular signaling pathway.
- FIGS. 9 to 12 show training results of the exemplary Bayesian network model based on the evidence curated list of target genes ( FIG. 9 ), the 19 target genes shortlist ( FIG. 10 ), the 13 target genes shortlist ( FIG. 11 ), and the 7 target genes shortlist of the NFkB cellular signaling pathway ( FIG. 12 ) (see Tables 3 to 6), respectively.
- Legend 1—ABC DLBCL; 2—Lymphoblasioid cell line; 3—Follicular lymphoma; 4—GCB DLBCL; 5—Memory H-cells, 6—Na ⁇ ve H-cells, 7—Normal; 8—DLBCL unknown subtype
- FIG. 13 shows NFkB cellular signaling pathway activity predictions of the trained exemplary Bayesian network model using the evidence curated list of target genes (see Table 3) for diffuse large B-cell lymphoma (DLBCL) samples from GSE34171.
- FIGS. 14 to 17 show NFkB cellular signaling pathway activity predictions of the trained exemplary Bayesian network model using the evidence curated list of target genes ( FIG. 14 ), the 19 target genes shortlist ( FIG. 15 ), the 13 target genes shortlist ( FIG. 16 ), and the 7 target genes shortlist ( FIG. 17 )(see Tables 3 to 6), respectively, for normal human bronchial epithelial (NHBE) cell line samples from E-MTAB-1312, which were stimulated with different TNF ⁇ concentrations for different stimulation times.
- NHBE normal human bronchial epithelial
- FIG. 18 shows NFkB cellular signaling pathway activity predictions of the trained exemplary Bayesian network model using the evidence curated list of target genes (see Table 3) for THP-1 monocytic cells. (Legend: 1—No LPS; 2—LPS stimulation; 3—LPS stimulation coenzyme Q10)
- FIGS. 19 to 22 show NFkB cellular signaling pathway activity predictions of the trained exemplary Bayesian network model using the evidence curated list of target genes ( FIG. 19 ), the 19 target genes shortlist ( FIG. 20 ), the 13 target genes shortlist ( FIG. 21 ), and the 7 target genes shortlist ( FIG. 22 ) (see Tables 3 to 6), respectively, for colon samples from GSE4183.
- FIG. 23 shows NFkB cellular signaling pathway activity predictions of the trained exemplary Bayesian network model using the evidence curated list of target genes (see Table 3) for breast cancer cell lines from GSE10890. (Legend: 1 and 2—Unknown cellular signaling pathway driven cell lines; 3: Wnt cellular signaling pathway driven cell lines)
- FIG. 24 shows NFkB cellular signaling pathway activity predictions of the trained exemplary Bayesian network model using the evidence curated list of target genes (see Table 3) for ovarian samples from GSE20565.
- FIG. 25 shows NFkB cellular signaling pathway activity predictions of the trained exemplary Bayesian network model using the evidence curated list of target genes (see Table 3) for breast cancer samples from E-MTAB-1006.
- FIG. 26 illustrates a prognosis of glioma patients (GSE16011) depicted in a Kaplan-Meier plot, wherein the trained exemplary Bayesian network model using the evidence curated list of target genes (see Table 3) is employed.
- FIG. 27 shows training results of the exemplary linear model based on the evidence curated list of target genes (see Table 3).
- Legend 1—ABC DLBCL; 2—Lymphoblastoid cell line; 3—Follicular Lymphoma: 4—GCB DLBCL; 5—Memory B-cells: 6—Na ⁇ ve B-cells; 7—Normal: 8—DLBCL unknown subtype
- FIG. 28 shows NFkB cellular signaling pathway activity predictions of the trained exemplary linear model using the evidence curated list of target genes (see Table 3) for normal human bronchial epithelial (NHBE) cell line samples from E-MTAB-1312, which were stimulated with different TNF ⁇ concentrations for different stimulation times.
- NHBE normal human bronchial epithelial
- FIG. 29 shows NFkB cellular signaling pathway activity predictions of the trained exemplary linear model using the evidence curated list of target genes (see Table 3) for colon samples from GSE4183.
- FIG. 30 shows training results of the exemplary Bayesian network model based on the broad literature list of putative target genes of the NFkB cellular signaling pathway (see Table 7).
- Legend 1—ABC DLBCL; 2—Lymphoblastoid cell line; 3—Follicular lymphoma; 4—GCB DLBCL; 5—Memory B-cells; 6—Na ⁇ ve B-cells; 7—Normal; 8—DLBCL unknown subtype
- FIG. 31 shows NFkB cellular signaling pathway activity predictions of the trained exemplary Bayesian network model using the broad literature list of putative target genes of the NFkB cellular signaling pathway (see Table 7) for normal human bronchial epithelial (NHBE) cell line samples from E-MTAB-1312, which were stimulated with different TNF ⁇ concentrations for different stimulation times.
- NHBE normal human bronchial epithelial
- FIG. 32 shows NFkB cellular signaling pathway activity predictions of the trained exemplary Bayesian network model using the broad literature list of putative target genes of the NFkB cellular signaling pathway (see Table 7) for colon samples from GSE4183.
- NFkB cellular signaling is calculated by a) calculating an activity level of NFkB transcription factor element in a sample isolated from a subject, and wherein the activity levels of the NFkB transcription factor element in the sample is calculated by measuring the expression levels of a unique set of target genes, wherein the NFkB transcription factor element controls transcription of the target genes, calculating the levels of the NFkB transcription factor element in the sample using a calibrated pathway model, wherein the calibrated pathway model compares the expression levels of the target genes in the sample with expression levels of the target genes in the calibrated pathway model which define a level of a NFkB transcription factor element; and calculating the NFkB cellular signaling in the sample based on the calculated levels of NFkB transcription factor element in the sample.
- the unique set of target genes whose expression level is analyzed in the model includes at least six target genes, at least seven target genes, at least eight target genes, at least nine target genes, at least ten or more target genes selected from BCL2L1, BIRC3, CCL2, CCL3, CCL4, CCL5, CCL20, CCL22, CX3CL1, CXCL1, CXCL2, CXCL3, ICAM1, IL1B, IL6, IL8, IRF1, MMP9, NFKB2, NFKBIA, NFKBIE, PTGS2, SELE, STAT5A, TNF, TNFAIP2, TNIP1, TRAF1, and VCAM1.
- analyzing a specific set of target genes as described herein in the disclosed pathway model provides for an advantageously accurate NFkB cellular signaling pathway activity determination. Accordingly, such status can be used to, for example but not limited to, identify the presence or absence of disease and/or particular disease state or advancement, diagnose a specific disease or disease state, or diagnose the presence or absence of a particular disease, derive a course of treatment based on the presence or absence of NFkB signaling activity, monitor disease progression in order to, for example, adjust therapeutic protocols based on a predicted drug efficacy in light of the determined activity of the NFkB signaling pathway in the sample, or develop NFkB targeted therapeutics.
- the “level” of a TF element denotes the level of activity of the TF element regarding transcription of its target genes.
- the term “subject” or “host”, as used herein, refers to any living being.
- the subject is an animal, for example a mammal, including a human.
- the subject is a human.
- the human is suspected of having a disorder mediated or exacerbated by an active NFkB cellular signaling pathway, for example, a cancer.
- the human has or is suspected of having a breast cancer.
- sample means any biological specimen isolated from a subject. Accordingly, “sample” as used herein is contemplated to encompasses the case where e.g. a tissue and/or cells and/or a body fluid of the subject have been isolated from the subject. Performing the claimed method may include where a portion of this sample is extracted, e.g., by means of Laser Capture Microdissection (LCM), or by scraping off the cells of interest from the slide, or by fluorescence-activated cell sorting techniques. In addition, the term “sample”, as used herein, also encompasses the case where e.g.
- samples may also encompass circulating tumor cells or CTCs.
- NFkB transcriptional factor element or “NFkB TF element” or “TF element” refers to a protein complex containing at least one or, preferably, a dimer of the NFkB members (NFKB1 or p50/p105, NFKB2 or p52/p100, RELA or p65, REL, and RELB), which is capable of binding to specific DNA sequences, thereby controlling transcription of target genes.
- NFkB transcriptional factor element or NFkB TF element or “TF element” refers to a protein complex containing at least one or, preferably, a dimer of the NFkB members (NFKB1 or p50/p105, NFKB2 or p52/p100, RELA or p65, REL, and RELB), which is capable of binding to specific DNA sequences, thereby controlling transcription of target genes.
- target gene means a gene whose transcription is directly or indirectly controlled by a NFkB transcription factor element.
- the “target gene” may be a “direct target gene” and/or an “indirect target gene” (as described herein).
- target genes include at least BCL2L1, BIRC3, CCL2, CCL3, CCL4, CCL5, CCL20, CCL22, CX3CL1, CXCL1, CXCL2, CXCL3, ICAM1, IL1B, IL6, IL8, IRF1, MMP9, NFKB2, NFKBIA, NFKBIE, PTGS2, SELE, STAT5A, TNF, TNFAIP2, TNIP1, TRAF1, and VCAM1.
- the present invention includes:
- a computer implemented method for determining the activity level of a NFkB cellular signaling pathway in a subject performed by a computerized device having a processor comprising.
- the method further comprises assigning a NFkB cellular signaling pathway activity status to the calculated activity level of the NFkB cellular signaling in the sample, wherein the activity status is indicative of either an active NFkB cellular signaling pathway or a passive NFkB cellular signaling pathway.
- the method further comprises displaying the NFkB cellular signaling pathway activity status.
- the at least six target genes are selected from BIRC3, CCL2, CCL5, CCL20, CXCL1, CXCL2, CXCL3, ICAM1, IL6, IL8, IRF1, MMP9, NFKB2, NFKBIA, NFKBIE, TNF, TNFAIP2, TRAF1, and VCAM1.
- the at least six target genes comprise at least three target genes selected from CCL2, CCL5, CCL20, CXCL1, CXCL2, CXCL3, ICAM1, IL6, IL8, MMP9, NFKB2, NFKBIA, and TNFAIP2.
- the at least three target genes are selected from CCL5, CXCL2, ICAM1, IL6, IL8, NFKBIA, and TNFAIP2.
- the calibrated pathway model is a probabilistic model incorporating conditional probabilistic relationships that compare the expression levels of the at least six target genes in the sample with expression levels of the at least six target genes in the model which define a level of NFkB transcription factor element to determine the activity level of the NFkB transcription factor element in the sample.
- the probabilistic model is a Bayesian network model.
- the calibrated pathway model is a linear model incorporating relationships that compare the expression levels of the at least six target genes in the sample with expression levels of the at least six target genes in the model which define a level of NFkB transcription factor element to determine the activity level of the NFkB transcription factor element in the sample.
- a computer program product for determining the activity level of a NFkB cellular signaling pathway in a subject comprising
- the computer readable program code is executable by at least one processor to assign a NFkB cellular signaling pathway activity status to the calculated activity level of the NFkB cellular signaling in the sample, wherein the activity status is indicative of either an active NFkB cellular signaling pathway or a passive NFkB cellular signaling pathway.
- the computer readable program code is executable by at least one processor to display the NFkB signaling pathway activity status.
- the at least six target genes are selected from BIRC3, CCL2, CCL5, CCL20, CXCL1, CXCL2, CXCL3, ICAM1, IL6, IL8, IRF1, MMP9, NFKB2, NFKBIA, NFKBIE, TNF, TNFAIP2, TRAF1, and VCAM1.
- the at least six target genes comprise at least three target genes selected from CCL2, CCL5, CCL20, CXCL1, CXCL2, CXCL3, ICAM1, IL6, IL8, MMP9, NFKB2, NFKBIA, and TNFAIP2.
- the at least three target genes are selected from CCL5, CXCL2, ICAM1, IL6, IL8, NFKBIA, and TNFAIP2.
- the calibrated pathway model is a probabilistic model incorporating conditional probabilistic relationships that compare the expression levels of the at least six target genes in the sample with expression levels of the at least six target genes in the model which define a level of NFkB transcription factor element to determine the activity level of NFkB transcription factor element in the sample.
- the probabilistic model is a Bayesian network model.
- the calibrated pathway model is a linear model incorporating relationships that compare the expression levels of the at least six target genes in the sample with expression levels of the at least six target genes in the model which define a level of NFkB transcription factor element to determine the activity level of a NFkB transcription factor element in the sample.
- a method of treating a subject suffering from a disease associated with an activated NFkB cellular signaling pathway comprising:
- the at least six target genes are selected from BIRC3, CCL2, CCL5, CCL20, CXCL1, CXCL2, CXCL3, ICAM1, IL6, IL8, IRF1, MMP9, NFKB2, NFKBIA, NFKBIE, TNF, TNFAIP2, TRAF1, and VCAM1.
- the at least six target genes comprise at least three target genes selected from CCL2, CCL5, CCL20, CXCL1, CXCL2, CXCL3, ICAM1, IL6, IL8, MMP9, NFKB2, NFKBIA, and TNFAIP2.
- the at least three target genes are selected from CCL5, CXCL2, ICAM1, IL6, IL8, NFKBIA, and TNFAIP2.
- the calibrated pathway model is a probabilistic model incorporating conditional probabilistic relationships that compare the expression levels of the at least six target genes in the sample with expression levels of the at least six target genes in the model which define a level of NFkB transcription factor element to determine the activity level of the NFkB transcription factor element in the sample.
- the probabilistic model is a Bayesian network model.
- the calibrated pathway model is a linear model incorporating relationships that compare the expression levels of the at least six target genes in the sample with expression levels of the at least six target genes in the model which define a level of NFkB transcription factor element to determine the activity level of the NFkB transcription factor element in the human cancer sample.
- the NFkB inhibitor is DHMEQ, bindarit, Bortesomib or BU-32 (proteazome inhibitors), BMS-345541, or glucocorticoids.
- the disease is a cancer.
- the cancer is a benign tumor (adenoma, hyperplasia) or a solid cancer: colon, breast, a male cancer (prostate, testicular, urethra, penis), pancreatic, liver, gastrointestinal tract cancer, head and neck cancer, lung, brain (medulloblastoma, glioblastoma, glioma), bladder cancer, an endocrine tumor (thyroid, parathyroid, adrenal, neuroendocrine, MEA), a female cancer (ovarian, cervical, endometrial, vagina), kidney cancer, skin cancer (BCC, squamous skin cancer, melanoma), a soft tissue cancer (sarcoma), childhood cancer (retinoblastoma, Wilms tumor), mesothelioma, or a hematological cancer (leukemia, lymphoma), or a glioma.
- a benign tumor as adenoma, hyperplasia
- a kit for measuring expression levels of NFkB cellular signaling pathway target genes comprising:
- the at least six target genes are selected from BIRC3, CCL2, CCL5, CCL20, CXCL1, CXCL2, CXCL3, ICAM1, IL6, IL8, IRF1, MMP9, NFKB2, NFKBIA, NFKBIE, TNF, TNFAIP2, TRAF1, and VCAM1.
- the at least six target genes comprise at least three target genes selected from CCL2, CCL5, CCL20, CXCL1, CXCL2, CXCL3, ICAM1, IL6, IL8, MMP9, NFKB2, NFKBIA, and TNFAIP2.
- the at least three target genes are selected from CCL5, CXCL2, ICAM1, IL6, IL8, NFKBIA, and TNFAIP2.
- the probes are labeled.
- the set of probes includes at least one of SEQ. ID. NOS. 46, 49, 52, 55, and 58.
- the set of primers include at least one of SEQ. ID. NOS. 44 and 45, 47 and 48, 50 and 51, 53 and 54, and 56 and 57.
- a computer program product for determining the activity level of a NFkB cellular signaling pathway in the subject comprising a non-transitory computer readable storage medium having computer readable program code embodied therewith, the computer readable program code executable by at least one processor to: (i) calculate a level of NFkB transcription factor element in the sample, wherein the level of the NFkB transcription factor element in the sample is associated with NFkB cellular signaling, and wherein the level of the NFkB transcription factor element in the sample is calculated by: (1) receiving data on the expression levels of the at least six target genes derived from the sample; (2) calculating the level of the NFkB transcription factor element in the sample using a calibrated pathway model, wherein the calibrated pathway model compares the expression levels of the at least six target genes in the sample with expression levels of the at least six target genes in the model which define an activity level of NFkB transcription factor element; and, (ii) calculate the activity level of the NFkB cellular signaling pathway in
- a kit for determining the activity level of a NFkB cellular signaling pathway in a subject comprising:
- a method of determining NFkB cellular signaling in a subject comprising the steps of:
- FIG. 2 provides an exemplary flow diagram used to determine the activity level of the NFkB cellular signaling pathway based on a computer implemented mathematical model constructed of three nodes: (a) a transcription factor (TF) element (for example, but not limited to being, discretized into the states “absent” and “present” or as a continuous observable) in a first layer 1; (b) target genes TG 1 , TG 2 , TG n (for example, but not limited to being, discretized into the states “down” and “up” or as a continuous observable) in a second layer 2, and; (c) measurement nodes linked to the expression levels of the target genes in a third layer 3.
- TF transcription factor
- the expression levels of the target genes can be determined by, for example, but not limited to, microarray probesets PS 1,1 , PS 1,2 , PS 1,3 , PS 2,1 , PS n,1 , PS n,m (for example, but limited to being, discretized into the states “low” and “high” or as a continuous observable), but could also be any other gene expression measurements such as, for example, RNAseq or RT-qPCR.
- the expression of the target genes depends on the activation of the respective transcription factor element, and the measured intensities of the selected probesets depend in turn on the expression of the respective target genes.
- the model is used to calculate NFKB pathway activity by first determining probeset intensities, i.e., the expression level of the target genes, and calculating backwards in the model what the probability is that the transcription factor element must be present.
- the present invention makes it possible to determine the activity of the NFkB cellular signaling pathway by (i) determining a level of an NFkB TF element in the sample, wherein the determining is based at least in part on evaluating a mathematical model relating expression levels of one or more target genes of the NFkB cellular signaling pathway, the transcription of which is controlled by the NFkB TF element, to the level of the NFkB TF element, and by (ii) inferring the activity of the NFkB cellular signaling pathway based on the determined level of the NFkB TF element in the sample.
- a cancer e.g., a diffuse large B-cell lymphoma (DLBCL), a multiple myeloma, a cancer of another haematological origin, or a solid tumor, such as a breast, melanoma, or prostate tumor, which is at least partially driven by a deregulated NFkB cellular signaling pathway, and that are therefore likely to respond to inhibitors of the NFkB cellular signaling pathway.
- An important advantage of the present invention is that it makes it possible to determine
- FIG. 3 An example flow chart illustrating an exemplary calculation of the activity level of NFkB cellular signaling from a sample isolated from a subject is provided in FIG. 3 .
- the mRNA from a sample is isolated ( 11 ).
- the mRNA expression levels of a unique set of at least three or more NFkB target genes, as described herein, are measured ( 12 ) using methods for measuring gene expression that are known in the art.
- the calculation of transcription factor element ( 13 ) is calculated using a calibrated pathway model ( 14 ), wherein the calibrated pathway model compares the expression levels of the at least three or more target genes in the sample with expression levels of the at least three target genes in the calibrated pathway model which have been correlated with a level of a NFkB transcription factor element.
- the activity level of the NFkB cellular signaling pathway is calculated in the sample based on the calculated levels of NFkB transcription factor element in the sample ( 15 ). For example, the NFkB signaling pathway is determined to be active if the activity is above a certain threshold, and can be categorized as passive if the activity falls below a certain threshold.
- the present invention utilizes the analyses of the expression levels of unique sets of target genes.
- Particularly suitable target genes are described in the following text passages as well as the examples below (see, e.g., Tables 3 to 6 below).
- the target genes are selected from the group consisting of the target genes listed in Table 3, Table 4, Table 5, or Table 6 below.
- the unique set of target genes whose expression is analyzed in the model includes at least six target genes, for example, seven, eight, nine, ten, eleven or more, selected from BCL2L1, BIRC3, CCL2, CCL3, CCL4, CCL5, CCL20, CCL22, CX3CL1, CXCL1, CXCL2, CXCL3, ICAM1, IL1B, IL6, IL8, IRF1, MMP9, NFKB2, NFKBIA, NFKBIE, PTGS2, SELE, STAT5A, TNF, TNFAIP2, TNIP1, TRAF1, and VCAM1.
- the at least six target genes are selected from BIRC3, CCL2, CCL5, CCL20, CXCL1, CXCL2, CXCL3, ICAM1, IL6, IL8, IRF1, MMP9, NFKB2, NFKBIA, NFKBIE, TNF, TNFAIP2, TRAF1, and VCAM1.
- the at least six target genes comprise at least three target genes, for example, four, five, six or more, selected from CCL2, CCL5, CCL20, CXCL1, CXCL2, CXCL3, ICAM1, IL6, IL8, MMP9, NFKB2, NFKBIA, and TNFAIP2.
- the at least three target genes are selected from CCL5, CXCL2, ICAM1, IL6, IL8, NFKBIA, and TNFAIP2.
- Data derived from the unique set of target genes described herein is further utilized to determine the activity level of the NFkB cellular signaling pathway using the methods described herein.
- Methods for analyzing gene expression levels in isolated samples are generally known. For example, methods such as Northern blotting, the use of PCR, nested PCR, quantitative real-time PCR (qPCR), RNA-seq, or microarrays can all be used to derive gene expression level data. All methods known in the art for analyzing gene expression of the target genes are contemplated herein.
- Methods of determining the expression product of a gene using PCR based methods may be of particular use.
- the amount of each PCR product of interest is typically estimated using conventional quantitative real-time PCR (qPCR) to measure the accumulation of PCR products in real time after each cycle of amplification.
- qPCR quantitative real-time PCR
- This typically utilizes a detectible reporter such as an intercalating dye, minor groove binding dye, or fluorogenic probe whereby the application of light excites the reporter to fluoresce and the resulting fluorescence is typically detected using a CCD camera or photomultiplier detection system, such as that disclosed in U.S. Pat. No. 6,713,297 which is hereby incorporated by reference.
- the probes used in the detection of PCR products in the quantitative real-time PCR (qPCR) assay can include a fluorescent marker.
- fluorescent markers are commercially available.
- Molecular Probes, Inc. (Eugene, Oreg.) sells a wide variety of fluorescent dyes. Non-limiting examples include Cy5, Cy3, TAMRA, R6G, R110, ROX, JOE, FAM, Texas RedTM, and Oregon GreenTM.
- Additional fluorescent markers can include IDT ZEN Double-Quenched Probes with traditional 5′ hydrolysis probes in qPCR assays.
- probes can contain, for example, a 5 FAM dye with either a 3′ TAMRA Quencher, a 3′ Black Hole Quencher (BHQ, Biosearch Technologies), or an internal ZEN Quencher and 3′ Iowa Black Fluorescent Quencher (IBFQ).
- a 5 FAM dye with either a 3′ TAMRA Quencher, a 3′ Black Hole Quencher (BHQ, Biosearch Technologies), or an internal ZEN Quencher and 3′ Iowa Black Fluorescent Quencher (IBFQ).
- Fluorescent dyes useful according to the invention can be attached to oligonucleotide primers using methods well known in the art.
- one common way to add a fluorescent label to an oligonucleotide is to react an N-Hydroxysuccinimide (NHS) ester of the dye with a reactive amino group on the target.
- Nucleotides can be modified to carry a reactive amino group by, for example, inclusion of an allyl amine group on the nucleobase. Labeling via allyl amine is described, for example, in U.S. Pat. Nos. 5,476,928 and 5,958,691, which are incorporated herein by reference.
- Other means of fluorescently labeling nucleotides, oligonucleotides and polynucleotides are well known to those of skill in the art.
- fluorogenic approaches include the use of generic detection systems such as SYBR-green dye, which fluoresces when intercalated with the amplified DNA from any gene expression product as disclosed in U.S. Pat. Nos. 5,436,134 and 5,658,751 which are hereby incorporated by reference.
- RNA-seq a powerful analytical tool used for transcriptome analyses, including gene expression level difference between different physiological conditions, or changes that occur during development or over the course of disease progression.
- RNA and DNA microarray are well known in the art.
- Microarrays can be used to quantify the expression of a large number of genes simultaneously.
- the expression levels of the unique set of target genes described herein are used to calculate the level NFkB transcription factor element using a calibrated pathway model as further described below.
- the calibrated pathway model compares the expression levels of the at least three target genes in the sample with expression levels of the at least three target genes in the calibrated pathway model which define a level of NFkB transcription factor element.
- the calibrated pathway model is based on the application of a mathematical model.
- the calibrated model can be based on a probabilistic model, for example a Bayesian network, or a linear or pseudo-linear model.
- the calibrated pathway model is a probabilistic model incorporating conditional probabilistic relationships that compare the expression levels of the at least three target genes in the sample with expression levels of the at least three target genes in the calibrated pathway model which define a level NFkB transcription factor element to determine the level of the NFkB transcription factor element in the sample.
- the probabilistic model is a Bayesian network model.
- the calibrated pathway model can be a linear or pseudo-linear model.
- the linear or pseudo-linear model is a linear or pseudo-linear combination model.
- FIG. 4 A non-limiting exemplary flow chart for a calibrated pathway model is shown in FIG. 4 .
- the training data for the mRNA expression levels is collected and normalized.
- the data can be collected using, for example microarray probeset intensities ( 101 ), real-time PCR Cq values ( 102 ), raw RNAseq reads ( 103 ), or alternative measurement modalities ( 104 ) known in the art.
- the raw expression level data can then be normalized for each method, respectively, by normalization using a normalization algorithm, for example, frozen robust military analysis (fRMA) or MAS5.0 ( 111 ), normalization to average Cq of reference genes ( 112 ), normalization of reads into reads/fragments per kilobase of transcript per million mapped reads (RPKM/FPKM) ( 113 ), or normalization to w.r.t. reference genes/proteins ( 114 ).
- This normalization procedure leads to a normalized probeset intensity ( 121 ), normalized Cq values ( 122 ), normalized RPKM/FPKM ( 123 ), or normalized measurement ( 124 ) for each method, respectively, which indicate target gene expression levels within the training samples.
- a training sample ID or IDs ( 131 ) is obtained and the training data of these specific samples is obtained from one of the methods for determining gene expression ( 132 ).
- the final gene expression results from the training sample are output as training data ( 133 ).
- All of the data from various training samples are incorporated to calibrate the model (including for example, thresholds, CPTs, for example in the case of the probabilistic or Bayesian network, weights, for example, in the case of the linear or pseudo-linear model, etc) ( 144 ).
- the pathway's target genes and measurement nodes ( 141 ) are used to generate the model structure for example, as described in FIG. 2 ( 142 ).
- the resulting model structure ( 143 ) of the pathway is then incorporated with the training data ( 133 ) to calibrate the model ( 144 ), wherein the gene expression levels of the target genes is indicative of the transcription factor element activity.
- a calibrated pathway model ( 145 ) is calculated which assigns the NFkB cellular signaling pathway activity level for a subsequently examined sample of interest, for example from a subject with a cancer, based on the target gene expression levels in the training samples.
- a non-limiting exemplary flow chart for calculating the Transcription Factor Element activity level is provided in FIG. 5 .
- the expression level data (test data) ( 163 ) from a sample isolated from a subject is input into the calibrated pathway model ( 145 ).
- the mathematical model may be a probabilistic model, for example a Bayesian network model, a linear model, or pseudo-linear model.
- the mathematical model may be a probabilistic model, for example a Bayesian network model, based at least in part on conditional probabilities relating the NFkB TF element and expression levels of the at least six target genes of the NFkB cellular signaling pathway measured in the sample of the subject, or the mathematical model may be based at least in part on one or more linear combination(s) of expression levels of the at least six target genes of the NFkB cellular signaling pathway measured in the sample of the subject.
- the determining of the activity of the NFkB cellular signaling pathway may be performed as disclosed in the published international patent application WO 2013/011479 A2 (“Assessment of cellular signaling pathway activity using probabilistic modeling of target gene expression”), and incorporated herein by reference.
- the data is entered into a Bayesian network (BN) inference engine call (for example, a BNT toolbox) ( 154 ).
- BN Bayesian network
- the mathematical model may be a linear model.
- a linear model can be used as described in the published international patent application WO 2014/102668 A2 (“Assessment of cellular signaling pathway activity using linear combination(s) of target gene expressions”), the contents of which are herewith incorporated in their entirety. Further details regarding the calculating/determining of cellular signaling pathway activity using mathematical modeling of target gene expression can also be found in Verhaegh W. et al., “Selection of personalized patient therapy through the use of knowledge-based computational models that identify tumor-driving signal transduction pathways”, Cancer Research, Vol. 74, No. 11, 2014, pages 2936 to 2945.
- the data is entered into a calculated weighted linear combination score (w/c) ( 151 ). This leads to a set of values for the calculated weighted linear combination score ( 152 ). From these weighted linear combination scores, the transcription factor (TF) node's weighted linear combination score ( 153 ) is determined and establishes the TF's element activity level ( 157 ).
- w/c calculated weighted linear combination score
- FIG. 6 A non-limiting exemplary flow chart for calculating the activity level of a NFkB cellular signaling pathway as a discretized observable is shown in FIG. 6 .
- the test sample is isolated and given a test sample ID ( 161 ).
- the test data for the mRNA expression levels is collected and normalized ( 162 ).
- the test data can be collected using the same methods as discussed for the training samples in FIG. 5 , using microarray probeset intensities ( 101 ), real-time PCR Cq values ( 102 ), raw RNAseq reads ( 103 ), or an alternative measurement modalities ( 104 ).
- the raw expression level data can then be normalized for each method, respectively, by normalization using an algorithm, for example fRMA or MAS5.0 ( 111 ), normalization to average Cq of reference genes ( 112 ), normalization of reads into RPKM/FPKM ( 113 ), and normalization to w.r.t. reference genes/proteins ( 114 ).
- This normalization procedure leads to a normalized probeset intensity ( 121 ), normalized Cq values ( 122 ), normalized RPKM/FPKM ( 123 ), or normalized measurement ( 124 ) for each method, respectively.
- the resulting test data ( 163 ) is analyzed in a thresholding step ( 164 ) based on the calibrated pathway model ( 145 ), resulting in the thresholded test data ( 165 ).
- every expression above a certain threshold is, for example, given a value of 1 and values below the threshold are given a value of 0, or in an alternative embodiment, the probability mass above the threshold as described herein is used as a thresholded value.
- this value represents the TF's element activity level ( 157 ), which is then used to calculate the pathway's activity level ( 171 ).
- the final output gives the pathway's activity level ( 172 ) in the test sample being examined from the subject.
- test sample is isolated and given a test sample ID ( 161 ).
- test sample ID 161
- test data for the mRNA expression levels is collected and normalized ( 162 ).
- the test data can be collected using the same methods as discussed for the training samples in FIG. 5 , using microarray probeset intensities ( 101 ), real-time PCR Cq values ( 102 ), raw RNAseq reads ( 103 ), or an alternative measurement modalities ( 104 ).
- the raw expression level data can then be normalized for each method, respectively, by normalization using an algorithm, for example fRMA ( 111 ), normalization to average Cq of reference genes ( 112 ), normalization of reads into RPKM/FPKM ( 113 ), and normalization to w.r.t. reference genes/proteins ( 114 ).
- This normalization procedure leads to a normalized probeset intensity ( 121 ), normalized Cq values ( 122 ), normalized RPKM/FPKM ( 123 ), or normalized measurement ( 124 ) for each method, respectively.
- the resulting test data ( 163 ) is analyzed in the calibrated pathway model ( 145 ).
- the expression levels are converted to values between 0 and 1 using a sigmoid function as described in further detail below.
- the transcription factor element calculation as described herein is used to interpret the test data in combination with the calibrated pathway model, the resulting value represents the TF's element activity level ( 157 ), which is then used to calculate the pathway's activity level ( 171 ).
- the final output then gives the pathway's activity level ( 172 ) in the test sample.
- kits comprising primer and probe sets for the analyses of the expression levels of unique sets of target genes (see Target Gene discussion above).
- Particularly suitable oligo sequences for use as primers and probes for inclusion in a kit are described in the following text passages (see, e.g., Tables 1 and 2).
- kits for measuring the expression levels of at least six or more NFkB cellular signaling pathway target genes for example, seven, eight, nine, ten, eleven, twelve, or more target genes as described herein.
- the kit includes one or more components, for example probes, for example labeled probes, and/or PCR primers, for measuring the expression levels of at least six target genes, at least seven target genes, at least eight target genes, or at least nine or more target genes selected from BCL2L1, BIRC3, CCL2, CCL3, CCL4, CCL5, CCL20, CCL22, CX3CL1, CXCL1, CXCL2, CXCL3, ICAM1, IL1B, IL6, IL8, IRF1, MMP9, NFKB2, NFKBIA, NFKBIE, PTGS2, SELE, STAT5A, TNF, TNFAIP2, TNIP1, TRAF1, and VCAM1.
- the kit includes one or more components for measuring the expression levels of at least six target genes, at least seven target genes, at least eight target genes, or at least nine or more target genes selected from BIRC3, CCL2, CCL5, CCL20, CXCL1, CXCL2, CXCL3, ICAM1, IL6, IL8, IRF1, MMP9, NFKB2, NFKBIA, NFKBIE, TNF, TNFAIP2, TRAF1, and VCAM1.
- the one or more components comprise one or more components for measuring the expression levels of at least three target genes, at least four target genes, at least five target genes, or at least six or more target genes selected from CCL2, CCL5, CCL20, CXCL1, CXCL2, CXCL3, ICAM1, IL6, 1L8, MMP9, NFKB2, NFKBIA, and TNFAIP2.
- the one or more components comprise one or more components for measuring the expression levels of at least three target genes, at least four target genes, at least five target genes, or at least six or more target genes selected from CCL5, CXCL2, ICAM1, IL6, IL8, NFKBIA, and TNFAIP2.
- the kit includes one or more components for measuring the expression levels of at least six or more NFkB cellular signaling pathway target genes, wherein the at least six or more target genes are selected from BCL2L1, BIRC3, CCL2, CCL3, CCL4, CCL5, CCL20, CCL22, CX3CL1, CXCL1, CXCL2, CXCL3, ICAM1, IL1B, IL6, IN8, IRF1, MMP9, NFKB2, NFKBIA, NFKBIE, PTGS2, SELE, STAT5A, TNF, TNFAIP2, TNIP1, TRAF1, and VCAM1, and the one or more components is selected from the PCR primers and probes listed in Table 1.
- the at least six or more target genes are selected from BIRC3, CCL2, CCL5, CCL20, CXCL1, CXCL2, CXCL3, ICAM1, IL6, IL8, IRF1, MMP9, NFKB2, NFKBIA, NFKBIE, TNF, TNFAIP2, TRAF1, and VCAM1, and the one or more components is selected from the PCR primers and probes listed in Table 1.
- the at least six target genes comprise at least three target genes selected from CCL2, CCL5, CCL20, CXCL1, CXCL2, CXCL3, ICAM1, IL6, IL8, MMP9, NFKB2, NFKBIA, and TNFAIP2, and the one or more components is selected from the PCR primers and probes listed in Table 1.
- the at least three target genes are selected from CCL5, CXCL2, ICAM1, IL6, IL8, NFKBIA, and TNFAIP2, and the one or more components is selected from the PCR primers and probes listed in Table 1.
- the PCR primers for each gene are designated Forward (For) and Reverse (Rev) and the probes for detection of the PCR products for each gene are labeled Probe.
- the probes listed in Table 2 are labeled with a 5′ FAM dye with an internal ZEN Quencher and 3′ Iowa Black Fluorescent Quencher (IBFQ).
- the kit includes one or more components for measuring the expression levels of control genes, wherein the one or more components includes a PCR primer set and probe for at least one of the control genes listed in Table 2.
- the PCR primers for each gene are designated Forward (F) and Reverse (R) and the probes for detection of the PCR products for each gene are labeled Probe (P or FAM).
- the probes listed in Table 2 are labeled with a 5′ FAM dye with an internal ZEN Quencher and 3′ Iowa Black Fluorescent Quencher (IBFQ).
- the one or more components for measuring the expression levels of the particular target genes can be selected from the group consisting of: an DNA array chip, an oligonucleotide array chip, a protein array chip, an antibody, a plurality of probes, for example, labeled probes, a set of RNA reverser-transcriptase sequencing components, and/or RNA or DNA, including cDNA, amplification primers.
- the kit includes a set of labeled probes directed to the cDNA sequence of the targeted genes as described herein contained in a standardized 96-well plate.
- the kit further includes a non-transitory storage medium containing instructions that are executable by a digital processing device to perform a method according to the present invention as described herein.
- a kit for measuring expression levels of at least six target genes of the NFkB cellular signaling pathway in a sample of a subject comprises:
- one or more components for determining the expression levels of the at least six target genes of the NFkB cellular signaling pathway
- the one or more components are, for example, selected from the group consisting of: an DNA array chip, an oligonucleotide array chip, a protein array chip, an antibody, a plurality of probes, RNA sequencing and a set of primers, and
- the at least six target genes of the NFkB cellular signaling pathway are selected from the group consisting of: BCL2L1, BIRC3, CCL2, CCL3, CCL4, CCL5, CCL20, CCL22, CX3CL1, CXCL1, CXCL2, CXCL3, ICAM1, IL1B, IL6, IL8, IRF1, MMP9, NFKB2, NFKBIA, NFKBIE, PTGS2, SELE, STAT5A, TNF, TNFAIP2, TNIP1, TRAF1, and VCAM1.
- the at least six target genes are selected from BIRC3, CCL2, CCL5, CCL20, CXCL1, CXCL2, CXCL3, ICAM1, IL6, IL8, IRF1, MMP9, NFKB2, NFKBIA, NFKBIE, TNF, TNFAIP2, TRAF1, and VCAM1.
- the at least six target genes comprise at least three target genes selected from CCL2, CCL5, CCL20, CXCL1, CXCL2, CXCL3, ICAM1, IL6, IL8, MMP9, NFKB2, NFKBIA, and TNFAIP2.
- the at least three target genes are selected from CCL5, CXCL2, ICAM1, IL6, IL8, NFKBIA, and TNFAIP2.
- the PCR cycling is performed in a microtiter or multi-well plate format.
- This format which uses plates comprising multiple reaction wells, not only increases the throughput of the assay process, but is also well adapted for automated sampling steps due to the modular nature of the plates and the uniform grid layout of the wells on the plates.
- Common microtiter plate designs useful according to the invention have, for example 12, 24, 48, 96, 384, or more wells, although any number of wells that physically fit on the plate and accommodate the desired reaction volume (usually 10-100 ⁇ l) can be used according to the invention.
- the 96 or 384 well plate format can be utilized.
- the method is performed in a 96 well plate format.
- the method is performed in a 384 well plate format.
- the kit comprises an apparatus comprising a digital processor.
- the kit comprises a non-transitory storage medium storing instructions that are executable by a digital processing device.
- the kit comprises a computer program comprising program code means for causing a digital processing device to perform the methods described herein.
- the kit contains one or more components that are for example selected from the group consisting of: a DNA array chip, an oligonucleotide array chip, a protein array chip, an antibody, a plurality of probes, RNA sequencing and a set of primers. In one embodiment, the kit contains a plurality of probes. In one embodiment, the kit contains a set of primers. In one embodiment, the kit contains a 6, 12, 24, 48, 96, or 384-well PCR plate. In one embodiment, the kit includes a 96 well PCR plate. In one embodiment, the kit includes a 384 well PCR plate.
- a kit for measuring the expression levels of NFkB cellular signaling target genes comprises a 96-well plate and a set of labeled probes for detecting expression of a set of NFkB cellular signaling pathway genes comprising BCL2L1, BIRC3, CCL2, CCL3, CCL4, CCL5, CCL20, CCL22, CX3CL1, CXCL1, CXCL2, CXCL3, ICAM1, IL1B, IL6, IL8, IRF1, MMP9, NFKB2, NFKBIA, NFKBIE, PTGS2, SELE, STAT5A, TNF, TNFAIP2, TNIP1, TRAF1, and VCAM1.
- a kit for measuring the expression levels of NFkB cellular signaling target genes comprises a 96-well plate and a set of labeled probes for detecting expression of a set of NFkB cellular signaling pathway genes comprising BIRC3, CCL2, CCL5, CCL20, CXCL1, CXCL2, CXCL3, ICAM1, IL6, IL8, IRF1, MMP9, NFKB2, NFKBIA, NFKBIE, TNF, TNFAIP2, TRAF1, and VCAM1.
- a kit for measuring the expression levels of NFkB cellular signaling target genes comprises a 96-well plate and a set of labeled probes for detecting expression of a set of NFkB cellular signaling pathway genes comprising CCL2, CCL5, CCL20, CXCL1, CXCL2, CXCL3, ICAM1, IL6, 118, MMP9, NFKB2, NFKBIA, and TNFAIP2.
- a kit for measuring the expression levels of NFkB cellular signaling target genes comprises a 96-well plate and a set of labeled probes for detecting expression of a set of NFkB cellular signaling pathway genes comprising CCL5, CXCL2, ICAM1, IL6, IL8, NFKBIA, and TNFAIP2.
- the kit further comprises an instruction manual measuring the expression levels of NFkB cellular signaling target genes.
- the kit further comprises an access code to access a computer program code for calculating the NFkB cellular signaling pathway activity in the sample.
- the kit further comprises an access code to access a website for calculating the NFkB cellular signaling pathway activity in the sample according to the methods described above.
- samples are received and registered in a laboratory.
- Samples can include, for example, Formalin-Fixed, Paraffin-Embedded (FFPE) samples ( 181 ) or fresh frozen (FF) samples ( 180 ).
- FF samples can be directly lysed ( 183 ).
- the paraffin can be removed with a heated incubation step upon addition of Proteinase K ( 182 ).
- Cells are then lysed ( 183 ), which destroys the cell and nuclear membranes which makes the nucleic acid (NA) available for further processing.
- FFPE Paraffin-Embedded
- FF samples can be directly lysed ( 183 ).
- the paraffin can be removed with a heated incubation step upon addition of Proteinase K ( 182 ).
- Cells are then lysed ( 183 ), which destroys the cell and nuclear membranes which makes the nucleic acid (NA) available for further processing.
- NA nucleic acid
- the nucleic acid is bound to a solid phase ( 184 ) which could for example, be beads or a filter.
- the nucleic acid is then washed with washing buffers to remove all the cell debris which is present after lysis ( 185 ).
- the clean nucleic acid is then detached from the solid phase with an elution buffer ( 186 ).
- the DNA is removed by DNAse treatment to ensure that only RNA is present in the sample ( 187 ).
- the nucleic acid sample can then be directly used in the RT-qPCR sample mix ( 188 ).
- the RT-qPCR sample mixes contains the RNA sample, the RT enzyme to prepare cDNA from the RNA sample and a PCR enzyme to amplify the cDNA, a buffer solution to ensure functioning of the enzymes and can potentially contain molecular grade water to set a fixed volume of concentration.
- the sample mix can then be added to a multiwell plate (i.e., 96 well or 384 well plate) which contains dried RT-qPCR assays ( 189 ).
- the RT-qPCR can then be run in a PCR machine according to a specified protocol ( 190 ).
- An example PCR protocol includes i) 30 minutes at 50° C.; ii) 5 minutes at 95° C.; iii) 15 seconds at 95° C.; iv) 45 seconds at 60° C.; v) 50 cycles repeating steps iii and iv.
- the Cq values are then determined with the raw data by using the second derivative method ( 191 ).
- the Cq values are exported for analysis ( 192 ).
- the calculation of NFkB signaling in the sample is performed on a computerized device having a processor capable of executing a readable program code for calculating the NFkB cellular signaling pathway activity in the sample according to the methods described above.
- the computerized device can include means for receiving expression level data, wherein the data is expression levels of at least three target genes derived from the sample, a means for calculating the level of NFkB transcription factor element in the sample using a calibrated pathway model, wherein the calibrated pathway model compares the expression levels of the at least three target genes in the sample with expression levels of the at least three target genes in the model which have been correlated with a level NFkB transcription factor element; a means for calculating the NFkB cellular signaling in the sample based on the calculated levels of NFkB transcription factor element in the sample; and a means for assigning a NFkB cellular signaling pathway activity probability or status to the calculated NFkB cellular signaling in the sample, and a means for displaying the NFkB signaling pathway activity probability or status.
- a non-transitory storage medium stores instructions that are executable by a digital processing device to perform a method according to the present invention as described herein.
- the non-transitory storage medium may be a computer-readable storage medium, such as a hard drive or other magnetic storage medium, an optical disk or other optical storage medium, a random access memory (RAM), read only memory (ROM), flash memory, or other electronic storage medium, a network server, or so forth.
- the digital processing device may be a handheld device (e.g., a personal data assistant or smartphone), a notebook computer, a desktop computer, a tablet computer or device, a remote network server, or so forth.
- an apparatus comprises a digital processor configured to perform a method according to the present invention as described herein.
- a computer program comprises program code means for causing a digital processing device to perform a method according to the present invention as described herein.
- the digital processing device may be a handheld device (e.g., a personal data assistant or smartphone), a notebook computer, a desktop computer, a tablet computer or device, a remote network server, or so forth.
- a computer program or system for predicting the activity status of a NFkB transcription factor element in a human cancer sample that includes a means for receiving data corresponding to the expression level of one or more NFkB target genes in a sample from a host.
- a means for receiving data can include, for example, a processor, a central processing unit, a circuit, a computer, or the data can be received through a website.
- a computer program or system for predicting the activity status of a NFkB transcription factor element in a human cancer sample that includes a means for displaying the NFkB pathway signaling status in a sample from a host.
- a means for displaying can include a computer monitor, a visual display, a paper print out, a liquid crystal display (LCD), a cathode ray tube (CRT), a graphical keyboard, a character recognizer, a plasma display, an organic light-emitting diode (OLED) display, or a light emitting diode (LED) display, or a physical print out.
- LCD liquid crystal display
- CRT cathode ray tube
- a graphical keyboard graphical keyboard
- a character recognizer a plasma display
- OLED organic light-emitting diode
- LED light emitting diode
- a signal represents a determined activity of a NFkB cellular signaling pathway in a subject, wherein the determined activity results from performing a method according to the present invention as described herein.
- the signal can be a digital signal or it can be an analog signal.
- a computer implemented method for predicting the activity status of a NFkB signaling pathway in a human cancer sample performed by a computerized device having a processor comprising: a) calculating an activity level of a NFkB transcription factor element in a human cancer sample, wherein the level of the NFkB transcription factor element in the human cancer sample is associated with the activity of a NFkB cellular signaling pathway, and wherein the level of the NFkB transcription factor element in the human cancer sample is calculated by i) receiving data on the expression levels of at least six target genes derived from the human cancer sample, wherein the NFkB transcription factor controls transcription of the at least six target genes, and wherein the at least six target genes are selected from BCL2L1, BIRC3, CCL2, CCL3, CCL4, CCL5, CCL20, CCL22, CX3CL1, CXCL1, CXCL2, CXCL3, ICAM1, IL1B, IL6, 118, IRF1, MMP9,
- a system for determining the activity level of a NFkB cellular signaling pathway in a subject comprising a) a processor capable of calculating an activity level of NFkB transcription factor element in a sample derived from the subject; b) a means for receiving data, wherein the data is an expression level of at least six target genes derived from the sample; c) a means for calculating the level of the NFkB transcription factor element in the sample using a calibrated pathway model, wherein the calibrated pathway model compares the expression levels of the at least six target genes in the sample with expression levels of the at least six target genes in the model which define an activity level of NFkB transcription factor element; d) a means for calculating the activity level of the NFkB cellular signaling pathway in the sample based on the calculated activity level of NFkB transcription factor element in the sample; a means for assigning a NFkB cellular signaling pathway activity status to the calculated activity level of the NFkB cellular signal
- the methods and apparatuses of the present invention can be utilized to assess NFkB cellular signaling pathway activity in a subject, for example a subject suspected of having, or having, a disease or disorder wherein the status of the NFkB signaling pathway is probative, either wholly or partially, of disease presence or progression.
- a method of treating a subject comprising receiving information regarding the activity status of a NFkB cellular signaling pathway derived from a sample isolated from the subject using the methods described herein and administering to the subject a NFkB inhibitor if the information regarding the level of NFkB cellular signaling pathway is indicative of an active NFkB signaling pathway.
- the NFkB cellular signaling pathway activity indication is set at a cutoff value of odds of the NFkB cellular signaling pathway being active of 10:1, 5:1, 4:1, 2:1, 1:1, 1:2, 1:4, 1:5, 1:10.
- NFkB inhibitors are known and include, but are not limited to, DHMEQ, bindarit, Bortesomib or BU-32 (proteazome inhibitors), BMS-345541, or glucocorticoids.
- the subject is suffering from, or suspected to have a benign or malignant tumor: a cancer or sarcoma or hematological malignancy, or brain tumor, for example, but not limited to, a primary tumor or a metastatic tumor, a solid tumor, for example, melanoma, lung cancer (including lung adenocarcinoma, basal cell carcinoma, squamous cell carcinoma, large cell carcinoma, bronchioloalveolar carcinoma, bronchogenic carcinoma, non-small-cell carcinoma, small cell carcinoma, mesothelioma); breast cancer (including ductal carcinoma, lobular carcinoma, inflammatory breast cancer, clear cell carcinoma, mucinous carcinoma, serosal cavities breast carcinoma); colorectal cancer (colon cancer, rectal cancer, colorectal adenocarcinoma): anal cancer; pancreatic cancer (including pancreatic adenocarcinoma, islet cell carcinoma, neuroendocrine tumors); prostate cancer; prostate adenocarcinoma;
- the methods described herein are useful for treating a host suffering from a lymphoma or lymphocytic or myelocytic proliferation disorder or abnormality.
- a host suffering from a lymphoma or lymphocytic or myelocytic proliferation disorder or abnormality For example, the subject suffering from a Hodgkin Lymphoma of a Non-Hodgkin Lymphoma.
- the subject can be suffering from a Non-Hodgkin Lymphoma such as, but not limited to: an AIDS-Related Lymphoma; Anaplastic Large-Cell Lymphoma; Angioimmunoblastic Lymphoma; Blastic NK-Cell Lymphoma; Burkitt's Lymphoma; Burkitt-like Lymphoma (Small Non-Cleaved Cell Lymphoma); Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Cutaneous T-Cell Lymphoma; Diffuse Large B-Cell Lymphoma; Enteropathy-Type T-Cell Lymphoma; Follicular Lymphoma; Hepatosplenic Gamma-Delta T-Cell Lymphoma; Lymphoblastic Lymphoma; Mantle Cell Lymphoma; Marginal Zone Lymphoma; Nasal T-Cell Lymphoma; Pediatric Lymphoma; Peripheral
- the subject may be suffering from a Hodgkin Lymphoma, such as, but not limited to: Nodular Sclerosis Classical Hodgkin's Lymphoma (CHL); Mixed Cellularity CHL; Lymphocyte-depletion CHL; Lymphocyte-rich CHL; Lymphocyte Predominant Hodgkin Lymphoma; or Nodular Lymphocyte Predominant HL.
- CHL Nodular Sclerosis Classical Hodgkin's Lymphoma
- Mixed Cellularity CHL Lymphocyte-depletion CHL
- Lymphocyte-rich CHL Lymphocyte Predominant Hodgkin Lymphoma
- Lymphocyte Predominant Hodgkin Lymphoma or Nodular Lymphocyte Predominant HL.
- the subject may be suffering from a specific T-cell, a B-cell, or a NK-cell based lymphoma, proliferative disorder, or abnormality.
- the subject can be suffering from a specific T-cell or NK-cell lymphoma, for example, but not limited to: Peripheral T-cell lymphoma, for example, peripheral T-cell lymphoma and peripheral T-cell lymphoma not otherwise specified (PTCL-NOS); anaplastic large cell lymphoma, for example anaplastic lymphoma kinase (ALK) positive, ALK negative anaplastic large cell lymphoma, or primary cutaneous anaplastic large cell lymphoma; angioimmunoblastic lymphoma; cutaneous T-cell lymphoma, for example mycosis fungoides, Sfzary syndrome, primary cutaneous anaplastic large cell lymphoma, primary cutaneous CD30+ T-cell lymphoproliferative disorder; primary cutaneous aggressive epiderm
- ALK
- T-cell Leukemia/Lymphoma ATLL
- Blastic NK-cell Lymphoma Enteropathy-type T-cell lymphoma
- Hematosplenic gamma-delta T-cell Lymphoma Lymphoblastic Lymphoma
- Nasal NK/T-cell Lymphomas Treatment-related T-cell lymphomas; for example lymphomas that appear after solid organ or bone marrow transplantation
- T-cell prolymphocytic leukemia T-cell large granular lymphocytic leukemia
- Chronic lymphoproliferative disorder of NK-cells Aggressive NK cell leukemia
- Systemic EBV+ T-cell lymphoproliferative disease of childhood associated with chronic active EBV infection
- Hydroa vacciniforme-like lymphoma Childhood T-cell leukemia/lymphoma
- Enteropathy-associated T-cell lymphoma Enteropathy-associated T-cell lymphoma
- the subject may be suffering from a specific B-cell lymphoma or proliferative disorder such as, but not limited to: multiple myeloma; Diffuse large B cell lymphoma; Follicular lymphoma; Mucosa-Associated Lymphatic Tissue lymphoma (MALT); Small cell lymphocytic lymphoma; Mantle cell lymphoma (MCL); Burkitt lymphoma; Mediastinal large B cell lymphoma; Waldenström macroglobulinemia; Nodal marginal zone B cell lymphoma (NMZL); Splenic marginal zone lymphoma (SMZL); Intravascular large B-cell lymphoma; Primary effusion lymphoma; or Lymphomatoid granulomatosis; Chronic lymphocytic leukemia/small lymphocytic lymphoma; B-cell prolymphocytic leukemia; Hairy cell leukemia; Splenic lymphoma/leukemia, unclassifiable; Sp
- the subject is suffering from a leukemia.
- the subject may be suffering from an acute or chronic leukemia of a lymphocytic or myelogenous origin, such as, but not limited to: Acute lymphoblastic leukemia (ALL); Acute myelogenous leukemia (AML); Chronic lymphocytic leukemia (CLL); Chronic myelogenous leukemia (CMI): juvenile myelomonocytic leukemia (JMML); hairy cell leukemia (HCL); acute promyelocytic leukemia (a subtype of AML); T-cell prolymphocytic leukemia (TPLL); large granular lymphocytic leukemia; or Adult T-cell chronic leukemia; large granular lymphocytic leukemia (LGL).
- ALL Acute lymphoblastic leukemia
- AML Acute myelogenous leukemia
- CLL Chronic lymphocytic leukemia
- CLI chronic myelogenous le
- the patient suffers from an acute myelogenous leukemia, for example an undifferentiated AML (M0); myeloblastic leukemia (M1; with/without minimal cell maturation); myeloblastic leukemia (M2; with cell maturation); promyelocytic leukemia (M3 or M3 variant [M3V]); myelomonocytic leukemia (M4 or M4 variant with eosinophilia [M4E]); monocytic leukemia (M5); erythroleukemia (M6): or megakaryoblastic leukemia (M7).
- M0 undifferentiated AML
- M1 myeloblastic leukemia
- M2 myeloblastic leukemia
- M3V promyelocytic leukemia
- M4 or M4 variant with eosinophilia [M4E] myelomonocytic leukemia
- M5 monocytic leukemia
- M6
- the subject is suffering, or suspected to be suffering from, a breast cancer, lung cancer, a colon cancer, pancreatic cancer, or brain cancer. In a particular embodiment, the subject is suffering from, or suspected to be suffering from, a breast cancer.
- the sample(s) to be used in accordance with the present invention can be an extracted sample, that is, a sample that has been extracted from the subject.
- the sample include, but are not limited to, a tissue, cells, blood and/or a body fluid of a subject. It can be, e.g., a sample obtained from a cancer lesion, or from a lesion suspected for cancer, or from a metastatic tumor, or from a body cavity in which fluid is present which is contaminated with cancer cells (e.g., pleural or abdominal cavity or bladder cavity), or from other body fluids containing cancer cells, and so forth, for example, via a biopsy procedure or other sample extraction procedure.
- a biopsy procedure e.g., pleural or abdominal cavity or bladder cavity
- the cells of which a sample is extracted may also be tumorous cells from hematologic malignancies (such as leukemia or lymphoma).
- the cell sample may also be circulating tumor cells, that is, tumor cells that have entered the bloodstream and may be extracted using suitable isolation techniques, e.g., apheresis or conventional venous blood withdrawal.
- suitable isolation techniques e.g., apheresis or conventional venous blood withdrawal.
- a body fluid of which a sample is extracted may be urine, gastrointestinal contents, or an extravasate.
- the methods and apparatuses described herein are used to identify an active NFkB cellular signaling pathway in a subject suffering from a cancer, and administering to the subject an anti-cancer agent, for example a NFkB inhibitor, selected from, but not limited to, DHMEQ, bindarit, Bortesomib or BU-32 (proteazome inhibitors), BMS-345541, or glucocorticoids.
- an anti-cancer agent for example a NFkB inhibitor, selected from, but not limited to, DHMEQ, bindarit, Bortesomib or BU-32 (proteazome inhibitors), BMS-345541, or glucocorticoids.
- a NFkB inhibitor selected from, but not limited to, DHMEQ, bindarit, Bortesomib or BU-32 (proteazome inhibitors), BMS-345541, or glucocorticoids.
- determining whether the NFkB cellular signaling pathway is operating abnormally in the subject based on the calculated activity of the NFkB cellular signaling pathway in the subject.
- abnormally denotes disease-promoting activity of the NFkB cellular signaling pathway, for example, a tumor-promoting activity.
- the present invention also relates to a method (as described herein) further comprising:
- a drug for example a NFkB inhibitor, for the subject that corrects for abnormal operation of the NFkB cellular signaling pathway
- the recommending is performed if the NFkB cellular signaling pathway is determined to be operating abnormally in the subject based on the calculated/determined activity of the NFkB cellular signaling pathway.
- the present invention also relates to a method (as described herein), wherein the calculating/determining comprises:
- calculating the activity of the NFkB cellular signaling pathway in the subject based at least on expression levels of two, three or more target genes of a set of target genes of the NFkB cellular signaling pathway measured in the sample of the subject.
- prognosis based on the determined activity of the NFkB cellular signaling pathway in the subject
- the following examples merely illustrate exemplary methods and selected aspects in connection therewith.
- the teaching provided therein may be used for constructing several tests and/or kits, e.g., to detect, predict and/or diagnose the abnormal activity of the NFKB cellular signaling pathways.
- drug prescription can advantageously be guided, drug response prediction and monitoring of drug efficacy (and/or adverse effects) can be made, drug resistance can be predicted and monitored, e.g., to select subsequent test(s) to be performed (like a companion diagnostic test).
- drug resistance can be predicted and monitored, e.g., to select subsequent test(s) to be performed (like a companion diagnostic test).
- the following examples are not to be construed as limiting the scope of the present invention.
- a probabilistic model e.g., a Bayesian network model, and incorporating conditional probabilistic relationships between expression levels of at least six target genes of a cellular signaling pathway, herein, the NFkB cellular signaling pathway, and the level of a transcription factor (TF) element, herein, the NFkB TF element, the TF element controlling transcription of the at least six target genes of the cellular signaling pathway
- a model may be used to determine the activity of the cellular signaling pathway with a high degree of accuracy.
- the probabilistic model can be readily updated to incorporate additional knowledge obtained by later clinical studies, by adjusting the conditional probabilities and/or adding new nodes to the model to represent additional information sources. In this way, the probabilistic model can be updated as appropriate to embody the most recent medical knowledge.
- the activity of a cellular signaling pathway may be determined by constructing and evaluating a linear or (pseudo-)linear model incorporating relationships between expression levels of at least six target genes of the cellular signaling pathway and the level of a transcription factor (TF) element, herein, the NFkB TF element, the TF element controlling transcription of the at least six target genes of the cellular signaling pathway, the model being based at least in part on one or more linear combination(s) of expression levels of the at least six target genes.
- TF transcription factor
- the expression levels of the at least six target genes may, for example, be measurements of the level of mRNA, which can be the result of, e.g., (RT)-PCR and microarray techniques using probes associated with the target genes mRNA sequences, and of RNA-sequencing.
- the expression levels of the at least six target genes can be measured by protein levels, e.g., the concentrations and/or activity of the protein(s) encoded by the target genes.
- the aforementioned expression levels may optionally be converted in many ways that might or might not suit the application better.
- four different transformations of the expression levels e.g., microarray-based mRNA levels, may be:
- One of the simplest linear models that can be constructed is a model having a node representing the transcription factor (TF) element, herein, the NFkB TF element, in a first layer and weighted nodes representing direct measurements of the target genes expression levels, e.g., by one probeset that is particularly highly correlated with the particular target gene, e.g., in microarray or (q)PCR experiments, in a second layer.
- the weights can be based either on calculations from a training data set or based on expert knowledge. This approach of using, in the case where possibly multiple expression levels are measured per target gene (e.g., in the case of microarray experiments, where one target gene can be measured with multiple probesets), only one expression level per target gene is particularly simple.
- a specific way of selecting the one expression level that is used for a particular target gene is to use the expression level from the probeset that is able to separate active and passive samples of a training data set the best.
- One method to determine this probeset is to perform a statistical test, e.g., the t-test, and select the probeset with the lowest p-value.
- the training data set's expression levels of the probeset with the lowest p-value is by definition the probeset with the least likely probability that the expression levels of the (known) active and passive samples overlap.
- Another selection method is based on odds-ratios.
- one or more expression level(s) are provided for each of the at least six target genes and the one or more linear combination(s) comprise a linear combination including for each of the at least six target genes a weighted term, each weighted term being based on only one expression level of the one or more expression level(s) provided for the respective target gene. If the only one expression level is chosen per target gene as described above, the model may be called a “most discriminant probesets” model.
- the “most discriminant probesets” model it is possible, in the case where possibly multiple expression levels are measured per target gene, to make use of all the expression levels that are provided per target gene.
- one or more expression level(s) are provided for each of the at least six target genes and the one or more linear combination(s) comprise a linear combination of all expression levels of the one or more expression level(s) provided for the at least six target genes.
- each of the one or more expression level(s) provided for the respective target gene may be weighted in the linear combination by its own (individual) weight.
- This variant may be called an “all probesets” model. It has an advantage of being relatively simple while making use of all the provided expression levels.
- the determined TF element level can be thresholded in order to infer the activity of the cellular signaling pathway, herein, the NFkB cellular signaling pathway.
- An exemplary method to calculate such an appropriate threshold is by comparing the determined TF element levels w/c of training samples known to have a passive cellular signaling pathway and training samples with an active cellular signaling pathway. A method that does so and also takes into account the variance in these groups is given by using a threshold
- ⁇ and ⁇ are the standard deviation and the mean of the determined TF element levels wlc for the training samples.
- a pseudocount may be added to the calculated variances based on the average of the variances of the two groups:
- ⁇ is the variance of the determined TF element levels wlc of the groups
- x is a positive pseudocount, e.g., 1 or 10
- nact and tgxrs are the number of active and passive samples, respectively
- the standard deviation a can next be obtained by taking the square root of the variance v.
- the threshold can be subtracted from the determined TF element levels wlc for ease of interpretation, resulting in a cellular signaling pathway's activity score in which negative values correspond to a passive cellular signaling pathway and positive values correspond to an active cellular signaling pathway.
- a “two-layer” may also be used in an example.
- a summary value is calculated for every target gene using a linear combination based on the measured intensities of its associated probesets (“first (bottom) layer”).
- the calculated summary value is subsequently combined with the summary values of the other target genes of the cellular signaling pathway using a further linear combination (“second (upper) layer”).
- second (upper) layer the weights can be either learned from a training data set or based on expert knowledge or a combination thereof.
- one or more expression level(s) are provided for each of the at least six target genes and the one or more linear combination(s) comprise for each of the at least six target genes a first linear combination of all expression levels of the one or more expression level(s) provided for the respective target gene (“first (bottom) layer”).
- the model is further based at least in part on a further linear combination including for each of the at least six target genes a weighted term, each weighted term being based on the first linear combination for the respective target gene (“second (upper) layer”).
- the calculation of the summary values can, in an exemplary version of the “two-layer” model, include defining a threshold for each target gene using the training data and subtracting the threshold from the calculated linear combination, yielding the target gene summary.
- the threshold may be chosen such that a negative target gene summary value corresponds to a down-regulated target gene and that a positive target gene summary value corresponds to an up-regulated target gene.
- the target gene summary values are transformed using, e.g., one of the above-described transformations (fuzzy, discrete, etc.), before they are combined in the “second (upper) layer”.
- the determined TF element level can be thresholded in order to infer the activity of the cellular signaling pathway, as described above.
- a transcription factor is a protein complex (i.e., a combination of proteins bound together in a specific structure) or a protein that is able to regulate transcription from target genes by binding to specific DNA sequences, thereby controlling the transcription of genetic information from DNA to mRNA.
- the mRNA directly produced due to this action of the TF complex is herein referred to as a “direct target gene” (of the transcription factor).
- Cellular signaling pathway activation may also result in more secondary gene transcription, referred to as “indirect target genes”.
- the MEDLINE database of the National Institute of Health accessible at “www.ncbi.nlm.nih.gov/pubmed” and herein further referred to as “Pubmed” was employed to generate a lists of target genes. Furthermore, three additional lists of target genes were selected based on the probative nature of their expression.
- Specific cellular signaling pathway mRNA target genes were selected from the scientific literature, by using a ranking system in which scientific evidence for a specific target gene was given a rating, depending on the type of scientific experiments in which the evidence was accumulated. While some experimental evidence is merely suggestive of a gene being a direct target gene, like for example an mRNA increasing as detected by means of an increasing intensity of a probeset on a microarray of a cell line in which it is known that the NFkB cellular signaling pathway is active, other evidence can be very strong, like the combination of an identified NFkB cellular signaling pathway TF binding site and retrieval of this site in a chromatin immunoprecipitation (ChIP) assay after stimulation of the specific cellular signaling pathway in the cell and increase in mRNA after specific stimulation of the cellular signaling pathway in a cell line.
- ChoIP chromatin immunoprecipitation
- ranking in another way can be used to identify the target genes that are most likely to be direct target genes, by giving a higher number of points to the technology that provides most evidence for an in vivo direct target gene. In the list above, this would mean 8 points for experimental approach 1), 7 for 2), and going down to 1 point for experimental approach 8). Such a list may be called a “general list of target genes”.
- a list of these target genes may be called an “evidence curated list of target genes”.
- Such an evidence curated list of target genes has been used to construct computational models of the NFkB cellular signaling pathway that can be applied to samples coming from different tissue sources.
- a scoring function was introduced that gave a point for each type of experimental evidence, such as ChIP, EMSA, differential expression, knock down/out, luciferase gene reporter assay, sequence analysis, that was reported in a publication.
- the same experimental evidence is sometimes mentioned in multiple publications resulting in a corresponding number of points, e.g., two publications mentioning a ChIP finding results in twice the score that is given for a single ChIP finding.
- Further analysis was performed to allow only for genes that had diverse types of experimental evidence and not only one type of experimental evidence, e.g., differential expression.
- an evidence score was calculated for all putative NFkB target genes and all putative NFkB target genes with an evidence score of 5 or more were selected (shown in Table 3). The cut-off level of 5 was chosen heuristically as providing strong enough evidence.
- a further selection of the evidence curated list of target genes was made by the inventors.
- the target genes of the evidence curated list that were proven to be more probative in determining the activity of the NFkB cellular signaling pathway from the training samples were selected.
- the selection was performed using a combination of the literature evidence score and training results using two different datasets. Three rankings were made based on the evidence score, highest score ranked first and every point less result in a lower rank, and the “soft” odds ratios of all included probesets (see Table 3) calculated as described herein using the GSE12195 and E-MTAB-1312 datasets.
- a preferred set of target genes having at least one associated probeset with an average ranking of less than or equal to 20 was selected for the “19 target genes shortlist”.
- a more preferred set of target genes having an average ranking of less than or equal to 15 was selected for the “13 target genes shortlist”.
- a most preferred set of target genes having an average ranking of less than or equal to 12 were selected for the “7 target genes shortlist”.
- the 19 target genes shortlist, the 13 target genes shortlist, and the 7 target genes shortlist are shown in Tables 4 to 6, respectively.
- Target gene Score Probeset Target gene Score Probeset BCL2L1 5 206665_s_at IL6 10 205207_at 212312_at IL8 12 202859_x_at 215037_s_at 211506_s_at 231228_at IRF1 5 202531_at BIRC3 11 210538_s_at 238725_at 230499_at MMP9 6 203936_s_at CCL2 8 216598_s_at NFKB2 14 207535_s_at CCL3 8 205114_s_at 209636_at CCL4 5 204103_at 211524_at CCL5 11 1405_i_at NFKBIA 10 201502_s_at 1555759_a_at NFKBIE 7 20
- the model Before the mathematical model can be used to infer the activity of the cellular signaling pathway, herein, the NFkB cellular signaling pathway, the model must be appropriately trained.
- the mathematical model is a probabilistic model, e.g., a Bayesian network model, based at least in part on conditional probabilities relating the NFkB TF element and expression levels of the at least six target genes of the NFkB cellular signaling pathway measured in a sample
- the training may preferably be performed as described in detail in the published international patent application WO 2013/011479 A2 (“Assessment of cellular signaling pathway activity using probabilistic modeling of target gene expression”).
- the training may preferably be performed as described in detail in the published international patent application WO 2014/102668 A2 (“Assessment of cellular signaling pathway activity using linear combination(s) of target gene expressions”).
- an exemplary Bayesian network model as shown in FIG. 2 was first used to model the transcriptional program of the NFkB cellular signaling pathway in a simple manner.
- the model consists of three types of nodes: (a) a transcription factor (TF) element (with states “absent” and “present”) in a first layer 1; (b) target genes TG 1 , TG 2 , TG n (with states “down” and “up”) in a second layer 2, and; (c) measurement nodes linked to the expression levels of the target genes in a third layer 3
- TF transcription factor
- target genes TG 1 , TG 2 , TG n with states “down” and “up” in a second layer 2
- measurement nodes linked to the expression levels of the target genes in a third layer 3 can be microarray probesets PS 1,1 , PS 1,2 , PS 1,3 , PS 2,1 , PS n,1 , PS n,m (with states “low” and “high”), as preferably used
- a suitable implementation of the mathematical model, herein, the exemplary Bayesian network model is based on microarray data.
- the model describes (i) how the expression levels of the target genes depend on the activation of the TF element, and (ii) how probeset intensities, in turn, depend on the expression levels of the respective target genes.
- probeset intensities may be taken from fRMA pre-processed Affymetrix HG-U133Plus2.0 microarrays, which are widely available from the Gene Expression Omnibus (GEO, www.ncbi.nlm.nih.gov/geo) and ArrayExpress (www.ebi.ac.uk/arrayexpress).
- the exemplary Bayesian network model is a simplification of the biology of a cellular signaling pathway, herein, the NFkB cellular signaling pathway, and as biological measurements are typically noisy, a probabilistic approach was opted for, i.e., the relationships between (i) the TF element and the target genes, and (ii) the target genes and their respective probesets, are described in probabilistic terms. Furthermore, it was assumed that the activity of the oncogenic cellular signaling pathway which drives tumor growth is not transiently and dynamically altered, but long term or even irreversibly altered. Therefore the exemplary Bayesian network model was developed for interpretation of a static cellular condition. For this reason complex dynamic cellular signaling pathway features were not incorporated into the model.
- the model can be used on microarray data of a new sample by entering the probeset measurements as observations in the third layer 3, and inferring backwards in the model what the probability must have been for the TF element to be “present”.
- “present” is considered to be the phenomenon that the TF element is bound to the DNA and is controlling transcription of the cellular signaling pathway's target genes, and “absent” the case that the TF element is not controlling transcription.
- This probability is hence the primary read-out that may be used to indicate activity of the cellular signaling pathway, herein, the NFkB cellular signaling pathway, which can next be translated into the odds of the cellular signaling pathway being active by taking the ratio of the probability of it being active vs. it being inactive (i.e., the odds are given by p/(1 ⁇ p), where p is the predicted probability of the cellular signaling pathway being active).
- the probabilistic relations have been made quantitative to allow for a quantitative probabilistic reasoning.
- the parameters describing the probabilistic relationships between (i) the TF element and the target genes have been carefully hand-picked. If the TF element is “absent”, it is most likely that the target gene is “down”, hence a probability of 0.95 is chosen for this, and a probability of 0.05 is chosen for the target gene being “up”. The latter (non-zero) probability is to account for the (rare) possibility that the target gene is regulated by other factors or that it is accidentally observed as being “up” (e.g. because of measurement noise).
- the target gene is considered “up”, and with a probability of 0.30 the target gene is considered “down”.
- the latter values are chosen this way, because there can be several causes why a target gene is not highly expressed even though the TF element is present, e.g., because the gene's promoter region is methylated.
- the probabilities are chosen in a similar way, but reflecting the down-regulation upon presence of the TF element.
- the parameters describing the relationships between (ii) the target genes and their respective probesets have been calibrated on experimental data.
- microarray data was used from patients samples which are known to have an active NFkB cellular signaling pathway whereas normal, healthy samples from the same dataset were used as inactive NFkB cellular signaling pathway samples, but this could also be performed using cell line experiments or other patient samples with known cellular signaling pathway activity status.
- the resulting conditional probability tables are given by:
- the variables AL i,j , AH i,j , PL i,j , and PH i,j indicate the number of calibration samples with an “absent” (A) or “present” (P) transcription complex that have a “low” (L) or “high” (H) probeset intensity, respectively. Dummy counts have been added to avoid extreme probabilities of 0 and 1.
- a threshold t i,j was used, below which the observation is called “low”, and above which it is called “high”.
- This threshold has been chosen to be the (weighted) median intensity of the probeset in the used calibration dataset. Due to the noisiness of microarray data, a fuzzy method was used when comparing an observed probeset intensity to its threshold, by assuming a normal distribution with a standard deviation of 0.25 (on a log 2 scale) around the reported intensity, and determining the probability mass below and above the threshold.
- an odds ratio calculated in combination with a pseudo-count and using probability masses instead of deterministic measurement values is called a “soft” odds ratio.
- the weights indicating the sign and magnitude of the correlation between the nodes and a threshold to call whether a node is either “absent” or “present” would need to be determined before the model could be used to infer cellular signaling pathway activity in a test sample.
- a first method boils down to a ternary system, in which each weight is an element of the set ⁇ 1, 0, 1 ⁇ . If this is put in a biological context, the ⁇ 1 and 1 correspond to target genes or probesets that are down- and up-regulated in case of cellular signaling pathway activity, respectively. In case a probeset or target gene cannot be statistically proven to be either up- or down-regulated, it receives a weight of 0.
- a left-sided and right-sided, two sample t-test of the expression levels of the active cellular signaling pathway samples versus the expression levels of the samples with a passive cellular signaling pathway can be used to determine whether a probe or gene is up- or down-regulated given the used training data.
- the target gene or probeset is determined to be up-regulated.
- the target gene or probeset is determined to be down-regulated upon activation of the cellular signaling pathway.
- the weight of the target gene or probeset can be defined to be 0.
- a second method is based on the logarithm (e.g., base e) of the odds ratio.
- the odds ratio for each target gene or probeset is calculated based on the number of positive and negative training samples for which the probeset/target gene level is above and below a corresponding threshold, e.g., the (weighted) median of all training samples.
- a pseudo-count can be added to circumvent divisions by zero.
- a further refinement is to count the samples above/below the threshold in a somewhat more probabilistic manner, by assuming that the probeset/target gene levels are e.g. normally distributed around its observed value with a certain specified standard deviation (e.g., 0.25 on a 2-log scale), and counting the probability mass above and below the threshold.
- FIGS. 9 to 12 show training results of the exemplary Bayesian network model based on the evidence curated list of target genes, the 19 target genes shortlist, the 13 target genes shortlist, and the 7 target genes shortlist of the NFkB cellular signaling pathway (see Tables 3 to 6), respectively.
- the vertical axis indicates the odds that the TF element is “present” resp. “absent”, which corresponds to the NFkB cellular signaling pathway being active resp. inactive, wherein values above the horizontal axis correspond to the TF element being more likely “present”/active and values below the horizontal axis indicate that the odds that the TF element is “absent”/inactive are larger than the odds that it is “present”/active.
- the activated B-cell (ABC) group (group 1), which is known to have an active NFkB cellular signaling pathway, was assigned an active NFkB label, whereas the group encompassing the normal samples (group 7) known to have a passive NFkB cellular signaling pathway were labeled NFkB inactive.
- a perfect score for the training samples was achieved for all four models with all ABC being active and all normal samples having a passive NFkB cellular signaling pathway. Unsurprisingly, the probabilities of the training samples become less extreme as fewer target genes are included in the model.
- the healthy, unstimulated memory B-cells and na ⁇ ve B-cells were correctly predicted to have a passive NFkB cellular signaling pathway with a few exceptions in the 19 and 7 target genes models.
- the vast majority of the other lymphoma samples in the germinal center B-cell (GCB) (group 4), follicular lymphoma (group 3), lymphoblastoid cell line (group 2) and all but one in further diffuse large B-cell lymphoma (DLBCL) samples with unknown subtype (group 8) were predicted to have an active NFkB cellular signaling pathway in all four models.
- NFkB For GCB, it is known that a high fraction of tumors (>50%) have a mutation in at least one NFkB regulatory genes, which is likely to correlate with aberrant NFkB activity (see, e.g., Campagno M. et al., “Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma”, Nature, Vol. 459, No. 7247, 2009, pages 717 to 721). Also other studies pointed out that constitutive NFkB activation is a common feature for most haematological malignacies (see, e.g., Keutgens A.
- validation results of the trained exemplary Bayesian network model using the evidence curated list of target genes, the 19 target genes shortlist, the 13 target genes shortlist, and the 7 target genes shortlist, respectively, are shown in FIGS. 13 to 25 .
- FIG. 13 shows NFkB cellular signaling pathway activity predictions of the trained exemplary Bayesian network model using the evidence curated list of target genes (see Table 3) for diffuse large B-cell lymphoma (DLBCL) samples from GSE34171.
- the vertical axis indicates the odds that the TF element is “present” resp. “absent”, which corresponds to the NFkB cellular signaling pathway being active resp. inactive, wherein values above the horizontal axis correspond to the TF element being more likely “present”/active and values below the horizontal axis indicate that the odds that the TF element is “absent”/inactive are larger than the odds that it is “present”/active. All samples were predicted to have an active NFkB cellular signaling pathway.
- DLBCL lymphomas are known to have an aberrant NFkB activity (see, e.g., Keutgens A. et al., “Deregulated NF-kB activity in haematological malignancies”, Biochemical Pharmacology, Vol. 72, No. 9, 2006, pages 1069 to 1080).
- FIGS. 14 to 17 show NFkB cellular signaling pathway activity predictions of the trained exemplary Bayesian network model using the evidence curated list of target genes, the 19 target genes shortlist, the 13 target genes shortlist, and the 7 target genes shortlist (see Tables 3 to 6), respectively, for normal human bronchial epithelial (NHBE) cell line samples from E-MTAB-1312, which were stimulated with different TNF ⁇ concentrations for different stimulation times.
- the vertical axis indicates the odds that the TF element is “present” resp. “absent”, which corresponds to the NFkB cellular signaling pathway being active resp.
- FIG. 18 shows NFkB cellular signaling pathway activity predictions of the trained exemplary Bayesian network model using the evidence curated list of target genes (see Table 3) for THP-1 monocytic cells.
- the vertical axis indicates the odds that the TF element is “present” resp. “absent”, which corresponds to the NFkB cellular signaling pathway being active resp. inactive, wherein values above the horizontal axis correspond to the TF element being more likely “present”/active and values below the horizontal axis indicate that the odds that the TF element is “absent”/inactive are larger than the odds that it is “present”/active.
- the THP-1 cell line is known to express NFkB cellular signaling pathway activity upon stimulation with an immune response inducing agents such as lipopolysaccharide (LPS).
- the NFkB cellular signaling pathway activity in these monocytic cells is predicted to be low without LPS stimulation (group 1).
- the NFkB cellular signaling pathway activity is amplified (group 2).
- Coenzyme Q10 has been reported to have anti-inflammatory effects, however, the effect on NFkB cellular signaling pathway activity was reported to be limited (see, e.g., C. Schmelzer and F.
- FIGS. 19 to 22 show NFkB cellular signaling pathway activity predictions of the trained exemplary Bayesian network model using the evidence curated list of target genes, the 19 target genes shortlist, the 13 target genes shortlist, and the 7 target genes shortlist (see Tables 3 to 6), respectively, for colon samples from GSE4183.
- the vertical axis indicates the odds that the TF element is “present” resp. “absent”, which corresponds to the NFkB cellular signaling pathway being active resp. inactive, wherein values above the horizontal axis correspond to the TF element being more likely “present”/active and values below the horizontal axis indicate that the odds that the TF element is “absent”/inactive are larger than the odds that it is “present”/active.
- the NFkB cellular signaling pathway is more active in the more progressed colorectal carcinomas (CRC) (group 4) compared to the benign adenomas (group 2), which might be a result of progression of the tumor into a more malignant tumor resulting in more mutations, inflammation as a result of the progressed tumor, or infiltration of white blood cells as a result of the immune response to the later stage cancers.
- CRC colorectal carcinomas
- group 2 the NFkB cellular signaling pathway activity score might be used to predict the likelihood an adenoma will progress to become malignant.
- FIG. 23 shows NFkB cellular signaling pathway activity predictions of the trained exemplary Bayesian network model using the evidence curated list of target genes (see Table 3) for breast cancer cell lines from GSE10890.
- the vertical axis indicates the odds that the TF element is “present” resp. “absent”, which corresponds to the NFkB cellular signaling pathway being active resp. inactive, wherein values above the horizontal axis correspond to the TF element being more likely “present”/active and values below the horizontal axis indicate that the odds that the TF element is “absent”/inactive are larger than the odds that it is “present”/active.
- FIG. 24 shows NFkB cellular signaling pathway activity predictions of the trained exemplary Bayesian network model using the evidence curated list of target genes (see Table 3) for ovarian samples from GSE20565.
- the vertical axis indicates the odds that the TF element is “present” resp. “absent”, which corresponds to the NFkB cellular signaling pathway being active resp. inactive, wherein values above the horizontal axis correspond to the TF element being more likely “present”/active and values below the horizontal axis indicate that the odds that the TF element is “absent”/inactive are larger than the odds that it is “present”/active.
- Chronic inflammation has been associated with tumor initiation and progression. Recurring inflammatory processes in the ovaries due to ovulation, endometriosis and pelvic infections have been shown to be correlated with NFkB cellular signaling pathway active tumors (see, e.g., Alvero A. B., “Recent insights into the role of NF-kappaB in ovarian carcinogenesis”, Genome Medicine, Vol. 2, No. 8, 2010, page 56, and Guo R. X.
- FIG. 25 shows NFkB cellular signaling pathway activity predictions of the trained exemplary Bayesian network model using the evidence curated list of target genes (see Table 3) for breast cancer samples from E-MTAB-1006.
- the vertical axis indicates the odds that the TF element is “present” resp. “absent”, which corresponds to the NFkB cellular signaling pathway being active resp. inactive, wherein values above the horizontal axis correspond to the TF element being more likely “present”/active and values below the horizontal axis indicate that the odds that the TF element is “absent”/inactive are larger than the odds that it is “present”/active.
- the average of the logit NFkB odds ratio is significantly higher in the inflammatory breast cancer samples (IBC) (group 1) compared to the non-inflamed breast cancers (nIBC) (group 2), p ⁇ 0.01 (two-sample t-test). This is likely a reflection of the high inflammatory state in IBC compared to the nIBC.
- the predicted NFkB cellular signaling pathway activities in both groups largely overlap making a clear classification of IBC and nIBC based on NFkB cellular signaling pathway activity in the model's current state cumbersome.
- FIG. 26 illustrates overall survival of 272 glioma patients (GSE16011) depicted in a Kaplan-Meier plot, wherein the trained exemplary Bayesian network model using the evidence curated list of target genes (see Table 3) is employed.
- the vertical axis indicates the overall survival as a fraction of the patient group and the horizontal axis indicates time in years.
- the plot indicates that an active NFkB TF element (indicated by the steeper slope of the curve) is a prognostic marker for worse overall survival.
- the patient group with a predicted active NFkB TF element consisted of 113 patients (solid line), whereas the patient group with a predicted passive NFkB TF element consisted of 159 patients (dotted line)).
- an exemplary linear model was used to model the transcriptional program of the NFkB cellular signaling pathway in a simple manner.
- the structure of the model corresponded to the one shown in FIG. 3 of the published international patent application WO 2014/102668 A2 (“Assessment of cellular signaling pathway activity using linear combination(s) of target gene expressions”).
- the exemplary linear model consisted of a TF node, a layer of target gene expression and a layer of mRNA expression levels and made use of continuous expression data, all target genes from the evidence curated list of target genes (see Table 3) with all probesets included and without the use of a pseudocount.
- the training of the model was performed with the same active and passive training samples from GSE12195 and encompassed calculating the weights of the connections between the target genes expression levels, here represented by means of probeset intensities, and the target genes nodes using the “soft log odds”-method as described herein and subsequently the activity score of the transcription factor complex was calculated by summation of the calculated target genes expression score multiplied by either 1 or ⁇ 1 for up-regulated or down-regulated target genes, respectively.
- FIG. 27 shows training results of the exemplary linear model based on the evidence curated list of target genes (see Table 3).
- the vertical axis indicates the activity score, wherein positive values correspond to an active NFkB cellular signaling pathway and negative values correspond to a passive NFkB cellular signaling pathway.
- the activated B-cell (ABC) DLBCL (group 1) and normal (group 7) were used as active and passive training samples, respectively. All training samples were correctly classified; all ABC samples were predicted to have an active NFkB cellular signaling pathway, whereas the normal samples were predicted to have a passive NFkB cellular signaling pathway.
- FIG. 28 shows NFkB cellular signaling pathway activity predictions of the trained exemplary linear model using the evidence curated list of target genes (see Table 3) for normal human bronchial epithelial (NHBE) cell line samples from E-MTAB-1312, which were stimulated with different TNF ⁇ concentrations for different stimulation times.
- the vertical axis indicates the activity score, wherein positive values correspond to an active NFkB cellular signaling pathway and negative values correspond to a passive NFkB cellular signaling pathway.
- NHBE cell lines were unstimulated or stimulated with different TNF ⁇ concentrations for different timings. All unstimulated healthy cells (groups 1 to 4) are correctly predicted to have a passive NFkB cellular signaling pathway.
- a stimulation with all TNF ⁇ concentrations for only 0.5 h is predicted to be too short for the NFkB cellular signaling pathway to become active (groups 5, 9, and 13), similar to the Bayesian network model using the evidence curated list of target genes ( FIG. 8 ), whereas stimulation times of 2 to 24 hours resulted in an active NFkB cellular signaling pathway.
- the lowering of the NFkB cellular signaling pathway activity after 4 hours observed with the Bayesian network model especially using the evidence curated list of target genes (see FIG. 8 ) could not be reproduced with the trained exemplary linear model.
- FIG. 29 shows NFkB cellular signaling pathway activity predictions of the trained exemplary linear model using the evidence curated list of target genes (see Table 3) for colon samples from GSE4183.
- the vertical axis indicates the activity score, wherein positive values correspond to an active NFkB cellular signaling pathway and negative values correspond to a passive NFkB cellular signaling pathway.
- Most normal samples (group 1) were predicted to have a low NFkB cellular signaling pathway activity, albeit at higher activity scores than expected from other datasets.
- RNA/DNA sequences of the disclosed target genes can then be used to determine which primers and probes to select on such a platform.
- Validation of such a dedicated assay can be done by using the microarray-based mathematical model as a reference model, and verifying whether the developed assay gives similar results on a set of validation samples. Next to a dedicated assay, this can also be done to build and calibrate similar mathematical models using mRNA-sequencing data as input measurements.
- the set of target genes which are found to best indicate specific cellular signaling pathway activity can be translated into a multiplex quantitative PCR assay to be performed on a sample and/or a computer to interpret the expression measurements and/or to infer the activity of the NFkB cellular signaling pathway.
- a test e.g., FDA-approved or a CLIA waived test in a central service lab
- development of a standardized test kit is required, which needs to be clinically validated in clinical trials to obtain regulatory approval.
- the present invention relates to a method comprising inferring activity of an NFkB cellular signaling pathway based at least on expression levels of one or more target genes of the NFkB cellular signaling pathway measured in a sample.
- the present invention further relates to an apparatus comprising a digital processor configured to perform such a method, a non-transitory storage medium storing instructions that are executable by a digital processing device to perform such a method, and a computer program comprising program code means for causing a digital processing device to perform such a method.
- the method may be used, for instance, in diagnosing an (abnormal) activity of the NFkB cellular signaling pathway, in prognosis based on the inferred activity of the NFkB cellular signaling pathway, in the enrollment in a clinical trial based on the inferred activity of the NFkB cellular signaling pathway, in the selection of subsequent test(s) to be performed, in the selection of companion diagnostics tests, in clinical decision support systems, or the like
- WO 2013/011479 A2 (“Assessment of cellular signaling pathway activity using probabilistic modeling of target gene expression”)
- WO 2014/102668 A2 “Assessment of cellular signaling pathway activity using linear combination(s) of target gene expressions”
- Verhaegh W. et al. “Selection of personalized patient therapy through the use of knowledge-based computational models that identify tumor-driving signal transduction pathways”, Cancer Research, Vol. 74, No. 11,
- the alternative list is a compilation of genes attributed to responding to activity of the NFkB cellular signaling pathway provided within Thomson-Reuters's Metacore (last accessed Sep. 6, 2013).
- This database was queried for genes that are transcriptionally regulated directly downstream of the family of NFkB proteins, i.e., NFKB1 or p50/p105, NFKB2 or p52/p100, RELA or p65, REL, and RELB. This query resulted in 343 unique genes. A further selection was made based on the number of publication references supporting the attributed transcriptional regulation of the respective gene by the NFkB family. Genes that had ten or more references were selected for the broad literature list. In other words, no manual curation of the references and no calculation of an evidence score based on the experimental evidence was performed. This procedure resulted in 32 genes, see Table 7. The expression of the genes was measured by 56 probesets on the Affymetrix HG-U133Plus2.0 microarray platform which were selected using the Bioconductor plugin of R and one manually added probeset for DEFB4A, see Table 7.
- an exemplary Bayesian network model was constructed using the procedure as explained herein.
- the conditional probability tables of the edges between probesets and their respective putative target genes of this model including the broad literature list were trained using fRMA processed data from GSE12195.
- the training results are depicted in FIG. 24 .
- the vertical axis indicates the odds that the TF element is “present” resp. “absent”, which corresponds to the NFkB cellular signaling pathway being active resp.
- the healthy, unstimulated memory B-cells and na ⁇ ve B-cells are correctly predicted a lack of NFkB cellular signaling pathway activity.
- Legend 1—ABC DLBCL; 2—Lymphoblastoid cell line; 3—Follicular lymphoma; 4—GCB DLBCL; 5—Memory B-cells: 6—Na ⁇ ve B-cells: 7—Normal; 8—DLBCL unknown subtype).
- FIG. 31 shows NFkB cellular signaling pathway activity predictions of the trained exemplary Bayesian network model using the broad literature list of putative target genes of the NFkB cellular signaling pathway (see Table 7) for normal human bronchial epithelial (NHBE) cell line samples from E-MTAB-1312, which were stimulated with different TNF ⁇ concentrations for different stimulation times.
- the vertical axis indicates the odds that the TF element is “present” resp. “absent”, which corresponds to the NFkB cellular signaling pathway being active resp.
- a stimulation with all TNF ⁇ concentrations for only 0.5 h is predicted by the broad literature Bayesian model also to be too short for the NFkB cellular signaling pathway to become active (groups 5, 9, and 13), whereas stimulation times of 2-24 hours resulted in an active NFkB cellular signaling pathway (groups 5 to 8, 9 to 12 and 13 to 15).
- the lowering of the NFkB cellular signaling pathway activity after 4 hours observed with the Bayesian network model using the evidence curated list of target genes (see FIG. 8 ) was not reproduced with the trained broad literature Bayesian network model.
- FIG. 32 shows NFkB cellular signaling pathway activity predictions of the trained exemplary Bayesian network model using the broad literature list of putative target genes of the NFkB cellular signaling pathway (see Table 7) for colon samples from GSE4183.
- the vertical axis indicates the odds that the TF element is “present” resp. “absent”, which corresponds to the NFkB cellular signaling pathway being active resp. inactive, wherein values above the horizontal axis correspond to the TF element being more likely “present”/active and values below the horizontal axis indicate that the odds that the TF element is “absent”/inactive are larger than the odds that it is “present”/active.
- NFkB target gene sets in combination with the mathematical models described herein for determining the activity level of NFkB cellular signaling pathway in a sample produces a more robust, precise, and accurate activity status determination than the use of a broader literature list, despite the fact that the number of target genes is larger.
- a useful determination of NFkB cellular signaling pathway activity is provided that can be further used in treatment or prognostic modalities as described herein.
Abstract
A bioinformatics process which provides an improved means to detect NFkB cellular signaling pathway in a subject, such as a human, based on the expression levels of at least six unique target genes of the NFkB cellular signaling pathway measured in a sample. The invention includes an apparatus comprising a digital processor configured to perform such a method, a non-transitory storage medium storing instructions that are executable by a digital processing device to perform such a method, and a computer program comprising program code means for causing a digital processing device to perform such a method. Kits are also provided for measuring expression levels of unique sets of NFkB cellular signaling pathway target genes.
Description
- This application claims the benefit of European Patent Application No. EP15181029.8, filed Aug. 14, 2015, and is a continuation of U.S. patent Ser. No. 15/235,478, filed Aug. 12, 2016 (now issued as U.S. Pat. No. 11,450,409, the entirety of the specification and claims thereof are hereby incorporated by reference for all purposes.
- The instant application contains a Sequence Listing which has been submitted electronically in XML format and is hereby incorporated by reference in its entirety. Said XML copy, created on May 4, 2023, is named AOMB-005-US1_Sequence_Listing.xml and is 185,636 bytes in size.
- The present invention is in the field of systems biology, bioinformatics, genomic mathematical processing and proteomic mathematical processing. In particular, the invention includes a systems-based mathematical process for determining the activity of a NFkB cellular signaling pathway in a subject based on expression levels of a unique set of selected target genes in a subject. The invention further provides an apparatus that includes a digital processor configured to perform such a method, a non-transitory storage medium storing instructions that are executable by a digital processing device to perform such a method, and a computer program comprising a program code means for causing a digital processing device to perform such a method. The present invention also includes kits for the determination of expression levels of the unique combinations of target genes.
- As knowledge of tumors including cancers evolve, it becomes more clear that they are extraordinarily heterogeneous and multifactorial. Tumors and cancers have a wide range of genotypes and phenotypes, they are influenced by their individualized cell receptors (or lack thereof), micro-environment, extracellular matrix, tumor vascularization, neighboring immune cells, and accumulations of mutations, with differing capacities for proliferation, migration, stem cell properties and invasion. This scope of heterogeneity exists even among same classes of tumors. See generally: Nature Insight: Tumor Heterogeneity (entire issue of articles), 19 Sep. 2013 (Vol. 501, Issue 7467); Zellmer and Zhang, “Evolving concepts of tumor heterogeneity”, Cell and Bioscience 2014, 4:69.
- Traditionally, physicians have treated tumors, including cancers, as the same within class type (including within receptor type) without taking into account the enormous fundamental individualized nature of the diseased tissue. Patients have been treated with available chemotherapeutic agents based on class and receptor type, and if they do not respond, they are treated with an alternative therapeutic, if it exists. This is an empirical approach to medicine.
- There has been a growing trend toward taking into account the heterogeneity of tumors at a more fundamental level as a means to create individualized therapies, however, this trend is still in its formative stages. What is desperately needed are approaches to obtain more metadata about the tumor to inform therapeutic treatment in a manner that allows the prescription of approaches more closely tailored to the individual tumor, and perhaps more importantly, avoiding therapies destined to fail and waste valuable time, which can be life-determinative.
- A number of companies and institutions are active in the area of classical, and some more advanced, genetic testing, diagnostics, and predictions for the development of human diseases, including, for example: Affymetrix, Inc.; Bio-Rad, Inc; Roche Diagnostics; Genomic Health, Inc.; Regents of the University of California; Illumina; Fluidigm Corporation; Sequenom, Inc.; High Throughput Genomics; NanoString Technologies; Thermo Fisher; Danaher; Becton, Dickinson and Company; bioMerieux; Johnson & Johnson, Myriad Genetics, and Hologic.
- Several companies have developed technology or products directed to gene expression profiling and disease classification. For example, Genomic Health, Inc. is the assignee of numerous patents pertaining to gene expression profiling, for example: U.S. Pat. Nos. 7,081,340; 8,808,994; 8,034,565; 8,206,919; 7,858,304; 8,741,605; 8,765,383; 7,838,224; 8,071,286; 8,148,076; 8,008,003; 8,725,426; 7,888,019; 8,906,625; 8,703,736; 7,695,913; 7,569,345; 8,067,178; 7,056,674; 8,153,379; 8,153,380; 8,153,378; 8,026,060; 8,029,995; 8,198,024; 8,273,537; 8,632,980; 7,723,033; 8,367,345; 8,911,940; 7,939,261; 7,526,637; 8,868,352; 7,930,104; 7,816,084; 7,754,431 and 7,208,470, and their foreign counterparts.
- U.S. Pat. No. 9,076,104 to the Regents of the University of California titled “Systems and Methods for Identifying Drug Targets using Biological Networks” claims a method with computer executable instructions by a processor for predicting gene expression profile changes on inhibition of proteins or genes of drug targets on treating a disease, that includes constructing a genetic network using a dynamic Bayesian network based at least in part on knowledge of drug inhibiting effects on a disease, associating a set of parameters with the constructed dynamic Bayesian network, determining the values of a joint probability distribution via an automatic procedure, deriving a mean dynamic Bayesian network with averaged parameters and calculating a quantitative prediction based at least in part on the mean dynamic Bayesian network, wherein the method searches for an optimal combination of drug targets whose perturbed gene expression profiles are most similar to healthy cells.
- Affymetrix has developed a number of products related to gene expression profiling. Non-limiting examples of U.S. patents to Affymetrix include: U.S. Pat. Nos. 6,884,578; 8,029,997; 6,308,170; 6,720,149; 5,874,219; 6,171,798; and 6,391,550.
- Likewise, Bio-Rad has a number of products directed to gene expression profiling. Illustrative examples of U.S. patents to Bio-Rad include: U.S. Pat. Nos. 8,021,894; 8,451,450; 8,518,639; 6,004,761; 6,146,897; 7,299,134; 7,160,734; 6,675,104; 6,844,165; 6,225,047; 7,754,861 and 6,004,761.
- Koninklijke Philips N.V. (NL) has filed a number of patent applications in the general area of assessment of cellular signaling pathway activity using various mathematical models, including U.S. Ser. No. 14/233,546 (WO 2013/011479), titled “Assessment of Cellular Signaling Pathway Using Probabilistic Modeling of Target Gene Expression”; U.S. Ser. No. 14/652,805 (WO 2014/102668) titled “Assessment of Cellular Signaling Pathway Activity Using Linear Combinations of Target Gene Expressions”; WO 2014/174003 titled “Medical Prognosis and Prediction of Treatment Response Using Multiple Cellular Signaling Pathway Activities”; and WO 2015/101635 titled “Assessment of the PI3K Cellular Signaling Pathway Activity Using Mathematical Modeling of Target Gene Expression”.
- Despite this progress, more work is needed to definitively characterize tumor cellular behavior. In particular, there is a critical need to determine which pathways have become pathogenic to the cell. However, it is difficult to identify and separate abnormal cellular signaling from normal cellular pathway activity.
- Nuclear factor-kappa B (NFkB or NFκB) is an inducible transcription factor that regulates the expression of many genes involved in the immune response. The NFkB cellular signaling pathway is a key cellular signaling pathway involved in immune, inflammatory, and acute phase response, but is also implicated in the control of cell survival, proliferation, and apoptosis. In healthy, non-activated cells, the NFkB cellular signaling pathway associated transcription factors that are composed of dimers originating from five genes (NFKB1 or p50/p105, NFKB2 or p52/p100, RELA or p65, REL, and RELB) are predominantly cytoplasmic due to their interaction with the inhibitors of NFkB (IkBs) and therefore remain transcriptionally inactive, thus keeping the NFkB cellular signaling pathway inactive. Upon activation of the upstream signaling cascade, the IkBs become phosphorylated and undergo ubiquitin-dependent degradation by the proteasome, and NFkB dimers are translocated to the nucleus where they act as transcription factors. Besides this canonical NFkB cellular signaling pathway there is also an alternative pathway that is able to initiate NFkB regulated transcription (see
FIG. 1 ; CP=canonical pathway; AP=alternative pathway; PS=proteasome; NC=nucleus). The term “NFkB cellular signaling pathway” herein preferably refers to any signaling process that leads to transcriptional activity of the above mentioned NFkB transcription factors. - Although activity of the NFkB cellular signaling pathway is known to be associated with different types of cancer and to support the pro-survival phenotypes of cancer cells, there is no clinical assay available to assess the activity of the NFkB cellular signaling pathway. Thus, it is desirable to be able to improve the possibilities of characterizing patients that have a cancer, e.g., a diffuse large B-cell lymphoma (DLBCL), a multiple myeloma, a cancer of another haematological origin, or a solid tumor, such as a breast, melanoma, or prostate tumor, which is at least partially driven by a deregulated NFkB cellular signaling pathway, and that are therefore likely to respond to inhibitors of the NFkB cellular signaling pathway.
- It is therefore an object of the invention to provide a more accurate process to determine the tumorigenic propensity of the NFkB cellular signaling pathway in a cell, as well as associated methods of therapeutic treatment, kits, systems, etc.
- The present invention includes methods and apparatuses for determining the activity level of a NFkB cellular signaling pathway in a subject, typically a human with diseased tissue such as a tumor or cancer, wherein the activity level of the NFkB cellular signaling pathway is determined by calculating a level of NFkB transcription factor element in a sample of the involved tissue isolated from the subject, wherein the level of the NFkB transcription factor element in the sample are determined by measuring the expression levels of a unique set of target genes controlled by the NFkB transcription factor element using a calibrated pathway model that compares the expression levels of the target genes in the sample with expression levels of the target genes in the calibrated pathway model.
- In particular, the unique set of target genes whose expression level is analyzed in the model includes at least six target genes, at least seven target genes, at least eight target genes, at least nine target genes, at least ten or more target genes selected from BCL2L1, BIRC3, CCL2, CCL3, CCL4, CCL5, CCL20, CCL22, CX3CL1, CXCL1, CXCL2, CXCL3, ICAM1, IL1B, IL6, IL8, IRF1, MMP9, NFKB2, NFKBIA, NFKBIE, PTGS2, SELE, STAT5A, TNF, TNFAIP2, TNIP1, TRAF1, and VCAM1. In one embodiment, the unique set of target genes whose expression level is analyzed in the model is selected from BIRC3, CCL2, CCL5, CCL20, CXCL1, CXCL2, CXCL3, ICAM1, IL6, IL8, IRF1, MMP9, NFKB2, NFKBIA, NFKBIE, TNF, TNFAIP2, TRAF1, and VCAM1. In one embodiment, the unique set of target genes comprises at least three target genes, at least four target genes, at least five target genes, at least six or more target genes selected from CCL2, CCL5, CCL20, CXCL1, CXCL2, CXCL3, ICAM1, IL6, IL8, MMP9, NFKB2, NFKBIA, and TNFAIP2. In one embodiment, the unique set of target genes comprises at least three target genes, at least four target genes, at least five target genes, at least six or more target genes selected from CCL5, CXCL2, ICAM1, IL6, IL8, NFKBIA, and TNFAIP2.
- Using this invention, health care providers will be able to more accurately assess the functional state of the NFkB cellular signaling pathway at specific points in disease progression. Without being bound by any particular theory, it is believed that the identified target genes of the present invention in combination with the analytical methods described herein reduces the noise associated with the use of large subsets of target genes as previously described in the literature. Furthermore, as described and exemplified below, the use of specific combinations of select target genes allows for the precise determination of cellular signaling activity, and allows for an increased accuracy in the determination of disease state and prognosis. Accordingly, such cellular signaling pathway status can be used to, for example but not limited to, identify the presence or absence of disease and/or particular disease state or advancement, identify the presence or absence of a disorder or disease state, identify a particular subtype within a disease or disorder based one the activity level of the NFkB cellular signaling pathway, derive a course of treatment based on the presence or absence of NFkB signaling activity for example by administering a NFkB inhibitor, and/or monitor disease progression in order to, for example, adjust therapeutic protocols based on a predicted drug efficacy in light of the determined activity of the NFkB cellular signaling pathway in the sample.
- The term “NFkB transcriptional factor element” or “NFkB TF element” or “TF element” refers to a protein complex containing at least one or, preferably, a dimer of the NFkB members (NFKB1 or p50/p105, NFKB2 or p52/p100, RELA or p65, REL, and RELB), which is capable of binding to specific DNA sequences, thereby controlling transcription of target genes.
- The present invention is based on the realization of the inventors that a suitable way of identifying effects occurring in the NFkB cellular signaling pathway can be based on a measurement of the signaling output of the NFkB cellular signaling pathway, which is—amongst others—the transcription of the unique target genes described herein by a NFkB transcription factor (TF) element controlled by the NFkB cellular signaling pathway. This realization by the inventors assumes that the TF level is at a quasi-steady state in the sample which can be detected by means of—amongst others—the expression values of the target genes. The NFkB cellular signaling pathway targeted herein is known to be associated with different types of cancer and to support the pro-survival phenotypes of cancer cells as the NFkB cellular signaling pathway is known to regulate genes that control cell proliferation and cell survival processes. Many different types of human tumors are found to have a deregulated activity of the NFkB cellular signaling pathway. Furthermore, studies have shown that the inhibition of constitutive NFkB cellular signaling pathway activity blocks the oncogenic potential of cancerous cells.
- The present invention makes it possible to determine the activity of the NFkB cellular signaling pathway by (i) determining a level of an NFkB TF element in the sample, wherein the determining is based at least in part on evaluating a mathematical model relating expression levels of at least six target genes of the NFkB cellular signaling pathway, the transcription of which is controlled by the NFkB TF element, to the level of the NFkB TF element, and by (ii) inferring the activity of the NFkB cellular signaling pathway based on the determined level of the NFkB TF element in the sample. This preferably allows improving the possibilities of characterizing patients that have a cancer, e.g., a diffuse large B-cell lymphoma (DLBCL), a multiple myeloma, a cancer of another haematological origin, or a solid tumor, such as a breast, melanoma, or prostate tumor, which is at least partially driven by a deregulated NFkB cellular signaling pathway, and that are therefore likely to respond to inhibitors of the NFkB cellular signaling pathway. An important advantage of the present invention is that it makes it possible to determine the activity of the NFkB cellular signaling pathway using a single sample, rather than requiring a plurality of samples extracted at different points in time. In particular embodiments, treatment determination can be based on specific NFkB activity. In a particular embodiment the NFkB cellular signaling status can be set at a cutoff value of odds of the NFkB cellular signaling pathway being activate of, for example, 10:1, 5:1, 4:1, 2:1, 1:1, 1:2, 1:4, 1:5, or 1:10.
- In one aspect of the invention, provided herein is a computer implemented method for determining the activity level of a NFkB cellular signaling pathway in a subject performed by a computerized device having a processor comprising:
-
- a. calculating an activity level of NFkB transcription factor element in a sample isolated from the subject, wherein the activity level of NFkB transcription factor element in the sample is calculated by:
- i. receiving data on the expression levels of at least six target genes derived from the sample, wherein the NFkB transcription factor element controls transcription of the at least six target genes, and wherein the at least six target genes are selected from BCL2L1, BIRC3, CCL2, CCL3, CCL4, CCL5, CCL20, CCL22, CX3CL1, CXCL1, CXCL2, CXCL3, ICAM1, IL1B, IL6, IL8, IRF1, MMP9, NFKB2, NFKBIA, NFKBIE, PTGS2, SELE, STAT5A, TNF, TNFAIP2, TNIP1, TRAF1, and VCAM1;
- ii. calculating the activity level of the NFkB transcription factor element in the sample using a calibrated pathway model, wherein the calibrated pathway model compares the expression levels of the at least six target genes in the sample with expression levels of the at least six target genes in the model which define an activity level of NFkB transcription factor element; and,
- b. calculating the activity level of the NFkB cellular signaling pathway in the sample based on the calculated activity levels of NFkB transcription factor element in the sample.
- a. calculating an activity level of NFkB transcription factor element in a sample isolated from the subject, wherein the activity level of NFkB transcription factor element in the sample is calculated by:
- In one embodiment, the method further comprises assigning a NFkB cellular signaling pathway activity status to the calculated activity level of the NFkB cellular signaling pathway in the sample wherein the activity status is indicative of either an active NFkB cellular signaling pathway or a passive NFkB cellular signaling pathway.
- In one embodiment, the at least six target genes are selected from BIRC3, CCL2, CCL5, CCL20, CXCL1, CXCL2, CXCL3, ICAM1, IL6, IL8, IRF1, MMP9, NFKB2, NFKBIA, NFKBIE, TNF, TNFAIP2, TRAF1, and VCAM1. In one embodiment, the at least six target genes comprise at least three target genes selected from CCL2, CCL5, CCL20, CXCL1, CXCL2, CXCL3, ICAM1, IL6, IL8, MMP9, NFKB2, NFKBIA, and TNFAIP2. In one embodiment, the at least three target genes are selected from CCL5, CXCL2, ICAM1, IL6, IL8, NFKBIA, and TNFAIP2.
- In one embodiment, the status of the NFkB cellular signaling pathway is established by establishing a specific threshold for activity as described further below. In one embodiment, the threshold is set as a probability that the cellular signaling pathway is active, for example, a 10:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:4, 1:5, or 1:10. In one embodiment, the activity status is based, for example, on a minimum calculated activity. In one embodiment, the method further comprises assigning to the calculated NFkB cellular signaling in the sample a probability that the NFkB cellular signaling pathway is active.
- As contemplated herein, the level of the NFkB transcription factor element is determined using a calibrated pathway model executed by one or more computer processors, as further described below. The calibrated pathway model compares the expression levels of the at least six target genes in the sample with expression levels of the at least six target genes in the calibrated pathway model which define a level of a NFkB transcription factor element. In one embodiment, the calibrated pathway model is a probabilistic model incorporating conditional probabilistic relationships that compare the expression levels of the at least six target genes in the sample with expression levels of the at least six target genes in the model which define a level of a NFkB transcription factor element to determine the level of the NFkB transcription factor element in the sample. In one embodiment, the probabilistic model is a Bayesian network model. In an alternative embodiment, the calibrated pathway model can be a linear or pseudo-linear model. In an embodiment, the linear or pseudo-linear model is a linear or pseudo-linear combination model.
- As contemplated herein, the expression levels of the unique set of target genes can be determined using standard methods known in the art. For example, the expression levels of the target genes can be determined by measuring the level of mRNA of the target genes, through quantitative reverse transcriptase-polymerase chain reaction techniques, using probes associated with a mRNA sequence of the target genes, using a DNA or RNA microarray, and/or by measuring the protein level of the protein encoded by the target genes. Once the expression level of the target genes is determined, the expression levels of the target genes within the sample can be utilized in the model in a raw state or, alternatively, following normalization of the expression level data. For example, expression level data can be normalized by transforming it into continuous data, z-score data, discrete data, or fuzzy data.
- As contemplated herein, the calculation of NFkB signaling in the sample is performed on a computerized device having a processor capable of executing a readable program code for calculating the NFkB signaling in the sample according to the methods described above. Accordingly, the computerized device can include means for receiving expression level data, wherein the data is expression levels of at least six target genes derived from the sample, a means for calculating the level of a NFkB transcription factor element in the sample using a calibrated pathway model, wherein the calibrated pathway model compares the expression levels of the at least six target genes in the sample with expression levels of the at least six target genes in the model which define a level a NFkB transcription factor element; a means for calculating the NFkB cellular signaling in the sample based on the calculated levels of a NFkB transcription factor element in the sample; and a means for assigning a NFkB cellular signaling pathway activity probability or status to the calculated NFkB cellular signaling in the sample, and, optionally, a means for displaying the NFkB signaling pathway activity probability or status.
- In accordance with another disclosed aspect, further provided herein is a non-transitory storage medium capable of storing instructions that are executable by a digital processing device to perform the method according to the present invention as described herein. The non-transitory storage medium may be a computer-readable storage medium, such as a hard drive or other magnetic storage medium, an optical disk or other optical storage medium, a random access memory (RAM), read only memory (ROM), flash memory, or other electronic storage medium, a network server, or so forth. The digital processing device may be a handheld device (e.g., a personal data assistant or smartphone), a notebook computer, a desktop computer, a tablet computer or device, a remote network server, or so forth.
- Further contemplated herein are methods of treating a subject having a disease or disorder associated with an activated NFkB cellular signaling pathway, or a disorder whose advancement or progression is exacerbated or caused by, whether partially or wholly, an activated NFkB cellular signaling pathway, wherein the determination of the NFkB cellular signaling pathway activity is based on the methods described above, and administering to the subject a NFkB inhibitor if the information regarding the activity level of NFkB cellular signaling pathway is indicative of an active NFkB cellular signaling pathway. In one embodiment, the disorder is one of an auto-immune and other immune disorders, cancer, bronchial asthma, heart disease, diabetes, hereditary hemorrhagic telangiectasia, Marfan syndrome, Vascular Ehlers-Danlos syndrome, Loeys-Dietz syndrome, Parkinson's disease, Chronic kidney disease, Multiple Sclerosis, fibrotic diseases such as liver, Ing, or kidney fibrosis, Dupuytren's disease, or Alzheimer's disease. In a particular embodiment, the subject is suffering from a cancer, for example, a breast cancer, lung cancer, a colon cancer, pancreatic cancer, brain cancer, or breast cancer. In a more particular embodiment, the cancer is a breast cancer.
- Also contemplated herein is a kit for measuring the expression levels of at least six or more NFkB cellular signaling pathway target genes, for example, seven, eight, nine, ten, eleven, twelve, or more target genes as described herein. In one embodiment, the kit includes one or more components, for example probes, for example labeled probes, and/or PCR primers, for measuring the expression levels of at least six target genes, at least seven target genes, at least eight target genes, or at least nine or more target genes selected from BCL2L1, BIRC3, CCL2, CCL3, CCL4, CCL5, CCL20, CCL22, CX3CL1, CXCL1, CXCL2, CXCL3, ICAM1, IL1B, IL6, IL8, IRF1, MMP9, NFKB2, NFKBIA, NFKBIE, PTGS2, SELE, STAT5A, TNF, TNFAIP2, TNIP1, TRAF1, and VCAM1. In one embodiment, the kit includes one or more components for measurng the expression levels of at least six target genes, at least seven target genes, at least eight target genes, or at least nine or more target genes selected from B1RC3, CCL2, CCL5, CCL20, CXCL1, CXCL2, CXCL3, ICAM1, IL6, IL8, IRF1, MMP9, NFKB2, NFKBIA, NFKBIE, TNF, TNFAIP2, TRAF1, and VCAM1. In one embodiment, the one or more components comprise one or more components for measuring the expression levels of at least three target genes, at least four target genes, at least five target genes, or at least six or more target genes selected from CCL2, CCL5, CCL20, CXCL1, CXCL2, CXCL3, ICAM1, IL6, IL8, MMP9, NFKB2, NFKBIA, and TNFAIP2. In one embodiment, the one or more components comprise one or more components for measuring the expression levels of at least three target genes, at least four target genes, at least five target genes, or at least six or more target genes selected from CCL5, CXCL2, ICAM1, IL6, IL8, NFKBIA, and TNFAIP2.
- As contemplated herein, the one or more components or means for measuring the expression levels of the particular target genes can be selected from the group consisting of: an DNA array chip, an oligonucleotide array chip, a protein array chip, an antibody, a plurality of probes, for example, labeled probes, a set of RNA reverser-transcriptase sequencing components, and/or RNA or DNA, including cDNA, amplification primers. In one embodiment, the kit includes a set of labeled probes directed to a portion of an mRNA or cDNA sequence of the targeted genes as described herein. In one embodiment, the kit includes a set of primers and probes directed to a portion of an mRNA or cDNA sequence of the targeted genes as described further below, wherein, for example, the set includes specific primers or probes selected from the sequences of Table 1. In one embodiment, the labeled probes are contained in a standardized 96-well plate. In one embodiment, the kit further includes primers or probes directed to a set of reference genes, for example, as represented in Table 2. Such reference genes can be, for example, constitutively expressed genes useful in normalizing or standardizing expression levels of the target gene expression levels described herein.
- In one embodiment, the kit further includes a non-transitory storage medium containing instructions that are executable by a digital processing device to perform a method according to the present invention as described herein. In one embodiment, the kit includes an identification code that provides access to a server or computer network for analyzing the activity level of the NFkB cellular signaling pathway based on the expression levels of the target genes and the methods described herein.
-
FIG. 1 shows schematically and exemplarily canonical and alternative pathways of NFkB activation (see Dolcet X. et al, “NF-kB in development and progression of human cancer”, Virchows Archives, Vol. 446. No. 5, 2005, pages 475 to 482). -
FIG. 2 shows schematically and exemplarily a mathematical model, herein, a Bayesian network model, useful in modelling the transcriptional program of the NFkB cellular signaling pathway. -
FIG. 3 shows an exemplary flow chart for calculating the activity level of the NFkB cellular signaling pathway based on expression levels of target genes derived from a sample. -
FIG. 4 shows an exemplary flow chart for obtaining a calibrated pathway model as described herein. -
FIG. 5 shows an exemplary flow chart for calculating the Transcription Factor (TF) Element as described herein. -
FIG. 6 shows an exemplary flow chart for calculating the NFkB cellular signaling pathway activity level using discretized observables. -
FIG. 7 shows an exemplary flow chart for calculating the NFkB cellular signaling pathway activity level using continuous observables. -
FIG. 8 shows an exemplary flow chart for determining Cq values from RT-qPCR analysis of the target genes of the NFkB cellular signaling pathway. -
FIGS. 9 to 12 show training results of the exemplary Bayesian network model based on the evidence curated list of target genes (FIG. 9 ), the 19 target genes shortlist (FIG. 10 ), the 13 target genes shortlist (FIG. 11 ), and the 7 target genes shortlist of the NFkB cellular signaling pathway (FIG. 12 ) (see Tables 3 to 6), respectively. (Legend: 1—ABC DLBCL; 2—Lymphoblasioid cell line; 3—Follicular lymphoma; 4—GCB DLBCL; 5—Memory H-cells, 6—Naïve H-cells, 7—Normal; 8—DLBCL unknown subtype) -
FIG. 13 shows NFkB cellular signaling pathway activity predictions of the trained exemplary Bayesian network model using the evidence curated list of target genes (see Table 3) for diffuse large B-cell lymphoma (DLBCL) samples from GSE34171. -
FIGS. 14 to 17 show NFkB cellular signaling pathway activity predictions of the trained exemplary Bayesian network model using the evidence curated list of target genes (FIG. 14 ), the 19 target genes shortlist (FIG. 15 ), the 13 target genes shortlist (FIG. 16 ), and the 7 target genes shortlist (FIG. 17 )(see Tables 3 to 6), respectively, for normal human bronchial epithelial (NHBE) cell line samples from E-MTAB-1312, which were stimulated with different TNFα concentrations for different stimulation times. (Legend: 1—No TNFα (0.5 h); 2—No TNFα (2 h); 3—No TNFα (4 h); 4—No TNFα (24 h); 5—Low TNFα (0.5 h); 6—Low TNFα (2 h); 7—Low TNFα (4 h); 8—Low TNFα (24 h): 9—Medium TNFα (0.5 h); 10—Medium TNFα (2 h); 11—Medium TNFα (4 h); 12—Medium TNFα (24 h); 13—High TNFα (0.5 h); 14—High TNFα (2 h); 15—High TNFα (4 h); 16—High TNFα (24 h)) -
FIG. 18 shows NFkB cellular signaling pathway activity predictions of the trained exemplary Bayesian network model using the evidence curated list of target genes (see Table 3) for THP-1 monocytic cells. (Legend: 1—No LPS; 2—LPS stimulation; 3—LPS stimulation coenzyme Q10) -
FIGS. 19 to 22 show NFkB cellular signaling pathway activity predictions of the trained exemplary Bayesian network model using the evidence curated list of target genes (FIG. 19 ), the 19 target genes shortlist (FIG. 20 ), the 13 target genes shortlist (FIG. 21 ), and the 7 target genes shortlist (FIG. 22 ) (see Tables 3 to 6), respectively, for colon samples from GSE4183. (Legend: 1—Normal colon; 2—IBD; 3—Adenoma; 4—CRC) -
FIG. 23 shows NFkB cellular signaling pathway activity predictions of the trained exemplary Bayesian network model using the evidence curated list of target genes (see Table 3) for breast cancer cell lines from GSE10890. (Legend: 1 and 2—Unknown cellular signaling pathway driven cell lines; 3: Wnt cellular signaling pathway driven cell lines) -
FIG. 24 shows NFkB cellular signaling pathway activity predictions of the trained exemplary Bayesian network model using the evidence curated list of target genes (see Table 3) for ovarian samples from GSE20565. (Legend: 1—Primary ovarian carcinoma: 2—Plausible primary ovarian carcinoma; 3—Breast metastasis in ovary; 4—Plausible breast metastasis in ovary) -
FIG. 25 shows NFkB cellular signaling pathway activity predictions of the trained exemplary Bayesian network model using the evidence curated list of target genes (see Table 3) for breast cancer samples from E-MTAB-1006. (Legend: 1—Inflammatory breast cancer; 2—Non-inflammatory breast cancer) -
FIG. 26 illustrates a prognosis of glioma patients (GSE16011) depicted in a Kaplan-Meier plot, wherein the trained exemplary Bayesian network model using the evidence curated list of target genes (see Table 3) is employed. -
FIG. 27 shows training results of the exemplary linear model based on the evidence curated list of target genes (see Table 3). (Legend: 1—ABC DLBCL; 2—Lymphoblastoid cell line; 3—Follicular Lymphoma: 4—GCB DLBCL; 5—Memory B-cells: 6—Naïve B-cells; 7—Normal: 8—DLBCL unknown subtype) -
FIG. 28 shows NFkB cellular signaling pathway activity predictions of the trained exemplary linear model using the evidence curated list of target genes (see Table 3) for normal human bronchial epithelial (NHBE) cell line samples from E-MTAB-1312, which were stimulated with different TNFα concentrations for different stimulation times. (Legend: 1—No TNFα (0.5 h); 2—No TNFα (2 h): 3—No TNFα (4 h); 4—No TNFα (24 h); 5—Low TNFα (0.5 h); 6—Low TNFα (2 h); 7—Low TNFα (4 h): 8—Low TNFα (24 h): 9—Medium TNFα (0.5 h): 10—Medium TNFα (2 h); 11—Medium TNFα (4 h); 12—Medium TNFα (24 h); 13—High TNFα (0.5 h); 14—High TNFα (2 h); 15—High TNFα (4 h); 16—High TNFα (24 h)) -
FIG. 29 shows NFkB cellular signaling pathway activity predictions of the trained exemplary linear model using the evidence curated list of target genes (see Table 3) for colon samples from GSE4183. (Legend: 1—Normal colon; 2—IBD; 3—Adenoma; 4—CRC) -
FIG. 30 shows training results of the exemplary Bayesian network model based on the broad literature list of putative target genes of the NFkB cellular signaling pathway (see Table 7). (Legend: 1—ABC DLBCL; 2—Lymphoblastoid cell line; 3—Follicular lymphoma; 4—GCB DLBCL; 5—Memory B-cells; 6—Naïve B-cells; 7—Normal; 8—DLBCL unknown subtype) -
FIG. 31 shows NFkB cellular signaling pathway activity predictions of the trained exemplary Bayesian network model using the broad literature list of putative target genes of the NFkB cellular signaling pathway (see Table 7) for normal human bronchial epithelial (NHBE) cell line samples from E-MTAB-1312, which were stimulated with different TNFα concentrations for different stimulation times. (Legend: 1—No TNFα (0.5 h); 2—No TNFα (2 h); 3—No TNFα (4 h); 4—No TNFα (24 h); 5—Low TNFα (0.5 h): 6—Low TNFα (2 h); 7—Low TNFα (4 h); 8—Low TNFα (24 h); 9—Medium TNFα (0.5 h); 10—Medium TNFα (2 h); 11—Medium TNFα (4 h); 12—Medium TNFα (24 h); 13—High TNFα (0.5 h); 14—High TNFα (2 h); 15—High TNFα (4 h); 16—High TNFα (24 h)) -
FIG. 32 shows NFkB cellular signaling pathway activity predictions of the trained exemplary Bayesian network model using the broad literature list of putative target genes of the NFkB cellular signaling pathway (see Table 7) for colon samples from GSE4183. (Legend: 1—Normal colon; 2—IBD; 3—Adenoma; 4—CRC) - Provided herein are methods and apparatuses, and in particular computer implemented methods and apparatuses, for determining the activity levels of a NFkB cellular signaling pathway in a subject, wherein the NFkB cellular signaling is calculated by a) calculating an activity level of NFkB transcription factor element in a sample isolated from a subject, and wherein the activity levels of the NFkB transcription factor element in the sample is calculated by measuring the expression levels of a unique set of target genes, wherein the NFkB transcription factor element controls transcription of the target genes, calculating the levels of the NFkB transcription factor element in the sample using a calibrated pathway model, wherein the calibrated pathway model compares the expression levels of the target genes in the sample with expression levels of the target genes in the calibrated pathway model which define a level of a NFkB transcription factor element; and calculating the NFkB cellular signaling in the sample based on the calculated levels of NFkB transcription factor element in the sample.
- In particular, the unique set of target genes whose expression level is analyzed in the model includes at least six target genes, at least seven target genes, at least eight target genes, at least nine target genes, at least ten or more target genes selected from BCL2L1, BIRC3, CCL2, CCL3, CCL4, CCL5, CCL20, CCL22, CX3CL1, CXCL1, CXCL2, CXCL3, ICAM1, IL1B, IL6, IL8, IRF1, MMP9, NFKB2, NFKBIA, NFKBIE, PTGS2, SELE, STAT5A, TNF, TNFAIP2, TNIP1, TRAF1, and VCAM1. It has been discovered that analyzing a specific set of target genes as described herein in the disclosed pathway model provides for an advantageously accurate NFkB cellular signaling pathway activity determination. Accordingly, such status can be used to, for example but not limited to, identify the presence or absence of disease and/or particular disease state or advancement, diagnose a specific disease or disease state, or diagnose the presence or absence of a particular disease, derive a course of treatment based on the presence or absence of NFkB signaling activity, monitor disease progression in order to, for example, adjust therapeutic protocols based on a predicted drug efficacy in light of the determined activity of the NFkB signaling pathway in the sample, or develop NFkB targeted therapeutics.
- All terms used herein are intended to have their plain and ordinary meaning as normally ascribed in the art unless otherwise specifically indicated herein.
- Herein, the “level” of a TF element denotes the level of activity of the TF element regarding transcription of its target genes.
- The term “subject” or “host”, as used herein, refers to any living being. In some embodiments, the subject is an animal, for example a mammal, including a human. In a particular embodiment, the subject is a human. In one embodiment, the human is suspected of having a disorder mediated or exacerbated by an active NFkB cellular signaling pathway, for example, a cancer. In one embodiment, the human has or is suspected of having a breast cancer.
- The term “sample”, as used herein, means any biological specimen isolated from a subject. Accordingly, “sample” as used herein is contemplated to encompasses the case where e.g. a tissue and/or cells and/or a body fluid of the subject have been isolated from the subject. Performing the claimed method may include where a portion of this sample is extracted, e.g., by means of Laser Capture Microdissection (LCM), or by scraping off the cells of interest from the slide, or by fluorescence-activated cell sorting techniques. In addition, the term “sample”, as used herein, also encompasses the case where e.g. a tissue and/or cells and/or a body fluid of the subject has been taken from the subject and has been put on a microscope slide, and the claimed method is performed on the slide. In addition, the term “samples,” as used herein, may also encompass circulating tumor cells or CTCs.
- The term “NFkB transcriptional factor element” or “NFkB TF element” or “TF element” refers to a protein complex containing at least one or, preferably, a dimer of the NFkB members (NFKB1 or p50/p105, NFKB2 or p52/p100, RELA or p65, REL, and RELB), which is capable of binding to specific DNA sequences, thereby controlling transcription of target genes.
- The term “target gene” as used herein, means a gene whose transcription is directly or indirectly controlled by a NFkB transcription factor element. The “target gene” may be a “direct target gene” and/or an “indirect target gene” (as described herein).
- As contemplated herein, target genes include at least BCL2L1, BIRC3, CCL2, CCL3, CCL4, CCL5, CCL20, CCL22, CX3CL1, CXCL1, CXCL2, CXCL3, ICAM1, IL1B, IL6, IL8, IRF1, MMP9, NFKB2, NFKBIA, NFKBIE, PTGS2, SELE, STAT5A, TNF, TNFAIP2, TNIP1, TRAF1, and VCAM1.
- As contemplated herein, the present invention includes:
- A) A computer implemented method for determining the activity level of a NFkB cellular signaling pathway in a subject performed by a computerized device having a processor comprising.
-
- a. calculating an activity level of NFkB transcription factor element in a sample isolated from the subject, wherein the activity level of NFkB transcription factor element in the sample is calculated by:
- i. receiving data on the expression levels of at least six target genes derived from the sample, wherein the NFkB transcription factor element controls transcription of the at least six target genes, and wherein the at least six target genes are selected from BCL2L1, B1RC3, CCL2, CCL3, CCL4, CCL5, CCL20, CCL22, CX3CL1, CXCL1, CXCL2, CXCL3, ICAM1, IL1B, IL6, IL8, IRF1, MMP9, NFKB2, NFKBIA, NFKBIE, PTGS2, SELE, STAT5A, TNF, TNFAIP2, TNIP1, TRAF1, and VCAM1;
- ii. calculating the activity level of the NFkB transcription factor element in the sample using a calibrated pathway model, wherein the calibrated pathway model compares the expression levels of the at least six target genes in the sample with expression levels of the at least six target genes in the model which define an activity level of NFkB transcription factor element; and,
- b. calculating the activity level of the NFkB cellular signaling pathway in the sample based on the calculated activity levels of NFkB transcription factor element in the sample.
- a. calculating an activity level of NFkB transcription factor element in a sample isolated from the subject, wherein the activity level of NFkB transcription factor element in the sample is calculated by:
- In one embodiment, the method further comprises assigning a NFkB cellular signaling pathway activity status to the calculated activity level of the NFkB cellular signaling in the sample, wherein the activity status is indicative of either an active NFkB cellular signaling pathway or a passive NFkB cellular signaling pathway. In one embodiment, the method further comprises displaying the NFkB cellular signaling pathway activity status. In one embodiment, the at least six target genes are selected from BIRC3, CCL2, CCL5, CCL20, CXCL1, CXCL2, CXCL3, ICAM1, IL6, IL8, IRF1, MMP9, NFKB2, NFKBIA, NFKBIE, TNF, TNFAIP2, TRAF1, and VCAM1. In one embodiment, the at least six target genes comprise at least three target genes selected from CCL2, CCL5, CCL20, CXCL1, CXCL2, CXCL3, ICAM1, IL6, IL8, MMP9, NFKB2, NFKBIA, and TNFAIP2. In one embodiment, the at least three target genes are selected from CCL5, CXCL2, ICAM1, IL6, IL8, NFKBIA, and TNFAIP2. In one embodiment, the calibrated pathway model is a probabilistic model incorporating conditional probabilistic relationships that compare the expression levels of the at least six target genes in the sample with expression levels of the at least six target genes in the model which define a level of NFkB transcription factor element to determine the activity level of the NFkB transcription factor element in the sample. In one embodiment, the probabilistic model is a Bayesian network model. In one embodiment, the calibrated pathway model is a linear model incorporating relationships that compare the expression levels of the at least six target genes in the sample with expression levels of the at least six target genes in the model which define a level of NFkB transcription factor element to determine the activity level of the NFkB transcription factor element in the sample.
- B) A computer program product for determining the activity level of a NFkB cellular signaling pathway in a subject comprising
-
- a. a non-transitory computer readable storage medium having computer readable program code embodied therewith, the computer readable program code executable by at least one processor to:
- i. calculate a level of NFkB transcription factor element in a sample isolated from a subject, wherein the level of the NFkB transcription factor element in the sample is calculated by:
- 1. receiving data on the expression levels of at least six target genes derived from the sample, wherein the at least six target genes are selected from BCL2L1, BIRC3, CCL2, CCL3, CCL4, CCL5, CCL20, CCL22, CX3CL1, CXCL1, CXCL2, CXCL3, ICAM1, IL1B, IL6, IL8, IRF1, MMP9, NFKB2, NFKBIA, NFKBIE, PTGS2, SELE, STAT5A, TNF, TNFAIP2, TNIP1, TRAF1, and VCAM1;
- 2. calculating the level of the NFkB transcription factor element in the sample using a calibrated pathway model, wherein the calibrated pathway model compares the expression levels of the at least six target genes in the sample with expression levels of the at least six target genes in the model which define an activity level of NFkB transcription factor element; and,
- ii. calculate the activity level of the NFkB cellular signaling pathway in the sample based on the calculated NFkB transcription factor element level in the sample.
- i. calculate a level of NFkB transcription factor element in a sample isolated from a subject, wherein the level of the NFkB transcription factor element in the sample is calculated by:
- a. a non-transitory computer readable storage medium having computer readable program code embodied therewith, the computer readable program code executable by at least one processor to:
- In one embodiment, the computer readable program code is executable by at least one processor to assign a NFkB cellular signaling pathway activity status to the calculated activity level of the NFkB cellular signaling in the sample, wherein the activity status is indicative of either an active NFkB cellular signaling pathway or a passive NFkB cellular signaling pathway. In one embodiment, the computer readable program code is executable by at least one processor to display the NFkB signaling pathway activity status. In one embodiment, the at least six target genes are selected from BIRC3, CCL2, CCL5, CCL20, CXCL1, CXCL2, CXCL3, ICAM1, IL6, IL8, IRF1, MMP9, NFKB2, NFKBIA, NFKBIE, TNF, TNFAIP2, TRAF1, and VCAM1. In one embodiment, the at least six target genes comprise at least three target genes selected from CCL2, CCL5, CCL20, CXCL1, CXCL2, CXCL3, ICAM1, IL6, IL8, MMP9, NFKB2, NFKBIA, and TNFAIP2. In one embodiment, the at least three target genes are selected from CCL5, CXCL2, ICAM1, IL6, IL8, NFKBIA, and TNFAIP2. In one embodiment, the calibrated pathway model is a probabilistic model incorporating conditional probabilistic relationships that compare the expression levels of the at least six target genes in the sample with expression levels of the at least six target genes in the model which define a level of NFkB transcription factor element to determine the activity level of NFkB transcription factor element in the sample. In one embodiment, the probabilistic model is a Bayesian network model. In one embodiment, the calibrated pathway model is a linear model incorporating relationships that compare the expression levels of the at least six target genes in the sample with expression levels of the at least six target genes in the model which define a level of NFkB transcription factor element to determine the activity level of a NFkB transcription factor element in the sample.
- C) A method of treating a subject suffering from a disease associated with an activated NFkB cellular signaling pathway comprising:
-
- a. receiving information regarding the activity level of a NFkB cellular signaling pathway derived from a sample isolated from the subject, wherein the activity level of the NFkB cellular signaling pathway is determined by:
- i. calculating an activity level of NFkB transcription factor element in a sample isolated from the subject, wherein the level of the NFkB transcription factor element in the sample is calculated by:
- 1. receiving data on the expression levels of at least six target genes derived from the sample, wherein the NFkB transcription factor element controls transcription of the at least six target genes, and wherein the at least six target genes are selected from BCL2L1, BIRC3, CCL2, CCL3, CCL4, CCL5, CCL20, CCL22, CX3CL1, CXCL1, CXCL2, CXCL3, ICAM1, IL1B, IL6, IL8, IRF1, MMP9, NFKB2, NFKBIA, NFKBIE, PTGS2, SELE, STAT5A, TNF, TNFAIP2, TNIP1, TRAF1, and VCAM1;
- 2. calculating the level of the NFkB transcription factor element in the sample using a calibrated pathway model, wherein the calibrated pathway model compares the expression levels of the at least six target genes in the sample with expression levels of the at least six target genes in the model which define an activity level of the NFkB transcription factor element; and,
- ii. calculating the activity level of the NFkB cellular signaling pathway in the sample based on the calculated NFkB transcription factor element level in the sample; and,
- i. calculating an activity level of NFkB transcription factor element in a sample isolated from the subject, wherein the level of the NFkB transcription factor element in the sample is calculated by:
- b. administering to the subject a NFkB inhibitor if the information regarding the activity level of the NFkB cellular signaling pathway is indicative of an pathogenically active NFkB cellular signaling pathway.
- a. receiving information regarding the activity level of a NFkB cellular signaling pathway derived from a sample isolated from the subject, wherein the activity level of the NFkB cellular signaling pathway is determined by:
- In one embodiment, the at least six target genes are selected from BIRC3, CCL2, CCL5, CCL20, CXCL1, CXCL2, CXCL3, ICAM1, IL6, IL8, IRF1, MMP9, NFKB2, NFKBIA, NFKBIE, TNF, TNFAIP2, TRAF1, and VCAM1. In one embodiment, the at least six target genes comprise at least three target genes selected from CCL2, CCL5, CCL20, CXCL1, CXCL2, CXCL3, ICAM1, IL6, IL8, MMP9, NFKB2, NFKBIA, and TNFAIP2. In one embodiment, the at least three target genes are selected from CCL5, CXCL2, ICAM1, IL6, IL8, NFKBIA, and TNFAIP2. In one embodiment, the calibrated pathway model is a probabilistic model incorporating conditional probabilistic relationships that compare the expression levels of the at least six target genes in the sample with expression levels of the at least six target genes in the model which define a level of NFkB transcription factor element to determine the activity level of the NFkB transcription factor element in the sample. In one embodiment, the probabilistic model is a Bayesian network model. In one embodiment, the calibrated pathway model is a linear model incorporating relationships that compare the expression levels of the at least six target genes in the sample with expression levels of the at least six target genes in the model which define a level of NFkB transcription factor element to determine the activity level of the NFkB transcription factor element in the human cancer sample. In an illustrative embodiment, the NFkB inhibitor is DHMEQ, bindarit, Bortesomib or BU-32 (proteazome inhibitors), BMS-345541, or glucocorticoids.
- In one embodiment, the disease is a cancer. In one embodiment (not limited to), the cancer is a benign tumor (adenoma, hyperplasia) or a solid cancer: colon, breast, a male cancer (prostate, testicular, urethra, penis), pancreatic, liver, gastrointestinal tract cancer, head and neck cancer, lung, brain (medulloblastoma, glioblastoma, glioma), bladder cancer, an endocrine tumor (thyroid, parathyroid, adrenal, neuroendocrine, MEA), a female cancer (ovarian, cervical, endometrial, vagina), kidney cancer, skin cancer (BCC, squamous skin cancer, melanoma), a soft tissue cancer (sarcoma), childhood cancer (retinoblastoma, Wilms tumor), mesothelioma, or a hematological cancer (leukemia, lymphoma), or a glioma.
- D) A kit for measuring expression levels of NFkB cellular signaling pathway target genes comprising:
-
- a. a set of polymerase chain reaction primers directed to at least six NFkB cellular signaling pathway target genes from a sample isolated from a subject; and
- b. a set of probes directed to the at least six NFkB cellular signaling pathway target genes;
- wherein the at least six NFkB cellular signaling pathway target genes are selected from BCL2L1, BIRC3, CCL2, CCL3, CCL4, CCL5, CCL20, CCL22, CX3CL1, CXCL1, CXCL2, CXCL3, ICAM1, IL1B, IL6, IL8, IRF1, MMP9, NFKB2, NFKBIA, NFKBIE, PTGS2, SELE, STAT5A, TNF, TNFAIP2, TNIP1, TRAF1, and VCAM1.
- In one embodiment, the at least six target genes are selected from BIRC3, CCL2, CCL5, CCL20, CXCL1, CXCL2, CXCL3, ICAM1, IL6, IL8, IRF1, MMP9, NFKB2, NFKBIA, NFKBIE, TNF, TNFAIP2, TRAF1, and VCAM1. In one embodiment, the at least six target genes comprise at least three target genes selected from CCL2, CCL5, CCL20, CXCL1, CXCL2, CXCL3, ICAM1, IL6, IL8, MMP9, NFKB2, NFKBIA, and TNFAIP2. In one embodiment, the at least three target genes are selected from CCL5, CXCL2, ICAM1, IL6, IL8, NFKBIA, and TNFAIP2. In one embodiment, the probes are labeled. In one embodiment, the set of probes includes at least one of SEQ. ID. NOS. 46, 49, 52, 55, and 58. In one embodiment, the set of primers include at least one of SEQ. ID. NOS. 44 and 45, 47 and 48, 50 and 51, 53 and 54, and 56 and 57. In one embodiment, a computer program product for determining the activity level of a NFkB cellular signaling pathway in the subject comprising a non-transitory computer readable storage medium having computer readable program code embodied therewith, the computer readable program code executable by at least one processor to: (i) calculate a level of NFkB transcription factor element in the sample, wherein the level of the NFkB transcription factor element in the sample is associated with NFkB cellular signaling, and wherein the level of the NFkB transcription factor element in the sample is calculated by: (1) receiving data on the expression levels of the at least six target genes derived from the sample; (2) calculating the level of the NFkB transcription factor element in the sample using a calibrated pathway model, wherein the calibrated pathway model compares the expression levels of the at least six target genes in the sample with expression levels of the at least six target genes in the model which define an activity level of NFkB transcription factor element; and, (ii) calculate the activity level of the NFkB cellular signaling pathway in the sample based on the calculated NFkB transcription factor element level in the sample.
- E) A kit for determining the activity level of a NFkB cellular signaling pathway in a subject comprising:
-
- a. one or more components capable of identifying expression levels of at least six NFkB cellular signaling pathway target genes from a sample of the subject, wherein the at least six NFkB cellular signaling pathway target genes are selected from BCL2L1, BIRC3, CCL2, CCL3, CCL4, CCL5, CCL20, CCL22, CX3CL1, CXCL1, CXCL2, CXCL3, ICAM1, IL1B, IL6, IL8, IRF1, MMP9, NFKB2, NFKBIA, NFKBIE, PTGS2, SELE, STAT5A, TNF, TNFAIP2, TNIP1, TRAF1, and VCAM1; and,
- b. optionally, a non-transitory computer readable storage medium having computer readable program code embodied therewith, the computer readable program code executable by at least one processor to:
- i. calculate a level of NFkB transcription factor element in the sample, wherein the level of NFkB transcription factor element in the sample is associated with NFkB cellular signaling, and wherein the level of the NFkB transcription factor element in the sample is calculated by:
- 1. receiving data on the expression levels of the at least six target genes derived from the sample;
- 2. calculating the level of the NFkB transcription factor element in the sample using a calibrated pathway model, wherein the calibrated pathway model compares the expression levels of the at least six target genes in the sample with expression levels of the at least six target genes in the model which define an activity level of the NFkB transcription factor element; and,
- ii. calculate the activity level of the NFkB cellular signaling pathway in the sample based on the calculated NFkB transcription factor element level in the sample.
Determining the Activity Level of the NFkB Cellular Signaling Pathway The present invention provides new and improved methods and apparatuses, and in particular computer implemented methods and apparatuses, as disclosed herein, to assess the functional state or activity of the NFkB cellular signaling pathway.
- i. calculate a level of NFkB transcription factor element in the sample, wherein the level of NFkB transcription factor element in the sample is associated with NFkB cellular signaling, and wherein the level of the NFkB transcription factor element in the sample is calculated by:
- In one aspect of the invention, provided herein is a method of determining NFkB cellular signaling in a subject comprising the steps of:
-
- a. calculating a level of NFkB transcription factor element in a sample isolated from a subject, wherein the level of NFkB transcription factor element in the sample is associated with an activity level of the NFkB cellular signaling pathway, and wherein the activity level of the NFkB transcription factor element in the sample is calculated by:
- i. receiving data on the expression levels of at least six target genes derived from the sample, wherein the NFkB transcription factor element controls transcription of the at least six target genes,
- ii. calculating the level of NFkB transcription factor element in the sample using a calibrated pathway model, wherein the calibrated pathway model compares the expression levels of the at least six genes in the sample with expression levels of the at least six target genes in the calibrated pathway model which define an activity level of the NFkB transcription factor element; and,
- b. calculating the activity level of the NFkB cellular signaling pathway in the sample based on the calculated levels of NFkB transcription factor element in the sample. As contemplated herein, the method of calculating the activity level of the NFkB cellular signaling pathway is performed by a computer processor.
- a. calculating a level of NFkB transcription factor element in a sample isolated from a subject, wherein the level of NFkB transcription factor element in the sample is associated with an activity level of the NFkB cellular signaling pathway, and wherein the activity level of the NFkB transcription factor element in the sample is calculated by:
- As a non-limiting generalized example,
FIG. 2 provides an exemplary flow diagram used to determine the activity level of the NFkB cellular signaling pathway based on a computer implemented mathematical model constructed of three nodes: (a) a transcription factor (TF) element (for example, but not limited to being, discretized into the states “absent” and “present” or as a continuous observable) in afirst layer 1; (b) target genes TG1, TG2, TGn (for example, but not limited to being, discretized into the states “down” and “up” or as a continuous observable) in asecond layer 2, and; (c) measurement nodes linked to the expression levels of the target genes in athird layer 3. The expression levels of the target genes can be determined by, for example, but not limited to, microarray probesets PS1,1, PS1,2, PS1,3, PS2,1, PSn,1, PSn,m (for example, but limited to being, discretized into the states “low” and “high” or as a continuous observable), but could also be any other gene expression measurements such as, for example, RNAseq or RT-qPCR. The expression of the target genes depends on the activation of the respective transcription factor element, and the measured intensities of the selected probesets depend in turn on the expression of the respective target genes. The model is used to calculate NFKB pathway activity by first determining probeset intensities, i.e., the expression level of the target genes, and calculating backwards in the model what the probability is that the transcription factor element must be present. - The present invention makes it possible to determine the activity of the NFkB cellular signaling pathway by (i) determining a level of an NFkB TF element in the sample, wherein the determining is based at least in part on evaluating a mathematical model relating expression levels of one or more target genes of the NFkB cellular signaling pathway, the transcription of which is controlled by the NFkB TF element, to the level of the NFkB TF element, and by (ii) inferring the activity of the NFkB cellular signaling pathway based on the determined level of the NFkB TF element in the sample. This preferably allows improving the possibilities of characterizing patients that have a cancer, e.g., a diffuse large B-cell lymphoma (DLBCL), a multiple myeloma, a cancer of another haematological origin, or a solid tumor, such as a breast, melanoma, or prostate tumor, which is at least partially driven by a deregulated NFkB cellular signaling pathway, and that are therefore likely to respond to inhibitors of the NFkB cellular signaling pathway. An important advantage of the present invention is that it makes it possible to determine the activity of the NFkB cellular signaling pathway using a single sample, rather than requiring a plurality of samples extracted at different points in time.
- Generalized Workflow for Determining the Activity Level of NFkB Cellular Signaling An example flow chart illustrating an exemplary calculation of the activity level of NFkB cellular signaling from a sample isolated from a subject is provided in
FIG. 3 . First, the mRNA from a sample is isolated (11). Second, the mRNA expression levels of a unique set of at least three or more NFkB target genes, as described herein, are measured (12) using methods for measuring gene expression that are known in the art. Next, the calculation of transcription factor element (13) is calculated using a calibrated pathway model (14), wherein the calibrated pathway model compares the expression levels of the at least three or more target genes in the sample with expression levels of the at least three target genes in the calibrated pathway model which have been correlated with a level of a NFkB transcription factor element. Finally, the activity level of the NFkB cellular signaling pathway is calculated in the sample based on the calculated levels of NFkB transcription factor element in the sample (15). For example, the NFkB signaling pathway is determined to be active if the activity is above a certain threshold, and can be categorized as passive if the activity falls below a certain threshold. - The present invention utilizes the analyses of the expression levels of unique sets of target genes. Particularly suitable target genes are described in the following text passages as well as the examples below (see, e.g., Tables 3 to 6 below).
- Thus, according to an embodiment the target genes are selected from the group consisting of the target genes listed in Table 3, Table 4, Table 5, or Table 6 below.
- In particular, the unique set of target genes whose expression is analyzed in the model includes at least six target genes, for example, seven, eight, nine, ten, eleven or more, selected from BCL2L1, BIRC3, CCL2, CCL3, CCL4, CCL5, CCL20, CCL22, CX3CL1, CXCL1, CXCL2, CXCL3, ICAM1, IL1B, IL6, IL8, IRF1, MMP9, NFKB2, NFKBIA, NFKBIE, PTGS2, SELE, STAT5A, TNF, TNFAIP2, TNIP1, TRAF1, and VCAM1.
- In one embodiment, the at least six target genes are selected from BIRC3, CCL2, CCL5, CCL20, CXCL1, CXCL2, CXCL3, ICAM1, IL6, IL8, IRF1, MMP9, NFKB2, NFKBIA, NFKBIE, TNF, TNFAIP2, TRAF1, and VCAM1. In one embodiment, the at least six target genes comprise at least three target genes, for example, four, five, six or more, selected from CCL2, CCL5, CCL20, CXCL1, CXCL2, CXCL3, ICAM1, IL6, IL8, MMP9, NFKB2, NFKBIA, and TNFAIP2. In one embodiment, the at least three target genes are selected from CCL5, CXCL2, ICAM1, IL6, IL8, NFKBIA, and TNFAIP2.
- It has been found by the present inventors that the genes in the successively shorter lists become more and more probative for determining the activity of the NFkB cellular signaling pathway.
- Data derived from the unique set of target genes described herein is further utilized to determine the activity level of the NFkB cellular signaling pathway using the methods described herein.
- Methods for analyzing gene expression levels in isolated samples are generally known. For example, methods such as Northern blotting, the use of PCR, nested PCR, quantitative real-time PCR (qPCR), RNA-seq, or microarrays can all be used to derive gene expression level data. All methods known in the art for analyzing gene expression of the target genes are contemplated herein.
- Methods of determining the expression product of a gene using PCR based methods may be of particular use. In order to quantify the level of gene expression using PCR, the amount of each PCR product of interest is typically estimated using conventional quantitative real-time PCR (qPCR) to measure the accumulation of PCR products in real time after each cycle of amplification. This typically utilizes a detectible reporter such as an intercalating dye, minor groove binding dye, or fluorogenic probe whereby the application of light excites the reporter to fluoresce and the resulting fluorescence is typically detected using a CCD camera or photomultiplier detection system, such as that disclosed in U.S. Pat. No. 6,713,297 which is hereby incorporated by reference.
- In some embodiments, the probes used in the detection of PCR products in the quantitative real-time PCR (qPCR) assay can include a fluorescent marker. Numerous fluorescent markers are commercially available. For example, Molecular Probes, Inc. (Eugene, Oreg.) sells a wide variety of fluorescent dyes. Non-limiting examples include Cy5, Cy3, TAMRA, R6G, R110, ROX, JOE, FAM, Texas Red™, and Oregon Green™. Additional fluorescent markers can include IDT ZEN Double-Quenched Probes with traditional 5′ hydrolysis probes in qPCR assays. These probes can contain, for example, a 5 FAM dye with either a 3′ TAMRA Quencher, a 3′ Black Hole Quencher (BHQ, Biosearch Technologies), or an internal ZEN Quencher and 3′ Iowa Black Fluorescent Quencher (IBFQ).
- Fluorescent dyes useful according to the invention can be attached to oligonucleotide primers using methods well known in the art. For example, one common way to add a fluorescent label to an oligonucleotide is to react an N-Hydroxysuccinimide (NHS) ester of the dye with a reactive amino group on the target. Nucleotides can be modified to carry a reactive amino group by, for example, inclusion of an allyl amine group on the nucleobase. Labeling via allyl amine is described, for example, in U.S. Pat. Nos. 5,476,928 and 5,958,691, which are incorporated herein by reference. Other means of fluorescently labeling nucleotides, oligonucleotides and polynucleotides are well known to those of skill in the art.
- Other fluorogenic approaches include the use of generic detection systems such as SYBR-green dye, which fluoresces when intercalated with the amplified DNA from any gene expression product as disclosed in U.S. Pat. Nos. 5,436,134 and 5,658,751 which are hereby incorporated by reference.
- Another useful method for determining target gene expression levels includes RNA-seq, a powerful analytical tool used for transcriptome analyses, including gene expression level difference between different physiological conditions, or changes that occur during development or over the course of disease progression.
- Another approach to determine gene expression levels includes the use of microarrays for example RNA and DNA microarray, which are well known in the art. Microarrays can be used to quantify the expression of a large number of genes simultaneously.
- As contemplated herein, the expression levels of the unique set of target genes described herein are used to calculate the level NFkB transcription factor element using a calibrated pathway model as further described below. The calibrated pathway model compares the expression levels of the at least three target genes in the sample with expression levels of the at least three target genes in the calibrated pathway model which define a level of NFkB transcription factor element.
- As contemplated herein, the calibrated pathway model is based on the application of a mathematical model. For example, the calibrated model can be based on a probabilistic model, for example a Bayesian network, or a linear or pseudo-linear model.
- In one embodiment, the calibrated pathway model is a probabilistic model incorporating conditional probabilistic relationships that compare the expression levels of the at least three target genes in the sample with expression levels of the at least three target genes in the calibrated pathway model which define a level NFkB transcription factor element to determine the level of the NFkB transcription factor element in the sample. In one embodiment, the probabilistic model is a Bayesian network model.
- In an alternative embodiment, the calibrated pathway model can be a linear or pseudo-linear model. In an embodiment, the linear or pseudo-linear model is a linear or pseudo-linear combination model.
- A non-limiting exemplary flow chart for a calibrated pathway model is shown in
FIG. 4 . As an initial step, the training data for the mRNA expression levels is collected and normalized. The data can be collected using, for example microarray probeset intensities (101), real-time PCR Cq values (102), raw RNAseq reads (103), or alternative measurement modalities (104) known in the art. The raw expression level data can then be normalized for each method, respectively, by normalization using a normalization algorithm, for example, frozen robust military analysis (fRMA) or MAS5.0 (111), normalization to average Cq of reference genes (112), normalization of reads into reads/fragments per kilobase of transcript per million mapped reads (RPKM/FPKM) (113), or normalization to w.r.t. reference genes/proteins (114). This normalization procedure leads to a normalized probeset intensity (121), normalized Cq values (122), normalized RPKM/FPKM (123), or normalized measurement (124) for each method, respectively, which indicate target gene expression levels within the training samples. - Once the training data has been normalized, a training sample ID or IDs (131) is obtained and the training data of these specific samples is obtained from one of the methods for determining gene expression (132). The final gene expression results from the training sample are output as training data (133). All of the data from various training samples are incorporated to calibrate the model (including for example, thresholds, CPTs, for example in the case of the probabilistic or Bayesian network, weights, for example, in the case of the linear or pseudo-linear model, etc) (144). In addition, the pathway's target genes and measurement nodes (141) are used to generate the model structure for example, as described in
FIG. 2 (142). The resulting model structure (143) of the pathway is then incorporated with the training data (133) to calibrate the model (144), wherein the gene expression levels of the target genes is indicative of the transcription factor element activity. As a result of the transcription factor element calculations in the training samples, a calibrated pathway model (145) is calculated which assigns the NFkB cellular signaling pathway activity level for a subsequently examined sample of interest, for example from a subject with a cancer, based on the target gene expression levels in the training samples. - A non-limiting exemplary flow chart for calculating the Transcription Factor Element activity level is provided in
FIG. 5 . The expression level data (test data) (163) from a sample isolated from a subject is input into the calibrated pathway model (145). The mathematical model may be a probabilistic model, for example a Bayesian network model, a linear model, or pseudo-linear model. - The mathematical model may be a probabilistic model, for example a Bayesian network model, based at least in part on conditional probabilities relating the NFkB TF element and expression levels of the at least six target genes of the NFkB cellular signaling pathway measured in the sample of the subject, or the mathematical model may be based at least in part on one or more linear combination(s) of expression levels of the at least six target genes of the NFkB cellular signaling pathway measured in the sample of the subject. In particular, the determining of the activity of the NFkB cellular signaling pathway may be performed as disclosed in the published international patent application WO 2013/011479 A2 (“Assessment of cellular signaling pathway activity using probabilistic modeling of target gene expression”), and incorporated herein by reference. Briefly, the data is entered into a Bayesian network (BN) inference engine call (for example, a BNT toolbox) (154). This leads to a set of values for the calculated marginal BN probabilities of all the nodes in the BN (155). From these probabilities, the transcription factor (IT) node's probability (156) is determined and establishes the TF's element activity level (157).
- Alternatively, the mathematical model may be a linear model. For example, a linear model can be used as described in the published international patent application WO 2014/102668 A2 (“Assessment of cellular signaling pathway activity using linear combination(s) of target gene expressions”), the contents of which are herewith incorporated in their entirety. Further details regarding the calculating/determining of cellular signaling pathway activity using mathematical modeling of target gene expression can also be found in Verhaegh W. et al., “Selection of personalized patient therapy through the use of knowledge-based computational models that identify tumor-driving signal transduction pathways”, Cancer Research, Vol. 74, No. 11, 2014, pages 2936 to 2945. Briefly, the data is entered into a calculated weighted linear combination score (w/c) (151). This leads to a set of values for the calculated weighted linear combination score (152). From these weighted linear combination scores, the transcription factor (TF) node's weighted linear combination score (153) is determined and establishes the TF's element activity level (157).
- A non-limiting exemplary flow chart for calculating the activity level of a NFkB cellular signaling pathway as a discretized observable is shown in
FIG. 6 . First, the test sample is isolated and given a test sample ID (161). Next, the test data for the mRNA expression levels is collected and normalized (162). The test data can be collected using the same methods as discussed for the training samples inFIG. 5 , using microarray probeset intensities (101), real-time PCR Cq values (102), raw RNAseq reads (103), or an alternative measurement modalities (104). The raw expression level data can then be normalized for each method, respectively, by normalization using an algorithm, for example fRMA or MAS5.0 (111), normalization to average Cq of reference genes (112), normalization of reads into RPKM/FPKM (113), and normalization to w.r.t. reference genes/proteins (114). This normalization procedure leads to a normalized probeset intensity (121), normalized Cq values (122), normalized RPKM/FPKM (123), or normalized measurement (124) for each method, respectively. - Once the test data has been normalized, the resulting test data (163) is analyzed in a thresholding step (164) based on the calibrated pathway model (145), resulting in the thresholded test data (165). In using discrete observables, in one non-limiting example, every expression above a certain threshold is, for example, given a value of 1 and values below the threshold are given a value of 0, or in an alternative embodiment, the probability mass above the threshold as described herein is used as a thresholded value. Based on the calibrated pathway model, this value represents the TF's element activity level (157), which is then used to calculate the pathway's activity level (171). The final output gives the pathway's activity level (172) in the test sample being examined from the subject.
- A non-limiting exemplary flow chart for calculating the activity level of a NFkB cellular signaling pathway as a continuous observable is shown in
FIG. 7 . First, the test sample is isolated and given a test sample ID (161). Next, the test data for the mRNA expression levels is collected and normalized (162). The test data can be collected using the same methods as discussed for the training samples inFIG. 5 , using microarray probeset intensities (101), real-time PCR Cq values (102), raw RNAseq reads (103), or an alternative measurement modalities (104). The raw expression level data can then be normalized for each method, respectively, by normalization using an algorithm, for example fRMA (111), normalization to average Cq of reference genes (112), normalization of reads into RPKM/FPKM (113), and normalization to w.r.t. reference genes/proteins (114). This normalization procedure leads to a normalized probeset intensity (121), normalized Cq values (122), normalized RPKM/FPKM (123), or normalized measurement (124) for each method, respectively. - Once the test data has been normalized, the resulting test data (163) is analyzed in the calibrated pathway model (145). In using continuous observables, as one non-limiting example, the expression levels are converted to values between 0 and 1 using a sigmoid function as described in further detail below. The transcription factor element calculation as described herein is used to interpret the test data in combination with the calibrated pathway model, the resulting value represents the TF's element activity level (157), which is then used to calculate the pathway's activity level (171). The final output then gives the pathway's activity level (172) in the test sample.
- In some embodiments, the present invention utilizes kits comprising primer and probe sets for the analyses of the expression levels of unique sets of target genes (see Target Gene discussion above). Particularly suitable oligo sequences for use as primers and probes for inclusion in a kit are described in the following text passages (see, e.g., Tables 1 and 2).
- Also contemplated herein is a kit for measuring the expression levels of at least six or more NFkB cellular signaling pathway target genes, for example, seven, eight, nine, ten, eleven, twelve, or more target genes as described herein. In one embodiment, the kit includes one or more components, for example probes, for example labeled probes, and/or PCR primers, for measuring the expression levels of at least six target genes, at least seven target genes, at least eight target genes, or at least nine or more target genes selected from BCL2L1, BIRC3, CCL2, CCL3, CCL4, CCL5, CCL20, CCL22, CX3CL1, CXCL1, CXCL2, CXCL3, ICAM1, IL1B, IL6, IL8, IRF1, MMP9, NFKB2, NFKBIA, NFKBIE, PTGS2, SELE, STAT5A, TNF, TNFAIP2, TNIP1, TRAF1, and VCAM1. In one embodiment, the kit includes one or more components for measuring the expression levels of at least six target genes, at least seven target genes, at least eight target genes, or at least nine or more target genes selected from BIRC3, CCL2, CCL5, CCL20, CXCL1, CXCL2, CXCL3, ICAM1, IL6, IL8, IRF1, MMP9, NFKB2, NFKBIA, NFKBIE, TNF, TNFAIP2, TRAF1, and VCAM1. In one embodiment, the one or more components comprise one or more components for measuring the expression levels of at least three target genes, at least four target genes, at least five target genes, or at least six or more target genes selected from CCL2, CCL5, CCL20, CXCL1, CXCL2, CXCL3, ICAM1, IL6, 1L8, MMP9, NFKB2, NFKBIA, and TNFAIP2.
- In one embodiment, the one or more components comprise one or more components for measuring the expression levels of at least three target genes, at least four target genes, at least five target genes, or at least six or more target genes selected from CCL5, CXCL2, ICAM1, IL6, IL8, NFKBIA, and TNFAIP2.
- In one embodiment, the kit includes one or more components for measuring the expression levels of at least six or more NFkB cellular signaling pathway target genes, wherein the at least six or more target genes are selected from BCL2L1, BIRC3, CCL2, CCL3, CCL4, CCL5, CCL20, CCL22, CX3CL1, CXCL1, CXCL2, CXCL3, ICAM1, IL1B, IL6, IN8, IRF1, MMP9, NFKB2, NFKBIA, NFKBIE, PTGS2, SELE, STAT5A, TNF, TNFAIP2, TNIP1, TRAF1, and VCAM1, and the one or more components is selected from the PCR primers and probes listed in Table 1. In one embodiment, the at least six or more target genes are selected from BIRC3, CCL2, CCL5, CCL20, CXCL1, CXCL2, CXCL3, ICAM1, IL6, IL8, IRF1, MMP9, NFKB2, NFKBIA, NFKBIE, TNF, TNFAIP2, TRAF1, and VCAM1, and the one or more components is selected from the PCR primers and probes listed in Table 1. In one embodiment, the at least six target genes comprise at least three target genes selected from CCL2, CCL5, CCL20, CXCL1, CXCL2, CXCL3, ICAM1, IL6, IL8, MMP9, NFKB2, NFKBIA, and TNFAIP2, and the one or more components is selected from the PCR primers and probes listed in Table 1. In one embodiment, the at least three target genes are selected from CCL5, CXCL2, ICAM1, IL6, IL8, NFKBIA, and TNFAIP2, and the one or more components is selected from the PCR primers and probes listed in Table 1. The PCR primers for each gene are designated Forward (For) and Reverse (Rev) and the probes for detection of the PCR products for each gene are labeled Probe. In one non-limiting embodiment, the probes listed in Table 2 are labeled with a 5′ FAM dye with an internal ZEN Quencher and 3′ Iowa Black Fluorescent Quencher (IBFQ).
-
TABLE 1 Non-limiting example of primers and probes for a kit for measuring gene expression of NFkB target genes. SEQ ID Target Oligo Name Sequence 5′-3′ No. Gene CXCL8_For1 GGCAGCCTTCCTGATTTCTG 44 IL8 (a.k.a. CXCL8) CXCL8_Rev1 GGTGGAAAGGTTTGGAGTATG 45 IL8 (a.k.a. CXCL8) CXCL8_Probe1 CAGCTCTGTGTGAAGGTGCAGTTT 46 IL8 (a.k.a. CXCL8) BIRC3_For GGAGTTCATCCGTCAAGTTCAA 47 BIRC3 BIRC3_Rev TTTCATCTCCTGGGCTGTC 48 BIRC3 BIRC3_Probe ACCCTCATCTACTTGAACAGCTGCT 49 BIRC3 ICAM1_For TGCAGTAATACTGGGGAACC 50 ICAM1 ICAM1_Rev GCTTCGTCAGAATCACGTTGG 51 ICAM1 ICAM1_Probe TGACCATCTACAGCTTTCCGGCG 52 ICAM1 NFKBIA_For CCTCCACTCCATCCTGAAG 53 NFKBIA NFKBIA_Rev GCCATGGATAGAGGCTAAGT 54 NFKBIA NFKBIA_Probe ACCAACTACAATGGCCACACGTG 55 NFKBIA PTGS2_For TTTCAAGACAGATCATAAGCGAG 56 PTGS2 PTGS2_Rev AGCCAGAGTTTCACCGTAAATA 57 PTGS2 PTGS2_Probe TGGGCCATGGGGTGGACTTAAAT 58 PTGS2 - In one non-limiting embodiment, the kit includes one or more components for measuring the expression levels of control genes, wherein the one or more components includes a PCR primer set and probe for at least one of the control genes listed in Table 2. The PCR primers for each gene are designated Forward (F) and Reverse (R) and the probes for detection of the PCR products for each gene are labeled Probe (P or FAM). In one non-limiting embodiment, the probes listed in Table 2 are labeled with a 5′ FAM dye with an internal ZEN Quencher and 3′ Iowa Black Fluorescent Quencher (IBFQ).
-
TABLE 2 Oligo Sequences for Controls SEQ Refer- ID ence Oligo Name Sequence 5′-3′ No. gene Hum_BACT_F1 CCAACCGCGAGAAGATGA 59 ACTB Hum_BACT_R1 CCAGAGGCGTACAGGGATAG 60 ACTB Hum_BACT_P1 CCATGTACGTTGCTATCCAGGCT 61 ACTB Hum_POLR2A_ AGTCCTGAGTCCGGATGAA 62 POLR2A F1 Hum_POLR2A_ CCTCCCTCAGTCGTCTCT 63 POLR2A R1 Hum_POLR2A_ TGACGGAGGGTGGCATCAAATACC 64 POLR2A P1 Hum_PUM1_F2 GCCAGCTTGTCTTCAATGAAAT 65 PUM1 Hum_PUM1_R2 CAAAGCCAGCTTCTGTTCAAG 66 PUM1 Hum_PUM1_P1 ATCCACCATGAGTTGGTAGGCAGC 67 PUM1 Hum_TBP_F1 GCCAAGAAGAAAGTGAACATCAT 68 TBP Hum_TBP1_R1 ATAGGGATTCCGGGAGTCAT 69 TBP Hum_TBP_P1 TCAGAACAACAGCCTGCCACCTTA 70 TBP K-ALPHA-1_F1 TGACTCCTTCAACACCTTCTTC 71 TUBA1B K-ALPHA-1_R1 TGCCAGTGCGAACTTCAT 72 TUBA1B K-ALPHA-1_ CCGGGCTGTGTTTGTAGACTTGGA 73 TUBA1B FAM1 ALAS1_F1 AGCCACATCATCCCTGT 74 ALAS1 ALAS1_R1 CGTAGATGTTATGTCTGCTCAT 75 ALAS1 ALAS1_FAM1 TTTAGCAGCATCTGCAACCCGC 76 ALAS1 Hum_HPRT1_F1 GAGGATTTGGAAAGGGTGTTTATT 77 HPRT1 Hum_HPRT1_R1 ACAGAGGGCTACAATGTGATG 78 HPRT1 Hum_HPRT1_P1 ACGTCTTGCTCGAGATGTGATGAAGG 79 HPRT1 Hum_RPLP0_F2 TAAACCCTGCGTGGCAAT 80 RPLP0 Hum_RPLP0_R2 ACATTTCGGATAATCATCCAATAGT 81 RPLP0 TG Hum_RPLP0_P1 AAGTAGTTGGACTTCCAGGTCGCC 82 RPLP0 Hum_B2M_F1 CCGTGGCCTTAGCTGTG 83 B2M Hum_B2M_R1 CTGCTGGATGACGTGAGTAAA 84 B2M Hum_B2M_P1 TCTCTCTTTCTGGCCTGGAGGCTA 85 B2M TPT1_F_PACE AAATGTTAACAAATGTGGCAATTAT 86 TPT1 TPT1_R_PACE AACAATGCCTCCACTCCAAA 87 TPT1 TPT1_P_PACE TCCACACAACACCAGGACTT 88 TPT1 EEF1A1_F_ TGAAAACTACCCCTAAAAGCCA 89 EEF1A1 PACE EEF1A1_R_ TATCCAAGACCCAGGCATACT 90 EEF1A1 PACE EEF1A1_P_ TAGATTCGGGCAAGTCCACCA 91 EEF1A1 PACE RPL41_F_PACE AAGATGAGGCAGAGGTCCAA 92 RPL41 RPL41_R_PACE TCCAGAATGTCACAGGTCCA 93 RPL41 RPL41_P_PACE TGCTGGTACAAGTTGTGGGA 94 RPL41 - As contemplated herein, the one or more components for measuring the expression levels of the particular target genes can be selected from the group consisting of: an DNA array chip, an oligonucleotide array chip, a protein array chip, an antibody, a plurality of probes, for example, labeled probes, a set of RNA reverser-transcriptase sequencing components, and/or RNA or DNA, including cDNA, amplification primers. In one embodiment, the kit includes a set of labeled probes directed to the cDNA sequence of the targeted genes as described herein contained in a standardized 96-well plate. In one embodiment, the kit further includes a non-transitory storage medium containing instructions that are executable by a digital processing device to perform a method according to the present invention as described herein.
- In accordance with another disclosed aspect, a kit for measuring expression levels of at least six target genes of the NFkB cellular signaling pathway in a sample of a subject comprises:
- one or more components for determining the expression levels of the at least six target genes of the NFkB cellular signaling pathway,
- wherein the one or more components are, for example, selected from the group consisting of: an DNA array chip, an oligonucleotide array chip, a protein array chip, an antibody, a plurality of probes, RNA sequencing and a set of primers, and
- wherein the at least six target genes of the NFkB cellular signaling pathway are selected from the group consisting of: BCL2L1, BIRC3, CCL2, CCL3, CCL4, CCL5, CCL20, CCL22, CX3CL1, CXCL1, CXCL2, CXCL3, ICAM1, IL1B, IL6, IL8, IRF1, MMP9, NFKB2, NFKBIA, NFKBIE, PTGS2, SELE, STAT5A, TNF, TNFAIP2, TNIP1, TRAF1, and VCAM1. In one embodiment, the at least six target genes are selected from BIRC3, CCL2, CCL5, CCL20, CXCL1, CXCL2, CXCL3, ICAM1, IL6, IL8, IRF1, MMP9, NFKB2, NFKBIA, NFKBIE, TNF, TNFAIP2, TRAF1, and VCAM1. In one embodiment, the at least six target genes comprise at least three target genes selected from CCL2, CCL5, CCL20, CXCL1, CXCL2, CXCL3, ICAM1, IL6, IL8, MMP9, NFKB2, NFKBIA, and TNFAIP2. In one embodiment, the at least three target genes are selected from CCL5, CXCL2, ICAM1, IL6, IL8, NFKBIA, and TNFAIP2.
- In one embodiment, the PCR cycling is performed in a microtiter or multi-well plate format. This format, which uses plates comprising multiple reaction wells, not only increases the throughput of the assay process, but is also well adapted for automated sampling steps due to the modular nature of the plates and the uniform grid layout of the wells on the plates. Common microtiter plate designs useful according to the invention have, for example 12, 24, 48, 96, 384, or more wells, although any number of wells that physically fit on the plate and accommodate the desired reaction volume (usually 10-100 μl) can be used according to the invention. Generally, the 96 or 384 well plate format can be utilized. In one embodiment, the method is performed in a 96 well plate format. In one embodiment, the method is performed in a 384 well plate format.
- In one embodiment, the kit comprises an apparatus comprising a digital processor. In another embodiment, the kit comprises a non-transitory storage medium storing instructions that are executable by a digital processing device. In yet another embodiment, the kit comprises a computer program comprising program code means for causing a digital processing device to perform the methods described herein.
- In an additional embodiment, the kit contains one or more components that are for example selected from the group consisting of: a DNA array chip, an oligonucleotide array chip, a protein array chip, an antibody, a plurality of probes, RNA sequencing and a set of primers. In one embodiment, the kit contains a plurality of probes. In one embodiment, the kit contains a set of primers. In one embodiment, the kit contains a 6, 12, 24, 48, 96, or 384-well PCR plate. In one embodiment, the kit includes a 96 well PCR plate. In one embodiment, the kit includes a 384 well PCR plate.
- In one embodiment, a kit for measuring the expression levels of NFkB cellular signaling target genes comprises a 96-well plate and a set of labeled probes for detecting expression of a set of NFkB cellular signaling pathway genes comprising BCL2L1, BIRC3, CCL2, CCL3, CCL4, CCL5, CCL20, CCL22, CX3CL1, CXCL1, CXCL2, CXCL3, ICAM1, IL1B, IL6, IL8, IRF1, MMP9, NFKB2, NFKBIA, NFKBIE, PTGS2, SELE, STAT5A, TNF, TNFAIP2, TNIP1, TRAF1, and VCAM1. In one embodiment, a kit for measuring the expression levels of NFkB cellular signaling target genes comprises a 96-well plate and a set of labeled probes for detecting expression of a set of NFkB cellular signaling pathway genes comprising BIRC3, CCL2, CCL5, CCL20, CXCL1, CXCL2, CXCL3, ICAM1, IL6, IL8, IRF1, MMP9, NFKB2, NFKBIA, NFKBIE, TNF, TNFAIP2, TRAF1, and VCAM1. In one embodiment, a kit for measuring the expression levels of NFkB cellular signaling target genes comprises a 96-well plate and a set of labeled probes for detecting expression of a set of NFkB cellular signaling pathway genes comprising CCL2, CCL5, CCL20, CXCL1, CXCL2, CXCL3, ICAM1, IL6, 118, MMP9, NFKB2, NFKBIA, and TNFAIP2. In one embodiment, a kit for measuring the expression levels of NFkB cellular signaling target genes comprises a 96-well plate and a set of labeled probes for detecting expression of a set of NFkB cellular signaling pathway genes comprising CCL5, CXCL2, ICAM1, IL6, IL8, NFKBIA, and TNFAIP2.
- In one embodiment, the kit further comprises an instruction manual measuring the expression levels of NFkB cellular signaling target genes. In another embodiment, the kit further comprises an access code to access a computer program code for calculating the NFkB cellular signaling pathway activity in the sample. In a further embodiment, the kit further comprises an access code to access a website for calculating the NFkB cellular signaling pathway activity in the sample according to the methods described above.
- A non-limiting exemplary flow chart for deriving target gene expression levels from a sample isolated from a subject is shown in
FIG. 8 . In one exemplary embodiment, samples are received and registered in a laboratory. Samples can include, for example, Formalin-Fixed, Paraffin-Embedded (FFPE) samples (181) or fresh frozen (FF) samples (180). FF samples can be directly lysed (183). For FFPE samples, the paraffin can be removed with a heated incubation step upon addition of Proteinase K (182). Cells are then lysed (183), which destroys the cell and nuclear membranes which makes the nucleic acid (NA) available for further processing. The nucleic acid is bound to a solid phase (184) which could for example, be beads or a filter. The nucleic acid is then washed with washing buffers to remove all the cell debris which is present after lysis (185). The clean nucleic acid is then detached from the solid phase with an elution buffer (186). The DNA is removed by DNAse treatment to ensure that only RNA is present in the sample (187). The nucleic acid sample can then be directly used in the RT-qPCR sample mix (188). The RT-qPCR sample mixes contains the RNA sample, the RT enzyme to prepare cDNA from the RNA sample and a PCR enzyme to amplify the cDNA, a buffer solution to ensure functioning of the enzymes and can potentially contain molecular grade water to set a fixed volume of concentration. The sample mix can then be added to a multiwell plate (i.e., 96 well or 384 well plate) which contains dried RT-qPCR assays (189). The RT-qPCR can then be run in a PCR machine according to a specified protocol (190). An example PCR protocol includes i) 30 minutes at 50° C.; ii) 5 minutes at 95° C.; iii) 15 seconds at 95° C.; iv) 45 seconds at 60° C.; v) 50 cycles repeating steps iii and iv. The Cq values are then determined with the raw data by using the second derivative method (191). The Cq values are exported for analysis (192). - As contemplated herein, the calculation of NFkB signaling in the sample is performed on a computerized device having a processor capable of executing a readable program code for calculating the NFkB cellular signaling pathway activity in the sample according to the methods described above. Accordingly, the computerized device can include means for receiving expression level data, wherein the data is expression levels of at least three target genes derived from the sample, a means for calculating the level of NFkB transcription factor element in the sample using a calibrated pathway model, wherein the calibrated pathway model compares the expression levels of the at least three target genes in the sample with expression levels of the at least three target genes in the model which have been correlated with a level NFkB transcription factor element; a means for calculating the NFkB cellular signaling in the sample based on the calculated levels of NFkB transcription factor element in the sample; and a means for assigning a NFkB cellular signaling pathway activity probability or status to the calculated NFkB cellular signaling in the sample, and a means for displaying the NFkB signaling pathway activity probability or status.
- In accordance with another disclosed aspect, a non-transitory storage medium stores instructions that are executable by a digital processing device to perform a method according to the present invention as described herein. The non-transitory storage medium may be a computer-readable storage medium, such as a hard drive or other magnetic storage medium, an optical disk or other optical storage medium, a random access memory (RAM), read only memory (ROM), flash memory, or other electronic storage medium, a network server, or so forth. The digital processing device may be a handheld device (e.g., a personal data assistant or smartphone), a notebook computer, a desktop computer, a tablet computer or device, a remote network server, or so forth.
- In accordance with another disclosed aspect, an apparatus comprises a digital processor configured to perform a method according to the present invention as described herein.
- In accordance with another disclosed aspect, a computer program comprises program code means for causing a digital processing device to perform a method according to the present invention as described herein. The digital processing device may be a handheld device (e.g., a personal data assistant or smartphone), a notebook computer, a desktop computer, a tablet computer or device, a remote network server, or so forth.
- In one embodiment, a computer program or system is provided for predicting the activity status of a NFkB transcription factor element in a human cancer sample that includes a means for receiving data corresponding to the expression level of one or more NFkB target genes in a sample from a host. In some embodiments, a means for receiving data can include, for example, a processor, a central processing unit, a circuit, a computer, or the data can be received through a website.
- In one embodiment, a computer program or system is provided for predicting the activity status of a NFkB transcription factor element in a human cancer sample that includes a means for displaying the NFkB pathway signaling status in a sample from a host. In some embodiments, a means for displaying can include a computer monitor, a visual display, a paper print out, a liquid crystal display (LCD), a cathode ray tube (CRT), a graphical keyboard, a character recognizer, a plasma display, an organic light-emitting diode (OLED) display, or a light emitting diode (LED) display, or a physical print out.
- In accordance with another disclosed aspect, a signal represents a determined activity of a NFkB cellular signaling pathway in a subject, wherein the determined activity results from performing a method according to the present invention as described herein. The signal can be a digital signal or it can be an analog signal.
- In one aspect of the present invention, a computer implemented method is provided for predicting the activity status of a NFkB signaling pathway in a human cancer sample performed by a computerized device having a processor comprising: a) calculating an activity level of a NFkB transcription factor element in a human cancer sample, wherein the level of the NFkB transcription factor element in the human cancer sample is associated with the activity of a NFkB cellular signaling pathway, and wherein the level of the NFkB transcription factor element in the human cancer sample is calculated by i) receiving data on the expression levels of at least six target genes derived from the human cancer sample, wherein the NFkB transcription factor controls transcription of the at least six target genes, and wherein the at least six target genes are selected from BCL2L1, BIRC3, CCL2, CCL3, CCL4, CCL5, CCL20, CCL22, CX3CL1, CXCL1, CXCL2, CXCL3, ICAM1, IL1B, IL6, 118, IRF1, MMP9, NFKB2, NFKBIA, NFKBIE, PTGS2, SELE, STAT5A, TNF, TNFAIP2, TNIP1, TRAF1, and VCAM1; ii) calculating the activity level of the NFkB transcription factor element in the human cancer sample using a calibrated pathway model, wherein the calibrated pathway model compares the expression levels of the at least six target genes in the human cancer sample with expression levels of the at least six target genes in the model which have been correlated with an activity level of a NFkB transcription factor element; b) calculating the NFkB cellular signaling pathway activity in the human cancer sample based on the calculated NFkB transcription factor element activity level in the human cancer sample; c) assigning a NFkB cellular signaling pathway activity status to the NFkB cellular signaling pathway in the human cancer sample, wherein the activity status is indicative of either an active NFkB cellular signaling pathway or a passive NFkB cellular signaling pathway; and d) displaying the NFkB signaling pathway activity status.
- In one aspect of the invention, a system is provided for determining the activity level of a NFkB cellular signaling pathway in a subject comprising a) a processor capable of calculating an activity level of NFkB transcription factor element in a sample derived from the subject; b) a means for receiving data, wherein the data is an expression level of at least six target genes derived from the sample; c) a means for calculating the level of the NFkB transcription factor element in the sample using a calibrated pathway model, wherein the calibrated pathway model compares the expression levels of the at least six target genes in the sample with expression levels of the at least six target genes in the model which define an activity level of NFkB transcription factor element; d) a means for calculating the activity level of the NFkB cellular signaling pathway in the sample based on the calculated activity level of NFkB transcription factor element in the sample; a means for assigning a NFkB cellular signaling pathway activity status to the calculated activity level of the NFkB cellular signaling pathway in the sample, wherein the activity status is indicative of either an active NFkB cellular signaling pathway or a passive NFkB cellular signaling pathway; and f) a means for displaying the NFkB signaling pathway activity status.
- As contemplated herein, the methods and apparatuses of the present invention can be utilized to assess NFkB cellular signaling pathway activity in a subject, for example a subject suspected of having, or having, a disease or disorder wherein the status of the NFkB signaling pathway is probative, either wholly or partially, of disease presence or progression. In one embodiment, provided herein is a method of treating a subject comprising receiving information regarding the activity status of a NFkB cellular signaling pathway derived from a sample isolated from the subject using the methods described herein and administering to the subject a NFkB inhibitor if the information regarding the level of NFkB cellular signaling pathway is indicative of an active NFkB signaling pathway. In a particular embodiment, the NFkB cellular signaling pathway activity indication is set at a cutoff value of odds of the NFkB cellular signaling pathway being active of 10:1, 5:1, 4:1, 2:1, 1:1, 1:2, 1:4, 1:5, 1:10. NFkB inhibitors are known and include, but are not limited to, DHMEQ, bindarit, Bortesomib or BU-32 (proteazome inhibitors), BMS-345541, or glucocorticoids.
- In a particular embodiment, the subject is suffering from, or suspected to have a benign or malignant tumor: a cancer or sarcoma or hematological malignancy, or brain tumor, for example, but not limited to, a primary tumor or a metastatic tumor, a solid tumor, for example, melanoma, lung cancer (including lung adenocarcinoma, basal cell carcinoma, squamous cell carcinoma, large cell carcinoma, bronchioloalveolar carcinoma, bronchogenic carcinoma, non-small-cell carcinoma, small cell carcinoma, mesothelioma); breast cancer (including ductal carcinoma, lobular carcinoma, inflammatory breast cancer, clear cell carcinoma, mucinous carcinoma, serosal cavities breast carcinoma); colorectal cancer (colon cancer, rectal cancer, colorectal adenocarcinoma): anal cancer; pancreatic cancer (including pancreatic adenocarcinoma, islet cell carcinoma, neuroendocrine tumors); prostate cancer; prostate adenocarcinoma; ovarian carcinoma (ovarian epithelial carcinoma or surface epithelial-stromal tumor including serous tumor, endometrioid tumor and mucinous cystadenocarcinoma, sex-cord-stromal tumor); liver and bile duct carcinoma (including hepatocellular carcinoma, cholangiocarcinoma, hemangioma); esophageal carcinoma (including esophageal adenocarcinoma and squamous cell carcinoma); oral and oropharyngeal squamous cell carcinoma; salivary gland adenoid cystic carcinoma; bladder cancer; bladder carcinoma; carcinoma of the uterus (including endometrial adenocarcinoma, ocular, uterine papillary serous carcinoma, uterine clear-cell carcinoma, uterine sarcomas and leiomyosarcomas, mixed mullerian tumors); glioma, glioblastoma, medulloblastoma, and other tumors of the brain; kidney cancers (including renal cell carcinoma, clear cell carcinoma, Wilm's tumor); cancer of the head and neck (including squamous cell carcinomas); cancer of the stomach (gastric cancers, stomach adenocarcinoma, gastrointestinal stromal tumor); testicular cancer; germ cell tumor; neuroendocrine tumor, cervical cancer; carcinoids of the gastrointestinal tract, breast, and other organs; signet ring cell carcinoma: mesenchymal tumors including sarcomas, fibrosarcomas, haemangioma, angiomatosis, haemangiopericytoma, pseudoangiomatous stromal hyperplasia, myofibroblastoma, fibromatosis, inflammatory myofibroblastic tumor, lipoma, angiolipoma, granular cell tumor, neurofibroma, schwannoma, angiosarcoma, liposarcoma, rhabdomyosarcoma, osteosarcoma, leiomyoma, leiomysarcoma, skin, including melanoma, cervical, retinoblastoma, head and neck cancer, pancreatic, brain, thyroid, testicular, renal, bladder, soft tissue, adenal gland, urethra, cancers of the penis, myxosarcoma, chondrosarcoma, osteosarcoma, chordoma, malignant fibrous histiocytoma, lymphangiosarcoma, mesothelioma, squamous cell carcinoma: epidermoid carcinoma, malignant skin adnexal tumors, adenocarcinoma, hepatoma, hepatocellular carcinoma, renal cell carcinoma, hypernephroma, cholangiocarcinoma, transitional cell carcinoma, choriocarcinoma, seminoma, embryonal cell carcinoma, glioma anaplastic; glioblastoma multiforme, neuroblastoma, medulloblastoma, malignant meningioma, malignant schwannoma, neurofibrosarcoma, parathyroid carcinoma, medullary carcinoma of thyroid, bronchial carcinoid, pheochromocytoma, Islet cell carcinoma, malignant carcinoid, malignant paraganglioma, melanoma, Merkel cell neoplasm, cystosarcoma phylloide, salivary cancers, thymic carcinomas, and cancers of the vagina among others.
- In one embodiment, the methods described herein are useful for treating a host suffering from a lymphoma or lymphocytic or myelocytic proliferation disorder or abnormality. For example, the subject suffering from a Hodgkin Lymphoma of a Non-Hodgkin Lymphoma. For example, the subject can be suffering from a Non-Hodgkin Lymphoma such as, but not limited to: an AIDS-Related Lymphoma; Anaplastic Large-Cell Lymphoma; Angioimmunoblastic Lymphoma; Blastic NK-Cell Lymphoma; Burkitt's Lymphoma; Burkitt-like Lymphoma (Small Non-Cleaved Cell Lymphoma); Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Cutaneous T-Cell Lymphoma; Diffuse Large B-Cell Lymphoma; Enteropathy-Type T-Cell Lymphoma; Follicular Lymphoma; Hepatosplenic Gamma-Delta T-Cell Lymphoma; Lymphoblastic Lymphoma; Mantle Cell Lymphoma; Marginal Zone Lymphoma; Nasal T-Cell Lymphoma; Pediatric Lymphoma; Peripheral T-Cell Lymphomas; Primary Central Nervous System Lymphoma; T-Cell Leukemias; Transformed Lymphomas; Treatment-Related T-Cell Lymphomas; or Waldenstrom's Macroglobulinemia.
- Alternatively, the subject may be suffering from a Hodgkin Lymphoma, such as, but not limited to: Nodular Sclerosis Classical Hodgkin's Lymphoma (CHL); Mixed Cellularity CHL; Lymphocyte-depletion CHL; Lymphocyte-rich CHL; Lymphocyte Predominant Hodgkin Lymphoma; or Nodular Lymphocyte Predominant HL.
- In one embodiment, the subject may be suffering from a specific T-cell, a B-cell, or a NK-cell based lymphoma, proliferative disorder, or abnormality. For example, the subject can be suffering from a specific T-cell or NK-cell lymphoma, for example, but not limited to: Peripheral T-cell lymphoma, for example, peripheral T-cell lymphoma and peripheral T-cell lymphoma not otherwise specified (PTCL-NOS); anaplastic large cell lymphoma, for example anaplastic lymphoma kinase (ALK) positive, ALK negative anaplastic large cell lymphoma, or primary cutaneous anaplastic large cell lymphoma; angioimmunoblastic lymphoma; cutaneous T-cell lymphoma, for example mycosis fungoides, Sfzary syndrome, primary cutaneous anaplastic large cell lymphoma, primary cutaneous CD30+ T-cell lymphoproliferative disorder; primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma; primary cutaneous gamma-delta T-cell lymphoma; primary cutaneous small/medium CD4+ T-cell lymphoma. and lymphomatoid papulosis; Adult T-cell Leukemia/Lymphoma (ATLL); Blastic NK-cell Lymphoma; Enteropathy-type T-cell lymphoma; Hematosplenic gamma-delta T-cell Lymphoma; Lymphoblastic Lymphoma; Nasal NK/T-cell Lymphomas; Treatment-related T-cell lymphomas; for example lymphomas that appear after solid organ or bone marrow transplantation; T-cell prolymphocytic leukemia; T-cell large granular lymphocytic leukemia; Chronic lymphoproliferative disorder of NK-cells; Aggressive NK cell leukemia; Systemic EBV+ T-cell lymphoproliferative disease of childhood (associated with chronic active EBV infection); Hydroa vacciniforme-like lymphoma; Adult T-cell leukemia/lymphoma; Enteropathy-associated T-cell lymphoma; Hepatosplenic T-cell lymphoma; or Subcutaneous panniculitis-like T-cell lymphoma.
- Alternatively, the subject may be suffering from a specific B-cell lymphoma or proliferative disorder such as, but not limited to: multiple myeloma; Diffuse large B cell lymphoma; Follicular lymphoma; Mucosa-Associated Lymphatic Tissue lymphoma (MALT); Small cell lymphocytic lymphoma; Mantle cell lymphoma (MCL); Burkitt lymphoma; Mediastinal large B cell lymphoma; Waldenström macroglobulinemia; Nodal marginal zone B cell lymphoma (NMZL); Splenic marginal zone lymphoma (SMZL); Intravascular large B-cell lymphoma; Primary effusion lymphoma; or Lymphomatoid granulomatosis; Chronic lymphocytic leukemia/small lymphocytic lymphoma; B-cell prolymphocytic leukemia; Hairy cell leukemia; Splenic lymphoma/leukemia, unclassifiable; Splenic diffuse red pulp small B-cell lymphoma; Hairy cell leukemia-variant; Lymphoplasmacytic lymphoma; Heavy chain diseases, for example, Alpha heavy chain disease, Gamma heavy chain disease, Mu heavy chain disease; Plasma cell myeloma; Solitary plasmacytoma of bone; Extraosseous plasmacytoma; Primary cutaneous follicle center lymphoma; T cell/histiocyte rich large B-cell lymphoma; DLBCL associated with chronic inflammation; Epstein-Barr virus (EBV)+ DLBCL of the elderly; Primary mediastinal (thymic) large B-cell lymphoma; Primary cutaneous DLBCL, leg type; ALK+ large B-cell lymphoma; Plasmablastic lymphoma; Large B-cell lymphoma arising in HHV8-associated multicentric; Castleman disease; B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma; B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma; Nodular sclerosis classical Hodgkin lymphoma; Lymphocyte-rich classical Hodgkin lymphoma; Mixed cellularity classical Hodgkin lymphoma; or Lymphocyte-depleted classical Hodgkin lymphoma.
- In one embodiment, the subject is suffering from a leukemia. For example, the subject may be suffering from an acute or chronic leukemia of a lymphocytic or myelogenous origin, such as, but not limited to: Acute lymphoblastic leukemia (ALL); Acute myelogenous leukemia (AML); Chronic lymphocytic leukemia (CLL); Chronic myelogenous leukemia (CMI): juvenile myelomonocytic leukemia (JMML); hairy cell leukemia (HCL); acute promyelocytic leukemia (a subtype of AML); T-cell prolymphocytic leukemia (TPLL); large granular lymphocytic leukemia; or Adult T-cell chronic leukemia; large granular lymphocytic leukemia (LGL). In one embodiment, the patient suffers from an acute myelogenous leukemia, for example an undifferentiated AML (M0); myeloblastic leukemia (M1; with/without minimal cell maturation); myeloblastic leukemia (M2; with cell maturation); promyelocytic leukemia (M3 or M3 variant [M3V]); myelomonocytic leukemia (M4 or M4 variant with eosinophilia [M4E]); monocytic leukemia (M5); erythroleukemia (M6): or megakaryoblastic leukemia (M7).
- In a particular embodiment, the subject is suffering, or suspected to be suffering from, a breast cancer, lung cancer, a colon cancer, pancreatic cancer, or brain cancer. In a particular embodiment, the subject is suffering from, or suspected to be suffering from, a breast cancer.
- The sample(s) to be used in accordance with the present invention can be an extracted sample, that is, a sample that has been extracted from the subject. Examples of the sample include, but are not limited to, a tissue, cells, blood and/or a body fluid of a subject. It can be, e.g., a sample obtained from a cancer lesion, or from a lesion suspected for cancer, or from a metastatic tumor, or from a body cavity in which fluid is present which is contaminated with cancer cells (e.g., pleural or abdominal cavity or bladder cavity), or from other body fluids containing cancer cells, and so forth, for example, via a biopsy procedure or other sample extraction procedure. The cells of which a sample is extracted may also be tumorous cells from hematologic malignancies (such as leukemia or lymphoma). In some cases, the cell sample may also be circulating tumor cells, that is, tumor cells that have entered the bloodstream and may be extracted using suitable isolation techniques, e.g., apheresis or conventional venous blood withdrawal. Aside from blood, a body fluid of which a sample is extracted may be urine, gastrointestinal contents, or an extravasate.
- In one aspect of the present invention, the methods and apparatuses described herein are used to identify an active NFkB cellular signaling pathway in a subject suffering from a cancer, and administering to the subject an anti-cancer agent, for example a NFkB inhibitor, selected from, but not limited to, DHMEQ, bindarit, Bortesomib or BU-32 (proteazome inhibitors), BMS-345541, or glucocorticoids. Another aspect of the present invention relates to a method (as described herein), further comprising:
- determining whether the NFkB cellular signaling pathway is operating abnormally in the subject based on the calculated activity of the NFkB cellular signaling pathway in the subject.
- Here, the term “abnormally” denotes disease-promoting activity of the NFkB cellular signaling pathway, for example, a tumor-promoting activity.
- The present invention also relates to a method (as described herein) further comprising:
- recommending prescribing a drug, for example a NFkB inhibitor, for the subject that corrects for abnormal operation of the NFkB cellular signaling pathway,
- wherein the recommending is performed if the NFkB cellular signaling pathway is determined to be operating abnormally in the subject based on the calculated/determined activity of the NFkB cellular signaling pathway.
- The present invention also relates to a method (as described herein), wherein the calculating/determining comprises:
- calculating the activity of the NFkB cellular signaling pathway in the subject based at least on expression levels of two, three or more target genes of a set of target genes of the NFkB cellular signaling pathway measured in the sample of the subject.
- The present invention as described herein can, e.g., also advantageously be used in connection with:
- diagnosis based on the determined activity of the NFkB cellular signaling pathway in the subject;
- prognosis based on the determined activity of the NFkB cellular signaling pathway in the subject;
- drug prescription based on the determined activity of the NFkB cellular signaling pathway in the subject;
- prediction of drug efficacy based on the determined activity of the NFkB cellular signaling pathway in the subject;
- prediction of adverse effects based on the determined activity of the NFkB cellular signaling pathway in the subject;
- monitoring of drug efficacy;
- drug development;
- assay development;
- pathway research;
- cancer staging;
- enrollment of the subject in a clinical trial based on the determined activity of the NFkB cellular signaling pathway in the subject;
- selection of subsequent test to be performed; and
- selection of companion diagnostics tests.
- Further advantages will be apparent to those of ordinary skill in the art upon reading and understanding the attached figures, the following description and, in particular, upon reading the detailed examples provided herein below.
- It shall be understood that an embodiment of the present invention can also be any combination of the dependent claims or above embodiments with the respective independent claim.
- These and other aspects of the invention will be apparent from and elucidated with reference to the embodiments described hereinafter.
- The following examples merely illustrate exemplary methods and selected aspects in connection therewith. The teaching provided therein may be used for constructing several tests and/or kits, e.g., to detect, predict and/or diagnose the abnormal activity of the NFKB cellular signaling pathways. Furthermore, upon using methods as described herein drug prescription can advantageously be guided, drug response prediction and monitoring of drug efficacy (and/or adverse effects) can be made, drug resistance can be predicted and monitored, e.g., to select subsequent test(s) to be performed (like a companion diagnostic test). The following examples are not to be construed as limiting the scope of the present invention.
- As described in detail in the published international patent application WO 2013/011479 A2 (“Assessment of cellular signaling pathway activity using probabilistic modeling of target gene expression”), by constructing a probabilistic model, e.g., a Bayesian network model, and incorporating conditional probabilistic relationships between expression levels of at least six target genes of a cellular signaling pathway, herein, the NFkB cellular signaling pathway, and the level of a transcription factor (TF) element, herein, the NFkB TF element, the TF element controlling transcription of the at least six target genes of the cellular signaling pathway, such a model may be used to determine the activity of the cellular signaling pathway with a high degree of accuracy. Moreover, the probabilistic model can be readily updated to incorporate additional knowledge obtained by later clinical studies, by adjusting the conditional probabilities and/or adding new nodes to the model to represent additional information sources. In this way, the probabilistic model can be updated as appropriate to embody the most recent medical knowledge.
- In another easy to comprehend and interpret approach described in detail in the published international patent application WO 2014/102668 A2 (“Assessment of cellular signaling pathway activity using linear combination(s) of target gene expressions”), the activity of a cellular signaling pathway, herein, the NFkB cellular signaling pathway, may be determined by constructing and evaluating a linear or (pseudo-)linear model incorporating relationships between expression levels of at least six target genes of the cellular signaling pathway and the level of a transcription factor (TF) element, herein, the NFkB TF element, the TF element controlling transcription of the at least six target genes of the cellular signaling pathway, the model being based at least in part on one or more linear combination(s) of expression levels of the at least six target genes.
- In both approaches, the expression levels of the at least six target genes may, for example, be measurements of the level of mRNA, which can be the result of, e.g., (RT)-PCR and microarray techniques using probes associated with the target genes mRNA sequences, and of RNA-sequencing. In another embodiment, the expression levels of the at least six target genes can be measured by protein levels, e.g., the concentrations and/or activity of the protein(s) encoded by the target genes.
- The aforementioned expression levels may optionally be converted in many ways that might or might not suit the application better. For example, four different transformations of the expression levels, e.g., microarray-based mRNA levels, may be:
-
- “continuous data”, i.e., expression levels as obtained after preprocessing of microarrays using well known algorithms such as MAS5.0 and fRMA,
- “z-score”, i.e., continuous expression levels scaled such that the average across all samples is 0 and the standard deviation is 1,
- “discrete”, i.e., every expression above a certain threshold is set to t and below it to 0 (e.g., the threshold for a probeset may be chosen as the (weighted) median of its value in a set of a number of positive and the same number of negative clinical samples),
- “fuzzy”, i.e., the continuous expression levels are converted to values between 0 and 1 using a sigmoid function of the following format: 1/(1+exp((thr−expr)/se)), with expr being the continuous expression levels, thr being the threshold as mentioned before and se being a softening parameter influencing the difference between 0 and 1.
- One of the simplest linear models that can be constructed is a model having a node representing the transcription factor (TF) element, herein, the NFkB TF element, in a first layer and weighted nodes representing direct measurements of the target genes expression levels, e.g., by one probeset that is particularly highly correlated with the particular target gene, e.g., in microarray or (q)PCR experiments, in a second layer. The weights can be based either on calculations from a training data set or based on expert knowledge. This approach of using, in the case where possibly multiple expression levels are measured per target gene (e.g., in the case of microarray experiments, where one target gene can be measured with multiple probesets), only one expression level per target gene is particularly simple. A specific way of selecting the one expression level that is used for a particular target gene is to use the expression level from the probeset that is able to separate active and passive samples of a training data set the best. One method to determine this probeset is to perform a statistical test, e.g., the t-test, and select the probeset with the lowest p-value. The training data set's expression levels of the probeset with the lowest p-value is by definition the probeset with the least likely probability that the expression levels of the (known) active and passive samples overlap. Another selection method is based on odds-ratios. In such a model, one or more expression level(s) are provided for each of the at least six target genes and the one or more linear combination(s) comprise a linear combination including for each of the at least six target genes a weighted term, each weighted term being based on only one expression level of the one or more expression level(s) provided for the respective target gene. If the only one expression level is chosen per target gene as described above, the model may be called a “most discriminant probesets” model.
- In an alternative to the “most discriminant probesets” model, it is possible, in the case where possibly multiple expression levels are measured per target gene, to make use of all the expression levels that are provided per target gene. In such a model, one or more expression level(s) are provided for each of the at least six target genes and the one or more linear combination(s) comprise a linear combination of all expression levels of the one or more expression level(s) provided for the at least six target genes. In other words, for each of the at least six target genes, each of the one or more expression level(s) provided for the respective target gene may be weighted in the linear combination by its own (individual) weight. This variant may be called an “all probesets” model. It has an advantage of being relatively simple while making use of all the provided expression levels.
- Both models as described above have in common that they are what may be regarded as “single-layer” models, in which the level of the TF element is calculated based on a linear combination of expression levels of the one or more probeset of the one or more target genes.
- After the level of the TF element, herein, the NFkB TF element, has been determined by evaluating the respective model, the determined TF element level can be thresholded in order to infer the activity of the cellular signaling pathway, herein, the NFkB cellular signaling pathway. An exemplary method to calculate such an appropriate threshold is by comparing the determined TF element levels w/c of training samples known to have a passive cellular signaling pathway and training samples with an active cellular signaling pathway. A method that does so and also takes into account the variance in these groups is given by using a threshold
-
- where σ and μ are the standard deviation and the mean of the determined TF element levels wlc for the training samples. In case only a small number of samples are available in the active and/or passive training samples, a pseudocount may be added to the calculated variances based on the average of the variances of the two groups:
-
- where ν is the variance of the determined TF element levels wlc of the groups, x is a positive pseudocount, e.g., 1 or 10, and nact and tgxrs are the number of active and passive samples, respectively The standard deviation a can next be obtained by taking the square root of the variance v.
- The threshold can be subtracted from the determined TF element levels wlc for ease of interpretation, resulting in a cellular signaling pathway's activity score in which negative values correspond to a passive cellular signaling pathway and positive values correspond to an active cellular signaling pathway.
- As an alternative to the above-described “single-layer” models, a “two-layer” may also be used in an example. In such a model, a summary value is calculated for every target gene using a linear combination based on the measured intensities of its associated probesets (“first (bottom) layer”). The calculated summary value is subsequently combined with the summary values of the other target genes of the cellular signaling pathway using a further linear combination (“second (upper) layer”). Again, the weights can be either learned from a training data set or based on expert knowledge or a combination thereof. Phrased differently, in the “two-layer” model, one or more expression level(s) are provided for each of the at least six target genes and the one or more linear combination(s) comprise for each of the at least six target genes a first linear combination of all expression levels of the one or more expression level(s) provided for the respective target gene (“first (bottom) layer”). The model is further based at least in part on a further linear combination including for each of the at least six target genes a weighted term, each weighted term being based on the first linear combination for the respective target gene (“second (upper) layer”).
- The calculation of the summary values can, in an exemplary version of the “two-layer” model, include defining a threshold for each target gene using the training data and subtracting the threshold from the calculated linear combination, yielding the target gene summary. Here the threshold may be chosen such that a negative target gene summary value corresponds to a down-regulated target gene and that a positive target gene summary value corresponds to an up-regulated target gene. Also, it is possible that the target gene summary values are transformed using, e.g., one of the above-described transformations (fuzzy, discrete, etc.), before they are combined in the “second (upper) layer”.
- After the level of the TF element has been determined by evaluating the “two-layer” model, the determined TF element level can be thresholded in order to infer the activity of the cellular signaling pathway, as described above.
- In the following, the models described above are collectively denoted as “(pseudo-)linear” models. A more detailed description of the training and use of probabilistic models, e.g., a Bayesian network model, is provided in Example 3 below.
- A transcription factor (TF) is a protein complex (i.e., a combination of proteins bound together in a specific structure) or a protein that is able to regulate transcription from target genes by binding to specific DNA sequences, thereby controlling the transcription of genetic information from DNA to mRNA. The mRNA directly produced due to this action of the TF complex is herein referred to as a “direct target gene” (of the transcription factor). Cellular signaling pathway activation may also result in more secondary gene transcription, referred to as “indirect target genes”. In the following, (pseudo-)linear models or Bayesian network models (as exemplary mathematical models) comprising or consisting of direct target genes as direct links between cellular signaling pathway activity and mRNA level, are exemplified, however the distinction between direct and indirect target genes is not always evident. Herein, a method to select direct target genes using a scoring function based on available scientific literature data is presented. Nonetheless, an accidental selection of indirect target genes cannot be ruled out due to limited information as well as biological variations and uncertainties. In order to select the target genes, the MEDLINE database of the National Institute of Health accessible at “www.ncbi.nlm.nih.gov/pubmed” and herein further referred to as “Pubmed” was employed to generate a lists of target genes. Furthermore, three additional lists of target genes were selected based on the probative nature of their expression.
- Publications containing putative NFkB target genes were searched for by using queries such as (“NFkB” AND “target gene”) in the period of the second and third quarter of 2013. The resulting publications were further analyzed manually following the methodology described in more detail below.
- Specific cellular signaling pathway mRNA target genes were selected from the scientific literature, by using a ranking system in which scientific evidence for a specific target gene was given a rating, depending on the type of scientific experiments in which the evidence was accumulated. While some experimental evidence is merely suggestive of a gene being a direct target gene, like for example an mRNA increasing as detected by means of an increasing intensity of a probeset on a microarray of a cell line in which it is known that the NFkB cellular signaling pathway is active, other evidence can be very strong, like the combination of an identified NFkB cellular signaling pathway TF binding site and retrieval of this site in a chromatin immunoprecipitation (ChIP) assay after stimulation of the specific cellular signaling pathway in the cell and increase in mRNA after specific stimulation of the cellular signaling pathway in a cell line.
- Several types of experiments to find specific cellular signaling pathway target genes can be identified in the scientific literature:
-
- 1. ChIP experiments in which direct binding of a TF of the cellular signaling pathway of interest to its binding site on the genome is shown. Example: By using chromatin immunoprecipitation (ChIP) technology subsequently putative functional NFkB TF binding sites in the DNA of cell lines with and without active induction of the NFkB cellular signaling pathway, e.g., by stimulation with tumor necrosis factor α (TNFα) or lipopolysaccharide (LPS), were identified, as a subset of the binding sites recognized purely based on nucleotide sequence. Putative functionality was identified as ChIP-derived evidence that the TF was found to bind to the DNA binding site.
- 2. Electrophoretic Mobility Shift (EMSA) assays which show in vitro binding of a TF to a fragment of DNA containing the binding sequence. Compared to ChIP-based evidence EMSA-based evidence is less strong, since it cannot be translated to the in vivo situation.
- 3. Stimulation of the cellular signaling pathway and measuring mRNA expression using a microarray, RNA sequencing, quantitative PCR or other techniques, using NFkB cellular signaling pathway-inducible cell lines and measuring mRNA profiles measured at least one, but preferably several time points after induction—in the presence of cycloheximide, which inhibits translation to protein, thus the induced mRNAs are assumed to be direct target genes.
- 4. Similar to 3, but alternatively measure the mRNAs expression further downstream with protein abundance measurements, such as western blot.
- 5. Identification of TF binding sites in the genome using a bioinformatics approach. Example for the NFkB TF element: Using the
NFkB binding motif 5′-GGGRNWYYCC-3′ (R: A or G, N: any nucleotide, W: A or T, Y: C or T), a software program was run on the human genome sequence, and potential binding sites were identified, both in gene promoter regions and in other genomic regions. - 6. Similar as 3, only in the absence of cycloheximide.
- 7. Similar to 4, only in the absence of cycloheximide.
- In the simplest form one can give every
potential gene 1 point for each of these experimental approaches in which the gene was identified as being a target gene of the NFkB family of transcription factors. Using this relative ranking strategy, one can make a list of most reliable target genes. - Alternatively, ranking in another way can be used to identify the target genes that are most likely to be direct target genes, by giving a higher number of points to the technology that provides most evidence for an in vivo direct target gene. In the list above, this would mean 8 points for experimental approach 1), 7 for 2), and going down to 1 point for experimental approach 8). Such a list may be called a “general list of target genes”.
- Despite the biological variations and uncertainties, the inventors assumed that the direct target genes are the most likely to be induced in a tissue-independent manner. A list of these target genes may be called an “evidence curated list of target genes”. Such an evidence curated list of target genes has been used to construct computational models of the NFkB cellular signaling pathway that can be applied to samples coming from different tissue sources.
- The following will illustrate exemplary how the selection of an evidence curated target gene list specifically was constructed for the NFkB cellular signaling pathway.
- A scoring function was introduced that gave a point for each type of experimental evidence, such as ChIP, EMSA, differential expression, knock down/out, luciferase gene reporter assay, sequence analysis, that was reported in a publication. The same experimental evidence is sometimes mentioned in multiple publications resulting in a corresponding number of points, e.g., two publications mentioning a ChIP finding results in twice the score that is given for a single ChIP finding. Further analysis was performed to allow only for genes that had diverse types of experimental evidence and not only one type of experimental evidence, e.g., differential expression. Finally, an evidence score was calculated for all putative NFkB target genes and all putative NFkB target genes with an evidence score of 5 or more were selected (shown in Table 3). The cut-off level of 5 was chosen heuristically as providing strong enough evidence.
- A further selection of the evidence curated list of target genes (listed in Table 3) was made by the inventors. The target genes of the evidence curated list that were proven to be more probative in determining the activity of the NFkB cellular signaling pathway from the training samples were selected. The selection was performed using a combination of the literature evidence score and training results using two different datasets. Three rankings were made based on the evidence score, highest score ranked first and every point less result in a lower rank, and the “soft” odds ratios of all included probesets (see Table 3) calculated as described herein using the GSE12195 and E-MTAB-1312 datasets. The absolute values of the
log 2 transformed “soft” odds ratios were used to rank the probesets; the highest odds ratio were ranked first, et cetera. As described herein, samples from ABC DLBCL samples from GSE12195 were chosen as active NFkB training samples whereas the normal samples from this dataset were chosen as the passive NFkB training samples. In addition, a second set of “soft” odds ratios were calculated using samples from E-MTAB-1312, an alternative NFkB training dataset, the control samples were used as passive NFkB samples and samples stimulated with different concentrations of TNFα for 2 hours were selected as active NFkB training samples. Based on the average rank a preferred set of target genes having at least one associated probeset with an average ranking of less than or equal to 20 was selected for the “19 target genes shortlist”. A more preferred set of target genes having an average ranking of less than or equal to 15 was selected for the “13 target genes shortlist”. A most preferred set of target genes having an average ranking of less than or equal to 12 were selected for the “7 target genes shortlist”. The 19 target genes shortlist, the 13 target genes shortlist, and the 7 target genes shortlist are shown in Tables 4 to 6, respectively. -
TABLE 3 “Evidence curated list of target genes” of the NFkB cellular signaling pathway used in the NFkB cellular signaling pathway models and associated probesets used to measure the mRNA expression level of the target genes. Target gene Score Probeset Target gene Score Probeset BCL2L1 5 206665_s_at IL6 10 205207_at 212312_at IL8 12 202859_x_at 215037_s_at 211506_s_at 231228_at IRF1 5 202531_at BIRC3 11 210538_s_at 238725_at 230499_at MMP9 6 203936_s_at CCL2 8 216598_s_at NFKB2 14 207535_s_at CCL3 8 205114_s_at 209636_at CCL4 5 204103_at 211524_at CCL5 11 1405_i_at NFKBIA 10 201502_s_at 1555759_a_at NFKBIE 7 203927_at 204655_at PTGS2 13 1554997_a_at CCL20 5 205476_at 204748_at CCL22 5 207861_at SELE 5 206211_at CX3CL1 6 203687_at STAT5A 7 203010_at 823_at TNF 9 207113_s_at CXCL1 12 204470_at TNFAIP2 5 202509_s_at CXCL2 15 1569203_at 202510_s_at 209774_x_at TNIP1 12 207196_s_at 230101_at 243423_at CXCL3 9 207850_at TRAF1 9 205599_at ICAM1 10 202637_s_at 235116_at 202638_s_at VCAM1 6 203868_s_at 215485_s_at IL1B 5 205067_at 39402_at -
TABLE 4 “19 target genes shortlist” of target genes of the NFkB cellular signaling pathway based on the literature evidence score and “soft” odds ratios on GSE12195 and E-MAT-1312. CXCL2 ICAM1 IL6 CCL5 NFKBIA IL8 TNFAIP2 CXCL3 MMP9 NFKB2 CCL20 CCL2 CXCL1 TNF IRF1 TRAF1 NFKBIE VCAM1 BIRC3 -
TABLE 5 “13 target genes shortlist” of target genes of the NFkB cellular signaling pathway based on the literature evidence score and “soft” odds ratios on GSE12195 and E-MAT-1312. CXCL2 ICAM1 IL6 CCL5 NFKBIA IL8 TNFAIP2 CXCL3 MMP9 NFKB2 CCL20 CCL2 CXCL1 -
TABLE 6 “7 target genes shortlist” of target genes of the NFkB cellular signaling pathway based on the literature evidence score and “soft” odds ratios on GSE12195 and E-MAT-1312. CXCL2 ICAM1 IL6 CCL5 NFKBIA IL8 TNFAIP2 - Before the mathematical model can be used to infer the activity of the cellular signaling pathway, herein, the NFkB cellular signaling pathway, the model must be appropriately trained.
- If the mathematical model is a probabilistic model, e.g., a Bayesian network model, based at least in part on conditional probabilities relating the NFkB TF element and expression levels of the at least six target genes of the NFkB cellular signaling pathway measured in a sample, the training may preferably be performed as described in detail in the published international patent application WO 2013/011479 A2 (“Assessment of cellular signaling pathway activity using probabilistic modeling of target gene expression”).
- If the mathematical model is based at least in part on one or more linear combination(s) of expression levels of the at least six target genes of the NFkB cellular signaling pathway measured in the sample, the training may preferably be performed as described in detail in the published international patent application WO 2014/102668 A2 (“Assessment of cellular signaling pathway activity using linear combination(s) of target gene expressions”).
- Herein, an exemplary Bayesian network model as shown in
FIG. 2 was first used to model the transcriptional program of the NFkB cellular signaling pathway in a simple manner. The model consists of three types of nodes: (a) a transcription factor (TF) element (with states “absent” and “present”) in afirst layer 1; (b) target genes TG1, TG2, TGn (with states “down” and “up”) in asecond layer 2, and; (c) measurement nodes linked to the expression levels of the target genes in athird layer 3 These can be microarray probesets PS1,1, PS1,2, PS1,3, PS2,1, PSn,1, PSn,m (with states “low” and “high”), as preferably used herein, but could also be other gene expression measurements such as RNAseq or RT-qPCR. - A suitable implementation of the mathematical model, herein, the exemplary Bayesian network model, is based on microarray data. The model describes (i) how the expression levels of the target genes depend on the activation of the TF element, and (ii) how probeset intensities, in turn, depend on the expression levels of the respective target genes. For the latter, probeset intensities may be taken from fRMA pre-processed Affymetrix HG-U133Plus2.0 microarrays, which are widely available from the Gene Expression Omnibus (GEO, www.ncbi.nlm.nih.gov/geo) and ArrayExpress (www.ebi.ac.uk/arrayexpress).
- As the exemplary Bayesian network model is a simplification of the biology of a cellular signaling pathway, herein, the NFkB cellular signaling pathway, and as biological measurements are typically noisy, a probabilistic approach was opted for, i.e., the relationships between (i) the TF element and the target genes, and (ii) the target genes and their respective probesets, are described in probabilistic terms. Furthermore, it was assumed that the activity of the oncogenic cellular signaling pathway which drives tumor growth is not transiently and dynamically altered, but long term or even irreversibly altered. Therefore the exemplary Bayesian network model was developed for interpretation of a static cellular condition. For this reason complex dynamic cellular signaling pathway features were not incorporated into the model.
- Once the exemplary Bayesian network model is built and calibrated (see below), the model can be used on microarray data of a new sample by entering the probeset measurements as observations in the
third layer 3, and inferring backwards in the model what the probability must have been for the TF element to be “present”. Here, “present” is considered to be the phenomenon that the TF element is bound to the DNA and is controlling transcription of the cellular signaling pathway's target genes, and “absent” the case that the TF element is not controlling transcription. This probability is hence the primary read-out that may be used to indicate activity of the cellular signaling pathway, herein, the NFkB cellular signaling pathway, which can next be translated into the odds of the cellular signaling pathway being active by taking the ratio of the probability of it being active vs. it being inactive (i.e., the odds are given by p/(1−p), where p is the predicted probability of the cellular signaling pathway being active). - In the exemplary Bayesian network model, the probabilistic relations have been made quantitative to allow for a quantitative probabilistic reasoning. In order to improve the generalization behavior across tissue types, the parameters describing the probabilistic relationships between (i) the TF element and the target genes have been carefully hand-picked. If the TF element is “absent”, it is most likely that the target gene is “down”, hence a probability of 0.95 is chosen for this, and a probability of 0.05 is chosen for the target gene being “up”. The latter (non-zero) probability is to account for the (rare) possibility that the target gene is regulated by other factors or that it is accidentally observed as being “up” (e.g. because of measurement noise). If the TF element is “present”, then with a probability of 0.70 the target gene is considered “up”, and with a probability of 0.30 the target gene is considered “down”. The latter values are chosen this way, because there can be several causes why a target gene is not highly expressed even though the TF element is present, e.g., because the gene's promoter region is methylated. In the case that a target gene is not up-regulated by the TF element, but down-regulated, the probabilities are chosen in a similar way, but reflecting the down-regulation upon presence of the TF element. The parameters describing the relationships between (ii) the target genes and their respective probesets have been calibrated on experimental data. For the latter, in this example, microarray data was used from patients samples which are known to have an active NFkB cellular signaling pathway whereas normal, healthy samples from the same dataset were used as inactive NFkB cellular signaling pathway samples, but this could also be performed using cell line experiments or other patient samples with known cellular signaling pathway activity status. The resulting conditional probability tables are given by:
-
A: for upregulated target genes PSi,j = low PSi,j = high TGi = down TGi = up -
B: for downregulated target genes PSi,j = low PSi,j = high TGi = down TGi = up - In these tables, the variables ALi,j, AHi,j, PLi,j, and PHi,j indicate the number of calibration samples with an “absent” (A) or “present” (P) transcription complex that have a “low” (L) or “high” (H) probeset intensity, respectively. Dummy counts have been added to avoid extreme probabilities of 0 and 1.
- To discretize the observed probeset intensities, for each probeset PSi,j a threshold ti,j was used, below which the observation is called “low”, and above which it is called “high”. This threshold has been chosen to be the (weighted) median intensity of the probeset in the used calibration dataset. Due to the noisiness of microarray data, a fuzzy method was used when comparing an observed probeset intensity to its threshold, by assuming a normal distribution with a standard deviation of 0.25 (on a
log 2 scale) around the reported intensity, and determining the probability mass below and above the threshold. Herein, an odds ratio calculated in combination with a pseudo-count and using probability masses instead of deterministic measurement values is called a “soft” odds ratio. - Further details regarding the inferring of cellular signaling pathway activity using mathematical modeling of target gene expression can be found in Verhaegh W. et al., “Selection of personalized patient therapy through the use of knowledge-based computational models that identify tumor-driving signal transduction pathways”, Cancer Research, Vol. 74, No. 11, 2014, pages 2936 to 2945.
- If instead of the exemplary Bayesian network described above, a (pseudo-)linear model as described in Example 1 above is employed, the weights indicating the sign and magnitude of the correlation between the nodes and a threshold to call whether a node is either “absent” or “present” would need to be determined before the model could be used to infer cellular signaling pathway activity in a test sample. One could use expert knowledge to fill in the weights and the threshold a priori, but typically the model would be trained using a representative set of training samples, of which preferably the ground truth is known, e.g. expression data of probesets in samples with a known “presen” transcription factor complex (=active cellular signaling pathway) or “absent” transcription factor complex (=passive cellular signaling pathway).
- Known in the field are a multitude of training algorithms (e.g., regression) that take into account the model topology and changes the model parameters, here, the weights and the threshold, such that the model output, here, a weighted linear score, is optimized. Alternatively, it is also possible to calculate the weights directly from the expression observed levels without the need of an optimization algorithm.
- A first method, named “black and white”-method herein, boils down to a ternary system, in which each weight is an element of the set {−1, 0, 1}. If this is put in a biological context, the −1 and 1 correspond to target genes or probesets that are down- and up-regulated in case of cellular signaling pathway activity, respectively. In case a probeset or target gene cannot be statistically proven to be either up- or down-regulated, it receives a weight of 0. In one example, a left-sided and right-sided, two sample t-test of the expression levels of the active cellular signaling pathway samples versus the expression levels of the samples with a passive cellular signaling pathway can be used to determine whether a probe or gene is up- or down-regulated given the used training data. In cases where the average of the active samples is statistically larger than the passive samples, i.e., the p-value is below a certain threshold, e.g., 0.3, the target gene or probeset is determined to be up-regulated. Conversely, in cases where the average of the active samples is statistically lower than the passive samples, the target gene or probeset is determined to be down-regulated upon activation of the cellular signaling pathway. In case the lowest p-value (left- or right-sided) exceeds the aforementioned threshold, the weight of the target gene or probeset can be defined to be 0.
- A second method, named “log odds”-weights herein, is based on the logarithm (e.g., base e) of the odds ratio. The odds ratio for each target gene or probeset is calculated based on the number of positive and negative training samples for which the probeset/target gene level is above and below a corresponding threshold, e.g., the (weighted) median of all training samples. A pseudo-count can be added to circumvent divisions by zero. A further refinement is to count the samples above/below the threshold in a somewhat more probabilistic manner, by assuming that the probeset/target gene levels are e.g. normally distributed around its observed value with a certain specified standard deviation (e.g., 0.25 on a 2-log scale), and counting the probability mass above and below the threshold.
- Herein, publically available data on the expression of patient samples from activated B-cell like (ABC), diffuse large B-cell lymphoma (DLBCL), which is known to have an active NFkB cellular signaling pathway, and normal cells that are known to have a passive NFkB cellular signaling pathway (GSE12195 available from the Gene Expression Omnibus (GEO, www.ncbi.nlm.nih.gov/geo, last accessed Oct. 9, 2013) was used as an example. Alternatively, one can use patient samples or cell lines stimulated with and deprived of NFkB activating agents such as TNFα and LPS or other inflammatory tissue versus normal tissue, e.g., E-MTAB-1312 or GSE16650.
-
FIGS. 9 to 12 show training results of the exemplary Bayesian network model based on the evidence curated list of target genes, the 19 target genes shortlist, the 13 target genes shortlist, and the 7 target genes shortlist of the NFkB cellular signaling pathway (see Tables 3 to 6), respectively. In the diagrams, the vertical axis indicates the odds that the TF element is “present” resp. “absent”, which corresponds to the NFkB cellular signaling pathway being active resp. inactive, wherein values above the horizontal axis correspond to the TF element being more likely “present”/active and values below the horizontal axis indicate that the odds that the TF element is “absent”/inactive are larger than the odds that it is “present”/active. The activated B-cell (ABC) group (group 1), which is known to have an active NFkB cellular signaling pathway, was assigned an active NFkB label, whereas the group encompassing the normal samples (group 7) known to have a passive NFkB cellular signaling pathway were labeled NFkB inactive. A perfect score for the training samples was achieved for all four models with all ABC being active and all normal samples having a passive NFkB cellular signaling pathway. Unsurprisingly, the probabilities of the training samples become less extreme as fewer target genes are included in the model. Within the same dataset, the healthy, unstimulated memory B-cells and naïve B-cells (groups - In the following, validation results of the trained exemplary Bayesian network model using the evidence curated list of target genes, the 19 target genes shortlist, the 13 target genes shortlist, and the 7 target genes shortlist, respectively, are shown in
FIGS. 13 to 25 . -
FIG. 13 shows NFkB cellular signaling pathway activity predictions of the trained exemplary Bayesian network model using the evidence curated list of target genes (see Table 3) for diffuse large B-cell lymphoma (DLBCL) samples from GSE34171. In the diagram, the vertical axis indicates the odds that the TF element is “present” resp. “absent”, which corresponds to the NFkB cellular signaling pathway being active resp. inactive, wherein values above the horizontal axis correspond to the TF element being more likely “present”/active and values below the horizontal axis indicate that the odds that the TF element is “absent”/inactive are larger than the odds that it is “present”/active. All samples were predicted to have an active NFkB cellular signaling pathway. DLBCL lymphomas are known to have an aberrant NFkB activity (see, e.g., Keutgens A. et al., “Deregulated NF-kB activity in haematological malignancies”, Biochemical Pharmacology, Vol. 72, No. 9, 2006, pages 1069 to 1080). -
FIGS. 14 to 17 show NFkB cellular signaling pathway activity predictions of the trained exemplary Bayesian network model using the evidence curated list of target genes, the 19 target genes shortlist, the 13 target genes shortlist, and the 7 target genes shortlist (see Tables 3 to 6), respectively, for normal human bronchial epithelial (NHBE) cell line samples from E-MTAB-1312, which were stimulated with different TNFα concentrations for different stimulation times. In the diagrams, the vertical axis indicates the odds that the TF element is “present” resp. “absent”, which corresponds to the NFkB cellular signaling pathway being active resp. inactive, wherein values above the horizontal axis correspond to the TF element being more likely “present”/active and values below the horizontal axis indicate that the odds that the TF element is “absent”/inactive are larger than the odds that it is “present”/active. A stimulation of only 0.5 h is apparently too short for the NFkB cellular signaling pathway to become active (groups groups groups 1 to 4) were correctly predicted to have a passive NFkB cellular signaling pathway in all four models. There seemed to be not so much difference in cellular signaling pathway activity as a result of increased TNFα concentration as is apparent in the 2 and 4 hour stimulation; apparently all concentrations tested in this experiment were enough to have a full-blown NFkB cellular signaling pathway activity, even the lowest concentration. (Legend: 1—No TNFα (0.5 h); 2—No TNFα (2 h); 3—No TNFα (4 h); 4—No TNFα (24 h); 5—Low TNFα (0.5 h); 6—Low TNFα (2 h); 7—Low TNFα (4 h): 8—Low TNFα (24 h); 9—Medium TNFα (0.5 h); 10—Medium TNFα (2 h); 11—Medium TNFα (4 h); 12—Medium TNFα (24 h); 13—High TNFα (0.5 h); 14—High TNFα (2 h); 15—High TNFα (4 h); 16—High TNFα (24 h)) -
FIG. 18 shows NFkB cellular signaling pathway activity predictions of the trained exemplary Bayesian network model using the evidence curated list of target genes (see Table 3) for THP-1 monocytic cells. In the diagram, the vertical axis indicates the odds that the TF element is “present” resp. “absent”, which corresponds to the NFkB cellular signaling pathway being active resp. inactive, wherein values above the horizontal axis correspond to the TF element being more likely “present”/active and values below the horizontal axis indicate that the odds that the TF element is “absent”/inactive are larger than the odds that it is “present”/active. The THP-1 cell line is known to express NFkB cellular signaling pathway activity upon stimulation with an immune response inducing agents such as lipopolysaccharide (LPS). The NFkB cellular signaling pathway activity in these monocytic cells is predicted to be low without LPS stimulation (group 1). Upon stimulation of these cells with LPS, the NFkB cellular signaling pathway activity is amplified (group 2). Coenzyme Q10 (CoQ10) has been reported to have anti-inflammatory effects, however, the effect on NFkB cellular signaling pathway activity was reported to be limited (see, e.g., C. Schmelzer and F. Döring, “Identification of LPS-inducible genes downregulated by ubiquinone in human THP-1 monocytes”, Biofactors, Vol. 36, No. 3, 2010, pages 222 to 228). This is also reflected in the high predicted NFkB cellular signaling pathway activities in THP-1 cells treated with CoQ10 and stimulated with LPS (group 3). (Legend: 1—No LPS: 2—LPS stimulation; 3—LPS stimulation+coenzyme Q10) -
FIGS. 19 to 22 show NFkB cellular signaling pathway activity predictions of the trained exemplary Bayesian network model using the evidence curated list of target genes, the 19 target genes shortlist, the 13 target genes shortlist, and the 7 target genes shortlist (see Tables 3 to 6), respectively, for colon samples from GSE4183. In the diagrams, the vertical axis indicates the odds that the TF element is “present” resp. “absent”, which corresponds to the NFkB cellular signaling pathway being active resp. inactive, wherein values above the horizontal axis correspond to the TF element being more likely “present”/active and values below the horizontal axis indicate that the odds that the TF element is “absent”/inactive are larger than the odds that it is “present”/active. Most normal samples (group 1) were rightfully predicted with a low probability of NFkB cellular signaling pathway activity by the model using the evidence curated list of target genes, nevertheless the cellular signaling pathway activity for normal samples seems to be higher than expected from other datasets in the 19 target genes shortlist, the 13 target genes shortlist, and the 7 target genes shortlist. On the other hand, all inflammatory bowel disease (IBD) (group 2) samples were predicted by all four models to have an active NFkB cellular signaling pathway significantly higher than the normal samples, which is as expected owing to the inflamed status of the colon in these patients and the NFkB cellular signaling pathway being activated as a result of inflammation. In addition, it is clear from all four models that the NFkB cellular signaling pathway is more active in the more progressed colorectal carcinomas (CRC) (group 4) compared to the benign adenomas (group 2), which might be a result of progression of the tumor into a more malignant tumor resulting in more mutations, inflammation as a result of the progressed tumor, or infiltration of white blood cells as a result of the immune response to the later stage cancers. Potentially, the NFkB cellular signaling pathway activity score might be used to predict the likelihood an adenoma will progress to become malignant. (Legend: 1—Normal colon; 2—IBD; 3—Adenoma; 4—CRC) -
FIG. 23 shows NFkB cellular signaling pathway activity predictions of the trained exemplary Bayesian network model using the evidence curated list of target genes (see Table 3) for breast cancer cell lines from GSE10890. In the diagram, the vertical axis indicates the odds that the TF element is “present” resp. “absent”, which corresponds to the NFkB cellular signaling pathway being active resp. inactive, wherein values above the horizontal axis correspond to the TF element being more likely “present”/active and values below the horizontal axis indicate that the odds that the TF element is “absent”/inactive are larger than the odds that it is “present”/active. Some of the breast cancer cell lines with still an unknown pathway driving cell survival and proliferation (groups 1 and 2) were identified as having an aberrantly active NFkB cellular signaling pathway, which may be causative for cell survival and proliferation. In the 3rd group that was previously identified as having an active Wnt cellular signaling pathway (see the published international patent application WO 2013/011479 A2 “Assessment of cellular signaling pathway activity using probabilistic modeling of target gene expression”) no NFkB cellular signaling pathway active samples were found. (Legend: 1 and 2—Unknown cellular signaling pathway driven cell lines; 3: Wnt cellular signaling pathway driven cell lines) -
FIG. 24 shows NFkB cellular signaling pathway activity predictions of the trained exemplary Bayesian network model using the evidence curated list of target genes (see Table 3) for ovarian samples from GSE20565. In the diagram, the vertical axis indicates the odds that the TF element is “present” resp. “absent”, which corresponds to the NFkB cellular signaling pathway being active resp. inactive, wherein values above the horizontal axis correspond to the TF element being more likely “present”/active and values below the horizontal axis indicate that the odds that the TF element is “absent”/inactive are larger than the odds that it is “present”/active. The fraction of predicted NFkB cellular signaling pathway active samples is significantly higher in primary cancers (groups 1 and 2) compared to breast metastasis in the ovary (groups 3 and 4), p=6.0e-5 (Fisher's exact test). Chronic inflammation has been associated with tumor initiation and progression. Recurring inflammatory processes in the ovaries due to ovulation, endometriosis and pelvic infections have been shown to be correlated with NFkB cellular signaling pathway active tumors (see, e.g., Alvero A. B., “Recent insights into the role of NF-kappaB in ovarian carcinogenesis”, Genome Medicine, Vol. 2, No. 8, 2010, page 56, and Guo R. X. et al., “Increased staining for phosphorylated AKT and nuclear factor-kappaB p65 and their relationship with prognosis in epithelial ovarian cancer”, Pathology International, Vol. 58, No. 12, 2008, pages 746 to 756). In the ovary, carcinogenesis has been linked to inflammatory processes, such as repeated ovulation, endometriosis and pelvic infections, possibly resulting in a higher fraction of NFkB cellular signaling pathway active tumors originating in the ovary compared to the breast. (Legend: 1—Primary ovarian carcinoma; 2—Plausible primary ovarian carcinoma; 3—Breast metastasis in ovary; 4—Plausible breast metastasis in ovary) -
FIG. 25 shows NFkB cellular signaling pathway activity predictions of the trained exemplary Bayesian network model using the evidence curated list of target genes (see Table 3) for breast cancer samples from E-MTAB-1006. In the diagram, the vertical axis indicates the odds that the TF element is “present” resp. “absent”, which corresponds to the NFkB cellular signaling pathway being active resp. inactive, wherein values above the horizontal axis correspond to the TF element being more likely “present”/active and values below the horizontal axis indicate that the odds that the TF element is “absent”/inactive are larger than the odds that it is “present”/active. The average of the logit NFkB odds ratio is significantly higher in the inflammatory breast cancer samples (IBC) (group 1) compared to the non-inflamed breast cancers (nIBC) (group 2), p<0.01 (two-sample t-test). This is likely a reflection of the high inflammatory state in IBC compared to the nIBC. However, the predicted NFkB cellular signaling pathway activities in both groups largely overlap making a clear classification of IBC and nIBC based on NFkB cellular signaling pathway activity in the model's current state cumbersome. (Legend: 1—Inflammatory breast cancer; 2—Non-inflammatory breast cancer) -
FIG. 26 illustrates overall survival of 272 glioma patients (GSE16011) depicted in a Kaplan-Meier plot, wherein the trained exemplary Bayesian network model using the evidence curated list of target genes (see Table 3) is employed. In the diagram, the vertical axis indicates the overall survival as a fraction of the patient group and the horizontal axis indicates time in years. The plot indicates that an active NFkB TF element (indicated by the steeper slope of the curve) is a prognostic marker for worse overall survival. (The patient group with a predicted active NFkB TF element consisted of 113 patients (solid line), whereas the patient group with a predicted passive NFkB TF element consisted of 159 patients (dotted line)). The prognostic value of the activity level of the NFkB IT element is also demonstrated in the hazard ratio of the predicted probability of NFkB activity: 1.83 (95% CI: 1.34-2.49, p=7.2e-5). - Further to the exemplary Bayesian network model described above, an exemplary linear model was used to model the transcriptional program of the NFkB cellular signaling pathway in a simple manner. The structure of the model corresponded to the one shown in
FIG. 3 of the published international patent application WO 2014/102668 A2 (“Assessment of cellular signaling pathway activity using linear combination(s) of target gene expressions”). More specifically, the exemplary linear model consisted of a TF node, a layer of target gene expression and a layer of mRNA expression levels and made use of continuous expression data, all target genes from the evidence curated list of target genes (see Table 3) with all probesets included and without the use of a pseudocount. The training of the model was performed with the same active and passive training samples from GSE12195 and encompassed calculating the weights of the connections between the target genes expression levels, here represented by means of probeset intensities, and the target genes nodes using the “soft log odds”-method as described herein and subsequently the activity score of the transcription factor complex was calculated by summation of the calculated target genes expression score multiplied by either 1 or −1 for up-regulated or down-regulated target genes, respectively. -
FIG. 27 shows training results of the exemplary linear model based on the evidence curated list of target genes (see Table 3). In the diagram, the vertical axis indicates the activity score, wherein positive values correspond to an active NFkB cellular signaling pathway and negative values correspond to a passive NFkB cellular signaling pathway. The activated B-cell (ABC) DLBCL (group 1) and normal (group 7) were used as active and passive training samples, respectively. All training samples were correctly classified; all ABC samples were predicted to have an active NFkB cellular signaling pathway, whereas the normal samples were predicted to have a passive NFkB cellular signaling pathway. Within the same dataset all other lymphoma samples and cell lines and DLBCL (groups 2 to 4, 8) except one were predicted NFkB active, similar to the Bayesian network model using the evidence curated list of target genes (FIG. 3 ), which is plausible given the literature evidence discussed herein. The healthy, unstimulated memory B-cells and naïve B-cells (groups 5 and 6) are correctly predicted to lack NFkB activity. (Legend: 1—ABC DLBCL; 2—Lymphoblastoid cell line; 3—Follicular lymphoma; 4—GCB DLBCL; 5—Memory B-cells; 6—Naïve B-cells; 7—Normal; 8—DLBCL unknown subtype) -
FIG. 28 shows NFkB cellular signaling pathway activity predictions of the trained exemplary linear model using the evidence curated list of target genes (see Table 3) for normal human bronchial epithelial (NHBE) cell line samples from E-MTAB-1312, which were stimulated with different TNFα concentrations for different stimulation times. In the diagram, the vertical axis indicates the activity score, wherein positive values correspond to an active NFkB cellular signaling pathway and negative values correspond to a passive NFkB cellular signaling pathway. NHBE cell lines were unstimulated or stimulated with different TNFα concentrations for different timings. All unstimulated healthy cells (groups 1 to 4) are correctly predicted to have a passive NFkB cellular signaling pathway. A stimulation with all TNFα concentrations for only 0.5 h is predicted to be too short for the NFkB cellular signaling pathway to become active (groups FIG. 8 ), whereas stimulation times of 2 to 24 hours resulted in an active NFkB cellular signaling pathway. The lowering of the NFkB cellular signaling pathway activity after 4 hours observed with the Bayesian network model especially using the evidence curated list of target genes (seeFIG. 8 ) could not be reproduced with the trained exemplary linear model. (Legend: 1—No TNFα (0.5 h); 2—No TNFα (2 h); 3—No TNFα (4 h); 4—No TNFα (24 h); 5—Low TNFα (0.5 h); 6—Low TNFα (2 h); 7—Low TNFα (4 h); 8—Low TNFα (24 h); 9—Medium TNFα (0.5 h); 10—Medium TNFα (2 h); 11—Medium TNFα (4 h); 12—Medium TNFα (24 h); 13—High TNFα (0.5 h); 14—High TNFα (2 h); 15—High TNFα (4 h); 16—High TNFα (24 h)) -
FIG. 29 shows NFkB cellular signaling pathway activity predictions of the trained exemplary linear model using the evidence curated list of target genes (see Table 3) for colon samples from GSE4183. In the diagram, the vertical axis indicates the activity score, wherein positive values correspond to an active NFkB cellular signaling pathway and negative values correspond to a passive NFkB cellular signaling pathway. Most normal samples (group 1) were predicted to have a low NFkB cellular signaling pathway activity, albeit at higher activity scores than expected from other datasets. Compared to normal samples all inflammatory bowel disease samples (group 2) were predicted to have a higher NFkB activity score compared to the normal samples which is very reasonable considering the inflamed status of the colon in these patients which activates the NFkB cellular signaling pathway as one of the inflammatory response. In addition, it is clear that the samples in the adenoma samples (group 3) is on average lower than the more progressed colorectal carcinomas (CRC, group 4), which might be partially explained by the progression of the tumor into a more malignant tumor resulting in more mutations, inflammation as a result of the progressed tumor, or infiltration of white blood cells as a result of the immune response to the later stage cancers. (Legend: 1—Normal colon; 2—IBD; 3—Adenoma; 4—CRC) - Instead of applying the mathematical model, e.g., the exemplary Bayesian network model, on mRNA input data coming from microarrays or RNA sequencing, it may be beneficial in clinical applications to develop dedicated assays to perform the sample measurements, for instance on an integrated platform using qPCR to determine mRNA levels of target genes. The RNA/DNA sequences of the disclosed target genes can then be used to determine which primers and probes to select on such a platform.
- Validation of such a dedicated assay can be done by using the microarray-based mathematical model as a reference model, and verifying whether the developed assay gives similar results on a set of validation samples. Next to a dedicated assay, this can also be done to build and calibrate similar mathematical models using mRNA-sequencing data as input measurements.
- The set of target genes which are found to best indicate specific cellular signaling pathway activity, based on microarray/RNA sequencing based investigation using the mathematical model, e.g., the exemplary Bayesian network model, can be translated into a multiplex quantitative PCR assay to be performed on a sample and/or a computer to interpret the expression measurements and/or to infer the activity of the NFkB cellular signaling pathway. To develop such a test (e.g., FDA-approved or a CLIA waived test in a central service lab) for cellular signaling pathway activity, development of a standardized test kit is required, which needs to be clinically validated in clinical trials to obtain regulatory approval.
- The present invention relates to a method comprising inferring activity of an NFkB cellular signaling pathway based at least on expression levels of one or more target genes of the NFkB cellular signaling pathway measured in a sample. The present invention further relates to an apparatus comprising a digital processor configured to perform such a method, a non-transitory storage medium storing instructions that are executable by a digital processing device to perform such a method, and a computer program comprising program code means for causing a digital processing device to perform such a method.
- The method may be used, for instance, in diagnosing an (abnormal) activity of the NFkB cellular signaling pathway, in prognosis based on the inferred activity of the NFkB cellular signaling pathway, in the enrollment in a clinical trial based on the inferred activity of the NFkB cellular signaling pathway, in the selection of subsequent test(s) to be performed, in the selection of companion diagnostics tests, in clinical decision support systems, or the like In this regard, reference is made to the published international patent application WO 2013/011479 A2 (“Assessment of cellular signaling pathway activity using probabilistic modeling of target gene expression”), to the published international patent application WO 2014/102668 A2 (“Assessment of cellular signaling pathway activity using linear combination(s) of target gene expressions”), and to Verhaegh W. et al., “Selection of personalized patient therapy through the use of knowledge-based computational models that identify tumor-driving signal transduction pathways”, Cancer Research, Vol. 74, No. 11, 2014, pages 2936-2945, which describe these applications in more detail.
- The list of target genes of the NFkB cellular signaling pathway constructed based on literature evidence following the procedure as described herein (“evidence curated list of target genes”, see Table 3) is compared here with a “broad literature list” of putative target genes of the NFkB cellular signaling pathway constructed not following above mentioned procedure. The alternative list is a compilation of genes attributed to responding to activity of the NFkB cellular signaling pathway provided within Thomson-Reuters's Metacore (last accessed Sep. 6, 2013). This database was queried for genes that are transcriptionally regulated directly downstream of the family of NFkB proteins, i.e., NFKB1 or p50/p105, NFKB2 or p52/p100, RELA or p65, REL, and RELB. This query resulted in 343 unique genes. A further selection was made based on the number of publication references supporting the attributed transcriptional regulation of the respective gene by the NFkB family. Genes that had ten or more references were selected for the broad literature list. In other words, no manual curation of the references and no calculation of an evidence score based on the experimental evidence was performed. This procedure resulted in 32 genes, see Table 7. The expression of the genes was measured by 56 probesets on the Affymetrix HG-U133Plus2.0 microarray platform which were selected using the Bioconductor plugin of R and one manually added probeset for DEFB4A, see Table 7.
-
TABLE 7 “Broad literature list” of putative target genes of the NFkB cellular signaling pathway used in the NFkB cellular signaling pathway models and associated probesets used to measure the mRNA expression level of the genes. Gene Probeset Gene Probeset Gene Probeset PTGS2 1554997_a_at VCAM1 203868_s_at FASLG 210865_at 204748_at SELE 206211_at 211333_s_at IL8 202859_x_at IFNB1 208173_at CXCL1 204470_at 211506_s_at IL12B 207901_at IL1B 205067_at NOS2 210037_s_at BCL2L1 206665_s_at 39402_at IL6 205207_at 212312_at CXCL10 204533_at MMP9 203936_s_at 215037_s_at BIRC3 210538_s_at TNF 207113_s_at 231228_at 230499_at ICAM1 202637_s_at NFKBIA 201502_s_at MYC 202431_s_at 202638_s_at 231699_at CXCL3 207850_at 215485_s_at SOD2 1566342_at IER3 201631_s_at CCL2 216598_s_at IL2 207849_at IL23A 216857_at CCL5 1405_i_at CCL20 205476_at 217328_at 1555759_a_at GCLC 1555330_at 220054_at 204655_at 202922_at 234377_at BCL2 203684_s_at 202923_s_at 234865_at 203685_at CSF2 210228_at TRAF1 205599_at 207004_at 210229_s_at 235116_at 207005_s_at DEFB4A 207356_at - Subsequently an exemplary Bayesian network model was constructed using the procedure as explained herein. Similarly to the description of the NFkB cellular signaling pathway model based on the evidence curated list, the conditional probability tables of the edges between probesets and their respective putative target genes of this model including the broad literature list were trained using fRMA processed data from GSE12195. The training results are depicted in
FIG. 24 . In the diagram, the vertical axis indicates the odds that the TF element is “present” resp. “absent”, which corresponds to the NFkB cellular signaling pathway being active resp. inactive, wherein values above the horizontal axis correspond to the TF element being more likely “present”/active and values below the horizontal axis indicate that the odds that the TF element is “absent”/inactive are larger than the odds that it is “present”/active. The activated B-cell (ABC) DLBCL (group 1) were used as active training samples and the normal samples (group 7) were used as passive training samples. The training results depicted inFIG. 24 show a clear separation between passive (group 7) and active (group 1) training samples as expected. Within the same dataset all other lymphoma samples and cell lines and DLBCL (groups 2 to 4, 8) were predicted NFkB active which is plausible given the literature evidence discussed herein. The healthy, unstimulated memory B-cells and naïve B-cells (groups 5 and 6) are correctly predicted a lack of NFkB cellular signaling pathway activity. (Legend: 1—ABC DLBCL; 2—Lymphoblastoid cell line; 3—Follicular lymphoma; 4—GCB DLBCL; 5—Memory B-cells: 6—Naïve B-cells: 7—Normal; 8—DLBCL unknown subtype). - Next the trained exemplary network Bayesian model based on the broad literature list was tested on a number of datasets.
-
FIG. 31 shows NFkB cellular signaling pathway activity predictions of the trained exemplary Bayesian network model using the broad literature list of putative target genes of the NFkB cellular signaling pathway (see Table 7) for normal human bronchial epithelial (NHBE) cell line samples from E-MTAB-1312, which were stimulated with different TNFα concentrations for different stimulation times. In the diagram, the vertical axis indicates the odds that the TF element is “present” resp. “absent”, which corresponds to the NFkB cellular signaling pathway being active resp. inactive, wherein values above the horizontal axis correspond to the TF element being more likely “present”/active and values below the horizontal axis indicate that the odds that the TF element is “absent”/inactive are larger than the odds that it is “present”/active. All unstimulated healthy cells up to 24 hours (groups 1 to 3) are correctly predicted to have a passive NFkB cellular signaling pathway. Lack of stimulation for 24 hours resulted in an unexpected activation of the NFkB cellular signaling pathway prediction. A stimulation with all TNFα concentrations for only 0.5 h is predicted by the broad literature Bayesian model also to be too short for the NFkB cellular signaling pathway to become active (groups groups 5 to 8, 9 to 12 and 13 to 15). The lowering of the NFkB cellular signaling pathway activity after 4 hours observed with the Bayesian network model using the evidence curated list of target genes (seeFIG. 8 ) was not reproduced with the trained broad literature Bayesian network model. (Legend: 1—No TNFα (0.5 h); 2—No TNFα (2 h); 3—No TNFα (4 h); 4—No TNFα (24 h); 5—Low TNFα (0.5 h); 6—Low TNFα (2 h); 7—Low TNFα (4 h); 8—Low TNFα (24 h); 9—Medium TNFα (0.5 h); 10—Medium TNFα (2 h): 11—Medium TNFα (4 h); 12—Medium TNFα (24 h); 13—High TNFα (0.5 h); 14—High TNFα (2 h); 15—High TNFα (4 h); 16—High TNFα (24 h)) -
FIG. 32 shows NFkB cellular signaling pathway activity predictions of the trained exemplary Bayesian network model using the broad literature list of putative target genes of the NFkB cellular signaling pathway (see Table 7) for colon samples from GSE4183. In the diagram, the vertical axis indicates the odds that the TF element is “present” resp. “absent”, which corresponds to the NFkB cellular signaling pathway being active resp. inactive, wherein values above the horizontal axis correspond to the TF element being more likely “present”/active and values below the horizontal axis indicate that the odds that the TF element is “absent”/inactive are larger than the odds that it is “present”/active. All but one adenoma sample are predicted by the broad literature Bayesian network model to have an active NFkB cellular signaling pathway, which is especially not expected to be the case in normal, healthy colon samples (group 1). (Legend: 1—Normal colon; 2—IBD; 3—Adenoma; 4—CRC) - As evidenced by the above example, the selection of unique NFkB target gene sets in combination with the mathematical models described herein for determining the activity level of NFkB cellular signaling pathway in a sample produces a more robust, precise, and accurate activity status determination than the use of a broader literature list, despite the fact that the number of target genes is larger. By focusing on the specific target genes identified herein, a useful determination of NFkB cellular signaling pathway activity is provided that can be further used in treatment or prognostic modalities as described herein.
- This specification has been described with reference to embodiments, which are illustrated by the accompanying Examples. The invention can, however, be embodied in different forms and should not be construed as limited to the embodiments set forth herein. Given the teaching herein, one of ordinary skill in the art will be able to modify the invention for a desired purpose and such variations are considered within the scope of the disclosure.
-
-
Sequence Listing: Seq. No. Gene: Seq. 1 BCL2 Seq. 2 BCL2L1 Seq. 3 BIRC3 Seq. 4 CCL2 Seq. 5 CCL3 Seq. 6 CCL4 Seq. 7 CCL5 Seq. 8 CCL20 Seq. 9 CCL22 Seq. 10 CSF2 Seq. 11 CX3CL1 Seq. 12 CXCL1 Seq. 13 CXCL2 Seq. 14 CXCL3 Seq. 15 CXCL10 Seq. 16 DEFB4A Seq. 17 FASLG Seq. 18 GCLC Seq. 19 ICAM1 Seq. 20 IER3 Seq. 21 IFNB1 Seq. 22 IL12B Seq. 23 IL1B Seq. 24 IL2 Seq. 25 IL23A Seq. 26 IL6 Seq. 27 IL8 Seq. 28 IRF1 Seq. 29 MMP9 Seq. 30 MYC Seq. 31 NFKB2 Seq. 32 NFKBIA Seq. 33 NFKBIE Seq. 34 NOS2 Seq. 35 PTGS2 Seq. 36 SELE Seq. 37 SOD2 Seq. 38 STAT5A Seq. 39 TNF Seq. 40 TNFAIP2 Seq. 41 TNIP1 Seq. 42 TRAF1 Seq. 43 VCAM1
Claims (20)
1-20. (canceled)
21. A kit for determining an activity level of a NFkB cellular signaling pathway derived from a sample isolated from a subject suffering from a disease associated with an activated NFkB cellular signaling pathway, comprising:
a set of polymerase chain reaction primers directed to at least six NFkB cellular signaling pathway target genes; and
a set of probes directed to the at least six NFkB cellular signaling pathway target genes;
wherein the at least six NFkB cellular signaling pathway target genes are selected from BCL2L1, BIRC3, CCL2, CCL3, CCL4, CCL5, CCL20, CCL22, CX3CL1, CXCL1, CXCL2, CXCL3, ICAM1, IL1B, IL6, IL8, IRF1, MMP9, NFKB2, NFKBIA, NFKBIE, PTGS2, SELE, STAT5A, TNF, TNFAIP2, TNIP1, TRAF1, and VCAM1.
22. The kit of claim 21 , wherein the at least six NFkB cellular signaling pathway target genes are selected from BIRC3, CCL2, CCL5, CCL20, CXCL1, CXCL2, CXCL3, ICAM1, IL6, IL8, IRF1, MMP9, NFKB2, NFKBIA, NFKBIE, TNF, TNFAIP2, TRAF1, and VCAM1.
23. The kit of claim 21 , wherein the at least six NFkB cellular signaling pathway target genes comprise at least three target genes selected from CCL2, CCL5, CCL20, CXCL1, CXCL2, CXCL3, ICAM1, IL6, IL8, MMP9, NFKB2, NFKBIA, and TNFAIP2.
24. The kit of claim 23 , wherein the at least three target genes are selected from CCL5, CXCL2, ICAM1, IL6, IL8, NFKBIA, and TNFAIP2.
25. The kit of claim 21 , wherein the disease is a cancer.
26. The kit of claim 25 , wherein the cancer is colon, breast, prostate, pancreatic, lung, brain, leukemia, lymphoma, or glioma.
27. The kit of claim 21 , further comprising a calibrated pathway model configured to determine the activity level of the NFkB cellular signaling pathway by:
receiving data on the expression levels of the at least six NFkB cellular signaling pathway target genes amplified using the set of polymerase chain reaction primers and analyzed by the set of probes;
determining the level of a NFkB transcription factor element in the sample by comparing the received data on the expression levels of the at least six NFkB cellular signaling pathway target genes in the sample with expression levels of the at least six NFkB cellular signaling pathway target genes in the model which define an activity level of NFkB transcription factor element; and
determining the activity level of the NFkB cellular signaling pathway in the sample based on the determined NFkB transcription factor element level in the sample.
28. The kit of claim 27 , wherein the calibrated pathway model is a probabilistic model incorporating conditional probabilistic relationships that compare the expression levels of the at least six NFkB cellular signaling pathway target genes in the sample with expression levels of the at least six NFkB cellular signaling pathway target genes in the model which define a level of NFkB transcription factor element to determine the activity level of NFkB transcription factor element in the sample.
29. The kit of claim 27 , wherein the calibrated pathway model is a linear model incorporating relationships that compare the expression levels of the at least six NFkB cellular signaling pathway target genes in the sample with expression levels of the at least six NFkB cellular signaling pathway target genes in the model which define a level of NFkB transcription factor element to determine the activity level of NFkB transcription factor element in the sample.
30. The kit of claim 21 , wherein the probes are labeled.
31. A method for determining an activity level of a NFkB cellular signaling pathway derived from a biological sample isolated from a subject suffering from a disease associated with an activated NFkB cellular signaling pathway, comprising:
receiving a biological sample from the subject;
analyzing, using the kit of claim 21 , expression levels of at least six NFkB cellular signaling pathway target genes selected from BCL2L1, BIRC3, CCL2, CCL3, CCL4, CCL5, CCL20, CCL22, CX3CL1, CXCL1, CXCL2, CXCL3, ICAM1, IL1B, IL6, IL8, IRF1, MMP9, NFKB2, NFKBIA, NFKBIE, PTGS2, SELE, STAT5A, TNF, TNFAIP2, TNIP1, TRAF1, and VCAM1 by contacting the biological sample with the set of polymerase chain reaction primers directed to the at least six NFkB cellular signaling pathway target genes and the set of probes directed to the at least six NFkB cellular signaling pathway target genes.
32. The method of claim 31 , wherein the at least six NFkB cellular signaling pathway target genes comprise at least three target genes selected from CCL2, CCL5, CCL20, CXCL1, CXCL2, CXCL3, ICAM1, IL6, IL8, MMP9, NFKB2, NFKBIA, and TNFAIP2.
33. The method of claim 32 , wherein the at least three target genes are selected from CCL5, CXCL2, ICAM1, IL6, IL8, NFKBIA, and TNFAIP2.
34. The method of claim 31 , wherein the disease is a cancer.
35. The method of claim 34 , wherein the cancer is colon, breast, prostate, pancreatic, lung, brain, leukemia, lymphoma, or glioma.
36. The method of claim 31 , wherein analyzing the expression levels of the at least six NFkB cellular signaling pathway target genes comprises a calibrated pathway model configured to determine the activity level of the NFkB cellular signaling pathway by:
receiving data on the expression levels of the at least six NFkB cellular signaling pathway target genes amplified using the set of polymerase chain reaction primers and analyzed using the set of probes;
determining the level of a NFkB transcription factor element in the sample by comparing the received data on the expression levels of the at least six NFkB cellular signaling pathway target genes in the sample with expression levels of the at least six NFkB cellular signaling pathway target genes in the model which define an activity level of NFkB transcription factor element; and
determining the activity level of the NFkB cellular signaling pathway in the sample based on the determined NFkB transcription factor element level in the sample.
37. The method of claim 36 , wherein the calibrated pathway model is a probabilistic model incorporating conditional probabilistic relationships that compare the expression levels of the at least six NFkB cellular signaling pathway target genes in the sample with expression levels of the at least six NFkB cellular signaling pathway target genes in the model which define a level of NFkB transcription factor element to determine the activity level of NFkB transcription factor element in the sample.
38. The method of claim 36 , wherein the calibrated pathway model is a linear model incorporating relationships that compare the expression levels of the at least six NFkB cellular signaling pathway target genes in the sample with expression levels of the at least six NFkB cellular signaling pathway target genes in the model which define a level of NFkB transcription factor element to determine the activity level of NFkB transcription factor element in the sample.
39. The method of claim 31 , wherein the probes are labeled.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/931,919 US20230260595A1 (en) | 2015-08-14 | 2022-09-14 | Determination of nfkb pathway activity using unique combination of target genes |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15181029 | 2015-08-14 | ||
EP15181029.8 | 2015-08-14 | ||
US15/235,478 US11450409B2 (en) | 2015-08-14 | 2016-08-12 | Determination of NFkB pathway activity using unique combination of target genes |
US17/931,919 US20230260595A1 (en) | 2015-08-14 | 2022-09-14 | Determination of nfkb pathway activity using unique combination of target genes |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/235,478 Continuation US11450409B2 (en) | 2015-08-14 | 2016-08-12 | Determination of NFkB pathway activity using unique combination of target genes |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230260595A1 true US20230260595A1 (en) | 2023-08-17 |
Family
ID=53938129
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/235,478 Active 2039-01-07 US11450409B2 (en) | 2015-08-14 | 2016-08-12 | Determination of NFkB pathway activity using unique combination of target genes |
US17/931,919 Pending US20230260595A1 (en) | 2015-08-14 | 2022-09-14 | Determination of nfkb pathway activity using unique combination of target genes |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/235,478 Active 2039-01-07 US11450409B2 (en) | 2015-08-14 | 2016-08-12 | Determination of NFkB pathway activity using unique combination of target genes |
Country Status (10)
Country | Link |
---|---|
US (2) | US11450409B2 (en) |
EP (1) | EP3334837B1 (en) |
JP (1) | JP7028763B2 (en) |
CN (1) | CN108138237B (en) |
AU (1) | AU2016309659A1 (en) |
BR (1) | BR112018002848A2 (en) |
CA (1) | CA2995520A1 (en) |
DK (1) | DK3334837T3 (en) |
ES (1) | ES2861400T3 (en) |
WO (1) | WO2017029215A1 (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3431582A1 (en) | 2017-07-18 | 2019-01-23 | Koninklijke Philips N.V. | Cell culturing materials |
EP3462348A1 (en) | 2017-09-28 | 2019-04-03 | Koninklijke Philips N.V. | Bayesian inference |
EP3462349A1 (en) * | 2017-10-02 | 2019-04-03 | Koninklijke Philips N.V. | Assessment of notch cellular signaling pathway activity using mathematical modelling of target gene expression |
BR112020006605A2 (en) | 2017-10-02 | 2020-10-06 | Koninklijke Philips N.V. | method for determining the functional status of at least one type of immune cell in at least one sample of an individual, method for determining the activity status of an individual's innate or adaptive immune system, method for determining the activity status of the immune system overall value of an individual, device, non-transitory storage media, computer program and kit |
US11450405B2 (en) * | 2018-10-18 | 2022-09-20 | Fresenius Medical Care Holdings, Inc. | Techniques for modeling parathyroid gland functionality and calcimimetic drug activity |
WO2020225155A1 (en) | 2019-05-03 | 2020-11-12 | Koninklijke Philips N.V. | Methods of prognosis in high-grade serous ovarian cancer |
EP3812474A1 (en) | 2019-10-22 | 2021-04-28 | Koninklijke Philips N.V. | Methods of prognosis in high-grade serous ovarian cancer |
EP3739588A1 (en) | 2019-05-13 | 2020-11-18 | Koninklijke Philips N.V. | Assessment of multiple signaling pathway activity score in airway epithelial cells to predict airway epithelial abnormality and airway cancer risk |
EP3758005A1 (en) | 2019-06-24 | 2020-12-30 | Koninklijke Philips N.V. | Identification of the cellular function of an active nfkb pathway |
CN110779967B (en) * | 2019-09-18 | 2022-06-17 | 南京农业大学 | NF-kB electrochemical detection method based on traditional glassy carbon electrode |
EP3882363A1 (en) | 2020-03-17 | 2021-09-22 | Koninklijke Philips N.V. | Prognostic pathways for high risk sepsis patients |
EP4136261A1 (en) | 2020-04-16 | 2023-02-22 | InnoSIGN B.V. | Prognostic pathways for viral infections |
EP3978628A1 (en) | 2020-10-01 | 2022-04-06 | Koninklijke Philips N.V. | Prognostic pathways for viral infections |
CN111606976A (en) * | 2020-05-26 | 2020-09-01 | 中国人民解放军军事科学院军事医学研究院 | Small peptide and application thereof in inhibiting opiate addiction and tolerance |
EP3940704A1 (en) | 2020-07-14 | 2022-01-19 | Koninklijke Philips N.V. | Method for determining the differentiation state of a stem cell |
EP3960875A1 (en) | 2020-08-28 | 2022-03-02 | Koninklijke Philips N.V. | Pcr method and kit for determining pathway activity |
EP3965119A1 (en) | 2020-09-04 | 2022-03-09 | Koninklijke Philips N.V. | Methods for estimating heterogeneity of a tumour based on values for two or more genome mutation and/or gene expression related parameter, as well as corresponding devices |
EP3974540A1 (en) | 2020-09-25 | 2022-03-30 | Koninklijke Philips N.V. | Method for predicting immunotherapy resistance |
EP4015651A1 (en) | 2020-12-17 | 2022-06-22 | Koninklijke Philips N.V. | Treatment prediction and effectiveness of anti-tnf alpha treatment in ibd patients |
EP4039825A1 (en) | 2021-02-09 | 2022-08-10 | Koninklijke Philips N.V. | Comparison and standardization of cell and tissue culture |
CN117295824A (en) | 2021-03-11 | 2023-12-26 | 皇家飞利浦有限公司 | Prognostic pathway for high risk sepsis patients |
TW202340480A (en) * | 2021-11-23 | 2023-10-16 | 義大利商義大利藥品股份有限公司 | Method to detect rna biomarkers |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6004761A (en) | 1986-11-19 | 1999-12-21 | Sanofi | Method for detecting cancer using monoclonal antibodies to new mucin epitopes |
US5436134A (en) | 1993-04-13 | 1995-07-25 | Molecular Probes, Inc. | Cyclic-substituted unsymmetrical cyanine dyes |
US5658751A (en) | 1993-04-13 | 1997-08-19 | Molecular Probes, Inc. | Substituted unsymmetrical cyanine dyes with selected permeability |
US5545531A (en) | 1995-06-07 | 1996-08-13 | Affymax Technologies N.V. | Methods for making a device for concurrently processing multiple biological chip assays |
US6720149B1 (en) | 1995-06-07 | 2004-04-13 | Affymetrix, Inc. | Methods for concurrently processing multiple biological chip assays |
US6146897A (en) | 1995-11-13 | 2000-11-14 | Bio-Rad Laboratories | Method for the detection of cellular abnormalities using Fourier transform infrared spectroscopy |
US6391550B1 (en) | 1996-09-19 | 2002-05-21 | Affymetrix, Inc. | Identification of molecular sequence signatures and methods involving the same |
NZ516848A (en) | 1997-06-20 | 2004-03-26 | Ciphergen Biosystems Inc | Retentate chromatography apparatus with applications in biology and medicine |
DE69823206T2 (en) | 1997-07-25 | 2004-08-19 | Affymetrix, Inc. (a Delaware Corp.), Santa Clara | METHOD FOR PRODUCING A BIO-INFORMATICS DATABASE |
US6953662B2 (en) | 1997-08-29 | 2005-10-11 | Human Genome Sciences, Inc. | Follistatin-3 |
US6020135A (en) | 1998-03-27 | 2000-02-01 | Affymetrix, Inc. | P53-regulated genes |
US6884578B2 (en) | 2000-03-31 | 2005-04-26 | Affymetrix, Inc. | Genes differentially expressed in secretory versus proliferative endometrium |
CA2429633A1 (en) | 2000-11-16 | 2002-05-30 | Ciphergen Biosystems, Inc. | Method for analyzing mass spectra |
WO2002079491A2 (en) | 2001-02-16 | 2002-10-10 | Ciphergen Biosystems, Inc. | Method for correlating gene expression profiles with protein expression profiles |
EP2241636A1 (en) | 2002-03-13 | 2010-10-20 | Genomic Health, Inc. | Gene expression profiling in biopsied tumor tissues |
US7097976B2 (en) | 2002-06-17 | 2006-08-29 | Affymetrix, Inc. | Methods of analysis of allelic imbalance |
US8008003B2 (en) | 2002-11-15 | 2011-08-30 | Genomic Health, Inc. | Gene expression profiling of EGFR positive cancer |
US20040231909A1 (en) | 2003-01-15 | 2004-11-25 | Tai-Yang Luh | Motorized vehicle having forward and backward differential structure |
US20040180341A1 (en) * | 2003-03-07 | 2004-09-16 | Brown University | Transcriptional regulation of kinase inhibitors |
ES2609234T3 (en) | 2003-06-24 | 2017-04-19 | Genomic Health, Inc. | Prediction of the probability of cancer recurrence |
EP1644858B1 (en) | 2003-07-10 | 2017-12-06 | Genomic Health, Inc. | Expression profile algorithm and test for cancer prognosis |
DK1836629T3 (en) | 2004-11-05 | 2020-05-18 | Genomic Health Inc | PREDICTION OF RESPONSE TO CHEMOTHERAPY USING MARKERS FOR GENEPRESSION |
JP2008538112A (en) | 2005-03-23 | 2008-10-09 | バイオ−ラッド ラボラトリーズ インコーポレーティッド | Diverse chemical libraries bound to small particles with paramagnetic properties |
US20060234911A1 (en) | 2005-03-24 | 2006-10-19 | Hoffmann F M | Method of reversing epithelial mesenchymal transition |
US20090186024A1 (en) | 2005-05-13 | 2009-07-23 | Nevins Joseph R | Gene Expression Signatures for Oncogenic Pathway Deregulation |
KR100806274B1 (en) | 2005-12-06 | 2008-02-22 | 한국전자통신연구원 | Adaptive Execution Method for Multithreaded Processor Based Parallel Systems |
NZ593228A (en) | 2006-01-11 | 2012-10-26 | Genomic Health Inc | Gene expression markers (inhba) for colorectal cancer prognosis |
US7888019B2 (en) | 2006-03-31 | 2011-02-15 | Genomic Health, Inc. | Genes involved estrogen metabolism |
CA2648971A1 (en) | 2006-04-11 | 2007-10-18 | Bio-Rad Pasteur | Hpv detection and quantification by real-time multiplex amplification |
WO2008141275A1 (en) | 2007-05-11 | 2008-11-20 | The Johns Hopkins University | Biomarkers for melanoma |
WO2008157459A2 (en) | 2007-06-14 | 2008-12-24 | The Regents Of The University Of Michigan | Methods and systems for identifying molecular pathway elements |
CA2700978A1 (en) | 2007-09-28 | 2009-04-02 | Duke University | Individualized cancer treatments |
US7816084B2 (en) | 2007-11-30 | 2010-10-19 | Applied Genomics, Inc. | TLE3 as a marker for chemotherapy |
WO2009114836A1 (en) | 2008-03-14 | 2009-09-17 | Genomic Health, Inc. | Gene expression markers for prediction of patient response to chemotherapy |
US20110053804A1 (en) | 2008-04-03 | 2011-03-03 | Sloan-Kettering Institute For Cancer Research | Gene Signatures for the Prognosis of Cancer |
US20120009581A1 (en) | 2008-07-08 | 2012-01-12 | Bankaitis-Davis Danute M | Gene Expression Profiling for Predicting the Survivability of Prostate Cancer Subjects |
GB2477705B (en) | 2008-11-17 | 2014-04-23 | Veracyte Inc | Methods and compositions of molecular profiling for disease diagnostics |
US8765383B2 (en) | 2009-04-07 | 2014-07-01 | Genomic Health, Inc. | Methods of predicting cancer risk using gene expression in premalignant tissue |
EP2460005A4 (en) | 2009-07-31 | 2012-11-21 | Translational Genomics Res Inst | Methods of assessing a risk of cancer progression |
US8451450B2 (en) | 2009-09-14 | 2013-05-28 | Bio-Rad Laboratories, Inc. | Near real time optical phase conjugation |
WO2011146619A2 (en) | 2010-05-19 | 2011-11-24 | The Regents Of The University Of California | Systems and methods for identifying drug targets using biological networks |
US8703736B2 (en) | 2011-04-04 | 2014-04-22 | The Translational Genomics Research Institute | Therapeutic target for pancreatic cancer cells |
WO2012154567A2 (en) | 2011-05-06 | 2012-11-15 | Albert Einstein College Of Medicine Of Yeshiva University | Human invasion signature for prognosis of metastatic risk |
AU2012275500A1 (en) | 2011-06-27 | 2014-01-16 | Dana-Farber Cancer Institute, Inc. | Signatures and determinants associated with prostate cancer progression and methods of use thereof |
EP2549399A1 (en) * | 2011-07-19 | 2013-01-23 | Koninklijke Philips Electronics N.V. | Assessment of Wnt pathway activity using probabilistic modeling of target gene expression |
EP2780469A1 (en) | 2011-11-18 | 2014-09-24 | Vanderbilt University | Markers of triple-negative breast cancer and uses thereof |
NZ722902A (en) | 2012-01-31 | 2017-12-22 | Genomic Health Inc | Gene expression profile algorithm and test for determining prognosis of prostate cancer |
WO2014102668A2 (en) | 2012-12-26 | 2014-07-03 | Koninklijke Philips N.V. | Assessment of cellular signaling pathway activity using linear combination(s) of target gene expressions; |
MX366204B (en) | 2013-04-26 | 2019-07-02 | Koninklijke Philips Nv | Medical prognosis and prediction of treatment response using multiple cellular signalling pathway activities. |
CN105492630A (en) | 2014-01-03 | 2016-04-13 | 皇家飞利浦有限公司 | Assessment of the pi3k cellular signaling pathway activity using mathematical modelling of target gene expression. |
-
2016
- 2016-08-12 ES ES16753888T patent/ES2861400T3/en active Active
- 2016-08-12 AU AU2016309659A patent/AU2016309659A1/en not_active Abandoned
- 2016-08-12 US US15/235,478 patent/US11450409B2/en active Active
- 2016-08-12 CN CN201680056337.1A patent/CN108138237B/en not_active Expired - Fee Related
- 2016-08-12 WO PCT/EP2016/069237 patent/WO2017029215A1/en active Application Filing
- 2016-08-12 CA CA2995520A patent/CA2995520A1/en not_active Abandoned
- 2016-08-12 BR BR112018002848A patent/BR112018002848A2/en not_active IP Right Cessation
- 2016-08-12 JP JP2018507571A patent/JP7028763B2/en active Active
- 2016-08-12 DK DK16753888.3T patent/DK3334837T3/en active
- 2016-08-12 EP EP16753888.3A patent/EP3334837B1/en active Active
-
2022
- 2022-09-14 US US17/931,919 patent/US20230260595A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US11450409B2 (en) | 2022-09-20 |
CA2995520A1 (en) | 2017-02-23 |
CN108138237A (en) | 2018-06-08 |
EP3334837A1 (en) | 2018-06-20 |
EP3334837B1 (en) | 2020-12-16 |
CN108138237B (en) | 2022-04-05 |
AU2016309659A1 (en) | 2018-04-12 |
JP7028763B2 (en) | 2022-03-02 |
BR112018002848A2 (en) | 2018-11-06 |
ES2861400T3 (en) | 2021-10-06 |
JP2018522575A (en) | 2018-08-16 |
WO2017029215A1 (en) | 2017-02-23 |
DK3334837T3 (en) | 2021-02-15 |
US20170046477A1 (en) | 2017-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230260595A1 (en) | Determination of nfkb pathway activity using unique combination of target genes | |
US10016159B2 (en) | Determination of TGF-β pathway activity using unique combination of target genes | |
US11776661B2 (en) | Determination of MAPK-AP-1 pathway activity using unique combination of target genes | |
JP6721665B2 (en) | Evaluation of cell signaling pathway activity using linear combination of gene expression of interest | |
EP3692172B1 (en) | Assessment of jak-stat3 cellular signaling pathway activity using mathematical modelling of target gene expression | |
US11649488B2 (en) | Determination of JAK-STAT1/2 pathway activity using unique combination of target genes | |
US20190100790A1 (en) | Determination of notch pathway activity using unique combination of target genes | |
EP3013986B1 (en) | Assessment of the pi3k cellular signaling pathway activity using mathematical modelling of target gene expression | |
US20230071390A1 (en) | Assessment of pr cellular signaling pathway activity using mathematical modelling of target gene expression |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: INNOSIGN B.V., NETHERLANDS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:KONINKLIJKE PHILIPS N.V.;REEL/FRAME:061138/0462 Effective date: 20220621 Owner name: KONINKLIJKE PHILIPS N.V., NETHERLANDS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:VAN OOIJEN, HENDRIK JAN;REEL/FRAME:061138/0339 Effective date: 20160829 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |